

**THIS PAGE IS INSERTED BY OIPE SCANNING
AND IS NOT PART OF THE OFFICIAL RECORD**

Best Available Images

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

BLACK BORDERS 

TEXT CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT

BLURRY OR ILLEGIBLE TEXT

SKEWED/SLANTED IMAGES

COLORED PHOTOS HAVE BEEN RENDERED INTO BLACK AND WHITE

VERY DARK BLACK AND WHITE PHOTOS

UNDECIPHERABLE GRAY SCALE DOCUMENTS

**IMAGES ARE THE BEST AVAILABLE
COPY. AS RESCANNING *WILL NOT*
CORRECT IMAGES, PLEASE DO NOT
REPORT THE IMAGES TO THE
PROBLEM IMAGE BOX.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number
WO 02/059381 A2

(51) International Patent Classification⁷: **C12Q 1/68**,
C07K 14/47, C12N 15/63, 15/10, A01K 67/027

(21) International Application Number: PCT/US02/00473

(22) International Filing Date: 7 January 2002 (07.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/260,080 6 January 2001 (06.01.2001) US

1) Applicant (for all designated States except US): **THE GENERAL HOSPITAL CORPORATION** [US/US]; 55 Fruit Street, Boston, MA 02114 (US).

(72) Inventors: and

(75) Inventors/Applicants (for US only): **SLAUGENHAUPT, Susan** [US/US]; 23 Thomas Street, Quincy, MA 02169 (US). **GUSELLA, James, F.** [US/US]; 7 Woodstock Drive, Framingham, MA 01701 (US).

(74) Agent: **SONNENFELD, Kenneth, H.**; Morgan & Finnegan, L.L.P. 345 Park Avenue, New York, NY 10154 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE FOR IDENTIFYING INDIVIDUALS WITH FAMILIAL DYSAUTONOMIA

(57) Abstract: This invention relates to methods and compositions useful for detecting mutations which cause Familial Dysautonomia. Familial dysautonomia (FD; Riley-Day syndrome), an Ashkenazi Jewish disorder, is the best known and most frequent of a group of congenital sensory neuropathies and is characterized by widespread sensory and variable autonomic dysfunction. Previously, we mapped the FD gene, *DYS*, to a 0.5 cM region of chromosome 9q31 and showed that the ethnic bias is due to a founder effect, with >99.5% of disease alleles sharing a common ancestral haplotype. To investigate the molecular basis of FD, we sequenced the minimal candidate region and cloned and characterized its 5 genes. One of these, *IKBKAP*, harbors two mutations that can cause FD. The major haplotype mutation is located in the donor splice site of intron 20. This mutation can result in skipping of exon 20 in the mRNA from FD patients, although they continue to express varying levels of wild-type message in a tissue-specific manner. RNA isolated from patient lymphoblasts is primarily wild-type, whereas only the deleted message is seen in RNA isolated from brain. The mutation associated with the minor haplotype in four patients is a missense (R696P) mutation in exon 19 that is predicted to disrupt a potential phosphorylation site. Our findings indicate that almost all cases of FD are caused by an unusual splice defect that displays tissue-specific expression; and they also provide the basis for rapid carrier screening in the Ashkenazi Jewish population.

WO 02/059381 A2

GENE FOR IDENTIFYING INDIVIDUALS WITH FAMILIAL DYSAUTONOMIA

This application claims priority to provisional application Serial No. 60/260,080, the entirety of which is incorporated herein by reference.

This invention was made with government support under Grant Number NS36326 awarded by The National Institutes of Health. The U.S. government has certain rights in the invention.

FIELD OF THE INVENTION

This invention relates generally to the gene, and mutations thereto, that are responsible for the disease familial dysautonomia (FD). More particularly, the invention relates to the identification, isolation and cloning of the DNA sequence corresponding to the normal and mutant FD genes, as well as characterization of their transcripts and gene products. This invention also relates to genetic screening methods and kits for identifying FD mutant and wild-type alleles, and further relates to FD diagnosis, prenatal screening and diagnosis, and therapies of FD, including gene therapeutics and protein/antibody based therapeutics.

BACKGROUND OF THE INVENTION

Familial Dysautonomia (FD, Riley-Day Syndrome, Hereditary Sensory and Autonomic Neuropathy Type III) [OMIM 223900] is an autosomal recessive disorder present in 1 in 3,600 live births in the Ashkenazi Jewish population. This debilitating disorder is due to the poor development, survival, and progressive degeneration of the sensory and autonomic nervous system (Axelrod et al., 1974). FD was first described in 1949 based on five children who presented with defective lacrimation, excessive sweating, skin blotching, and hypertension (Riley et al., 1949). The following cardinal criteria have evolved for diagnosis of FD: absence of fungiform papillae on the tongue, absence of flare after injection of intradermal

histamine, decreased or absent deep tendon reflexes, absence of overflow emotional tears, and Ashkenazi Jewish descent (Axelrod and Pearson, 1984, Axelrod 1984).

The loss of neuronal function in FD has many repercussions, with patients displaying gastrointestinal dysfunction, abnormal respiratory responses to hypoxic and hypercarbic states, scoliosis, gastroesophageal reflux, vomiting crises, lack of overflow tears, inappropriate sweating, and postural hypotension (Riley et al. 1949; Axelrod et al. 1974, Axelrod 1996). Despite recent advances in the management of FD, the disorder is inevitably fatal with only 50% of patients reaching 30 years of age. The clinical features of FD are due to a genetic defect that causes a striking, progressive depletion of unmyelinated sensory and autonomic neurons (Pearson and Pytel 1978a; Pearson and Pytel 1978b; Pearson et al. 1978; Axelrod 1995). This neuronal deficiency begins during development, as extensive pathology is evident even in the youngest subjects. Fetal development and postnatal maintenance of dorsal root ganglion (DRG) neurons is abnormal, significantly decreasing their numbers and resulting in DRG of grossly reduced size. Slow progressive degeneration is evidenced by continued neuronal depletion with increasing age. In the autonomic nervous system, superior cervical sympathetic ganglia are also reduced in size due to a severe decrease in the neuronal population.

Previously, the FD gene, *DYS*, was mapped to an 11-cM region of chromosome 9q31 (Blumenfeld et al. 1993) which was then narrowed by haplotype analysis to <0.5cM or 471 kb (Blumenfeld et al. 1999). There is a single major haplotype that accounts for >99.5% of all FD chromosomes in the Ashkenazi Jewish (AJ) population. The recent identification of several single nucleotide polymorphisms (SNPs) in the candidate interval has allowed for further reduction of the candidate region to 177 kb by revealing a common core haplotype shared by the major and one previously described minor haplotype (Blumenfeld et al. 1999).

SUMMARY OF THE INVENTION

This invention relates to mutations in the *IKBKAP* gene which the inventors of this invention discovered and found to be associated with Familial Dysautonomia. The mutation associated with the major haplotype of FD is a base

pair mutation, wherein the thymine nucleotide located at bp 6 of intron 20 in the *IKBKAP* gene is replaced with a cytosine nucleotide (T → C) (hereinafter “FD1 mutation”). The mutation associated with the minor haplotype is a base pair mutation wherein the guanine nucleotide at bp 2397 (bp 73 of exon 19) is replaced with a cysteine nucleotide (G → C) (hereinafter “FD2 mutation”). This base pair mutation causes an arginine to proline missense mutation (R696P) in the amino acid sequence of the *IKBKAP* gene that is predicted to disrupt a potential phosphorylation site.

In accordance with one aspect of the present invention, there is provided an isolated nucleic acid comprising a nucleic acid sequence selected from the group consisting of:

- nucleic acid sequences corresponding to the genomic sequence of the FD gene including introns and exons as shown in Figure 6;

- nucleic acid sequences corresponding to the nucleic acid sequence of the FD gene as shown in Figure 6, wherein the thymine nucleotide at position 34,201 is replaced by a cytosine nucleotide;

- nucleic acid sequences corresponding to the nucleic acid sequence of the FD gene as shown in Figure 6, wherein the guanine nucleotide at position 33,714 is replaced by a cytosine nucleotide;

- nucleic acid sequences corresponding to the nucleic acid sequence of the FD gene as shown in Figure 6, wherein the thymine nucleotide at position 34,201 is replaced by a cytosine nucleotide and the guanine nucleotide at position 33,714 is replaced by a cytosine nucleotide;

- nucleic acid sequences corresponding to the cDNA sequence including the coding sequence of the FD gene as shown in Figure 7;

- nucleic acid sequences corresponding to the cDNA sequence shown in Figure 7, wherein the arginine at position 696 is replaced by a proline;

In accordance with another aspect of the present invention, there is provided a nucleic acid probe, comprising a nucleotide sequence corresponding to a portion of a nucleic acid as set forth in any one of the foregoing nucleic acid sequences.

In accordance with another aspect of the present invention, there is provided a cloning vector comprising a coding sequence of a nucleic acid as set forth above and a replicon operative in a host cell for the vector.

In accordance with another aspect of the present invention, there is provided an expression vector comprising a coding sequence of a nucleic acid set forth above operably linked with a promoter sequence capable of directing expression of the coding sequence in host cells for the vector.

In accordance with another aspect of the present invention, there is provided host cells transformed with a vector as set forth above.

In accordance with another aspect of the present invention, there is provided a method of producing a mutant FD polypeptide comprising: transforming host cells with a vector capable of expressing a polypeptide from a nucleic acid sequence as set forth above; culturing the cells under conditions suitable for production of the polypeptide; and recovering the polypeptide.

In accordance with another aspect of the present invention, there is provided a peptide product selected from the group consisting of: a polypeptide having an amino acid sequence corresponding to the amino acid sequence shown in Figure 8; a polypeptide containing a mutation in the amino acid sequence shown in Figure 8, wherein the arginine at position 696 is replaced with a proline; a peptide comprising at least 6 amino acid residues corresponding to the amino acid sequence shown in Figure 8, and a peptide comprising at least 6 amino acid residues corresponding to a mutated form of the amino acid sequence shown in Figure 8. In one embodiment, the peptide is labeled. In another embodiment, the peptide is a fusion protein.

In accordance with another aspect of the present invention, there is provided a use of a peptide as set forth above as an immunogen for the production of antibodies. In one embodiment, there is provided an antibody produced in such application. In one embodiment, the antibody is labeled. In another embodiment, the antibody is bound to a solid support. In accordance with another aspect of the present invention, there is provided a method to determine the presence or absence of the familial dysautonomia (FD) gene mutation in an individual, comprising: isolating genomic DNA, cDNA, or RNA from a potential FD disease

carrier or patient; and assessing the DNA for the presence or absence of an FD-associated allele, wherein said FD-associated allele is the FD1 and/or FD2 mutation wherein, the absence of either FD-associated allele indicates the absence of the FD gene mutation in the genome of the individual and the presence of the allele indicates that the individual is either affected with FD or a heterozygote carrier.

In one embodiment, the assessing step is performed by a process which comprises subjecting the DNA to amplification using oligonucleotide primers flanking the FD1 mutation and the FD2 mutation. In another embodiment, the assessing step further comprises an allele-specific oligonucleotide hybridization assay.

In another embodiment, DNA is amplified using the following oligonucleotide primers: 5'-GCCAGTGTTTTGCCTGAG-3'; 5'-CGGATTGTCACTGTTGTGC-3'; 5'-GACTGCTCTCATAGCATCGC-3'. In another embodiment, the assessing step further comprises an allele-specific oligonucleotide hybridization assay. In another embodiment, the allele-specific oligonucleotide hybridization assay is accomplished using the following oligonucleotides: 5'-AAGTAAG(T/C)GCCATTG-3' and 5'-GGTTCAC(G/C)GATTGTC. In yet another embodiment, neuronal tissue from an individual is screened for the presence of truncated IKBKAP mRNA or peptides, wherein the presence of said truncated mRNA or peptides indicates that said individual possesses the FD1 and/or FD2 mutation in the IKBKAP gene.

In accordance with another aspect of the present invention, there is provided an animal model for familial dysautonomia (FD), comprising a mammal possessing a mutant or knock-out or knock-in FD gene. In another embodiment, there is provided a method of producing a transgenic animal expressing a mutant IKAP mRNA comprising:

- (a) introducing into an embryonal cell of an animal a promoter operably linked to the nucleotide sequence containing a mutation associated with FD;
- (b) transplanting the transgenic embryonal target cell formed thereby into a recipient female parent; and

(c) identifying at least one offspring containing said nucleotide sequence in said offspring's genome.

In accordance with another aspect of the present invention, there is provided a method for screening potential therapeutic agents for activity, in connection with FD, comprising: providing a screening tool selected from the group consisting of a cell line, and a mammal containing or expressing a defective FD gene or gene product; contacting the screening tool with the potential therapeutic agent; and assaying the screening tool for an activity.

In accordance with another aspect of the present invention, there is provided a method for treating familial dysautonomia (FD) by gene therapy using recombinant DNA technology to deliver the normal form of the FD gene into patient cells or vectors which will supply the patient with gene product in vivo.

In another embodiment, there is provided a method for treating familial dysautonomia (FD), comprising: providing an antibody directed against an FD protein sequence or peptide product; and delivering the antibody to affected tissues or cells in a patient having FD.

In accordance with another aspect of the present invention, there is provided kits for carrying out the methods of the invention. These kits include nucleic acids, polypeptides and antibodies of the present invention. In another embodiment the kit for detecting FD mutations will also contain genetic tests for diagnosing additional genetic diseases, such as Canavan's disease, Tay-Sachs disease, Goucher disease, Cystic Fibrosis, Fanconi anemia, and Bloom syndrome.

It will be appreciated by a skilled worker in the art that the identification of the genetic defect in a genetic disease, coupled with the provision of the DNA sequences of both normal and disease-causing alleles, provides the full scope of diagnostic and therapeutic aspects of such an invention as can be envisaged using current technology.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Genomic structure of *IKBKAP*. The figure illustrates the orientation and placement of the 37 exons within a 68 kb genomic region of

chromosome 9q31. The primers used for analysis of the splice defect are indicated as 18F (exon 18), 19F (exon 19) and 23R (exon 23). Asterick indicates the locations of the two mutations identified; the mutation associated with the major AJ haplotype is located at bp 6 of intron 20, whereas the mutation association with the minor AJ haplotype is located at bp 73 of exon 19. The 4.8 and 5.9 designations at exon 37 indicate the lengths of the two *IKBKAP* messages that differ only in the length of their 3' UTRs.

Figures 2A-2C. Demonstration of mutations in *IKBKAP*. Figure 2A shows the antisense sequence of the T – C mutation (shown by arrows adjacent to the G and A lanes) at bp 6 of intron 20 that is associated with the major FD haplotype. Lanes 1 and 2 are FD patients homozygous for the major haplotype (homozygous GG), lane 3 is an FD patient heterozygous for the major haplotype and minor haplotype 2 (heterozygous GA), lane 4 is an FD patient heterozygous for the major haplotype and minor haplotype 3 (heterozygous GA), and lanes 5 and 6 are non-FD controls (homozygous AA). Figure 2b shows heterozygosity for the G – C mutation (shown by arrows adjacent to the G and C lanes) at bp 73 of exon 19. Lane 1 is an FD homozygous for the major haplotype (homozygous GG), lanes 2-4 are three patients heterozygous for the major haplotype and minor haplotype 2 (heterozygous GC), lane 5 is a patient heterozygous for the major haplotype and minor haplotype 3 (homozygous GG), and lane 6 is a non-FD control (homozygous GG). Figure 2c shows the sequence of the cDNA generated from the RT-PCR of a patient heterozygous for the major and minor 2 haplotypes. The arrow points to the heterozygous G-C mutation in exon 19. The boundary of exons 19 and 20 is also indicated, illustrating that this patient expresses wild-type message that includes exon 20, despite the presence of the major mutation on one allele.

Figures 3A-3B. Northern blot analysis of *IKBKAP*. Figure 3A is a human multiple tissue northern blot that was hybridized with *IKBKAP* exon 2 and shows the presence of two messages of 4.8 and 5.9 kb (northern blots hybridized with other *IKBKAP* probes yielded similar patterns). Figure 3b is a northern blot generated using mRNA isolated from lymphoblast cell lines: lanes 1, 2, and 5 FD patients homozygous for the major haplotype; lane 3 individual carrying two definitively

non-FD chromosomes, lane 4 FD patient heterozygous for the major haplotype and minor haplotype 2; lane 6 control brain RNA (Clontech). The level of expression of *IKBKAP* mRNA relative to β -actin mRNA is quite variable in lymphoblasts. We observed no consistent increase or decrease in mRNA levels between FD patients homozygous for the major haplotype, those heterozygous for the major haplotype and minor haplotype 2, and non-FD individuals.

Figures 4A-4B: RT-PCR analysis of the exon 20 region of *IKBKAP* showing expression of the wild-type message and protein in patients. Figure 4A was generated using primers 18F (exon 18) and 23R (exon 23). Lanes 1 and 2 are FD patients homozygous for the major haplotype, lane 3 is an FD patient heterozygous for the major haplotype and minor haplotype 2, lanes 4 and 5 are non-FD controls, lane 6 is a water control. Figure 4b is a western blot generated using cytoplasmic protein isolated from patient lymphoblast cell lines and detected with a carboxyl-terminal antibody. Lanes 2, 4, 6, and 8 are patients homozygous for the major haplotype, lanes 3, 5, 7, and 9 are non-FD controls, lane 1 is a patient heterozygous for the major and minor haplotype 3, and lane 10 is a patient heterozygous for the major and minor haplotype 2 and lane 11 is a HeLa cell line sample.

Figure 5. RT-PCR analysis of the exon 20 region of *IKBKAP* showing variable expression of the mutant message in FD patients. The analysis was done using primers 19F (exon 19) and 23F (exon 23). Lanes 1 and 2, control fibroblasts; lanes 3, 4, and 5, FD fibroblasts homozygous for the major mutation; lanes 6 and 7 FD lymphoblasts homozygous for the major mutation, lanes 8 and 9 non-FD lymphoblasts, lane 10 FD patient brain stem, lane 11 FD patient temporal lobe (showing a faint 319 bp band and no 393 bp band), lane 12 water control. RT-PCR of control brain RNA (Clontech) showed only the 393 bp band (data not shown).

Figure 6. The genomic sequence for *IKBKAP*.

Figure 7- The cDNA sequence for *IKBKAP*

Figure 8- the amino acid sequence of the *IKBKAP* gene

Figure 9- Comparison of the amino acid sequence of Ikap across several species. Alignment of the amino acid sequence of Ikap (M_musculus) with that of

Homo sapiens (H_sapiens), *Drosophila melanogaster* (D_melanogaster), *Saccharomyces cerevisiae* (S_cerevisiae), *Arabidopsis thaliana* (A_thaliana), and *Caenorhabditis elegans* (C_elegans).

Figure 10- Comparison of the Novel Mouse *Ikbkap* Gene with Multiple Species Homologs

Figure 11- Mouse *Ikbkap* Exon and Intron Boundaries

Figure 12- Comparison of the synthetic regions of mouse chromosome 4 (MMU4) and human chromosome 9 (HSA9q31). This diagram on the left shows the location of *Ikbkap* in relation to mapped and genetic markers (boldface). Distances are given in centimorgans. The positions of the homologous genes that map to human chromosome 9q31 are shown on the right.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to mutations in the *IKBKAP* gene, which the inventors of the instant application discovered are associated with Familial Dysautonomia. More specifically, the mutation associated with the major haplotype of FD is a T-C change located at bp 6 of intron 20 in the *IKBKAP* gene as shown in Figure 1. This mutation can result in skipping of exon 20 in the mRNA from FD patients, although they continue to express varying levels of wild-type message in a tissue specific manner. The mutation associated with the minor haplotype is a single G-C change at bp 2397 (bp 73 of exon 19) that causes an arginine to proline missense mutation (R696P) that is predicted to disrupt a potential phosphorylation site.

These findings have direct implications for understanding the clinical manifestations of FD, for preventing it and potentially for treating it. The IKAP protein produced from *IKBKAP* gene was originally isolated as part of a large interleukin-1-inducible IKK complex and described as a regulator of kinases involved in pro-inflammatory cytokine signaling (Cohen et al. 1998). However, a recent report questioned this conclusion, by reporting that cellular IKK complexes do not contain IKAP based on various protein-protein interaction and functional

assays. Rather, IKAP appears to be a member of a novel complex containing additional unidentified proteins of 100, 70, 45, and 39 kDa (Krappmann et al. 2000).

IKAP is homologous to the Elp1 protein of *S. cerevisiae*, which is encoded by the *IKI3* locus and is required for sensitivity to pGKL killer toxin. The human and yeast proteins exhibit 29% identity and 46% similarity over their entire lengths. Yeast Elp1 protein is part of the RNA polymerase II-associated elongator complex, which also contains Elp2, a WD-40 repeat protein, and Elp3, a histone acetyltransferase (Otero et al. 1999). The human *ELP3* gene encodes a 60 kDa histone acetyltransferase that shows more than 75% identity with yeast Elp3 protein, but no 60 kDa protein has been found in the human IKAP-containing protein complex. Consequently, it is considered unlikely that IKAP is a member of a functionally conserved mammalian elongator complex (Krappmann et al. 2000). Instead, it has been reported that the protein may play a role in general gene activation mechanisms, as overexpression of IKAP interferes with the activity of both NF- κ B-dependent and independent reporter genes (Krappmann et al. 2000). Therefore, the FD phenotype may be caused by aberrant expression of genes crucial to the development of the sensory and autonomic nervous systems, secondary to the loss of a functional IKAP protein in specific tissues.

FD is unique among Ashkenazi Jewish disorders in that one mutation accounts for > 99.5% of the disease chromosomes. As in other autosomal recessive diseases with no phenotype in heterozygous carriers, one might have expected to find several different types of mutations producing complete inactivation of the *DYS* gene in the AJ population. The fact that the major FD mutation does not produce complete inactivation, but rather allows variable tissue-specific expression of IKAP, may explain this lack of mutational diversity. Mutations causing complete inactivation of IKAP in all tissues might cause a more severe or even lethal phenotype. Indeed, *CG10535*, the apparent *Drosophila melanogaster* homologue of *IKBKAP*, maps coincident with a larval recessive lethal mutation (*l(3)04629*) supporting the essential nature of the protein (FlyBase). Thus, the array of mutations that can produce the FD phenotype may be limited if they must also allow expression of functional or partially functional IKAP in some tissues to permit

survival. With the identification of *IKBKAP* as *DYS*, it will now be possible to test this inactivation hypothesis in a mammalian model system.

Despite the overwhelming predominance of a single mutation in FD patients, the disease phenotype is remarkably variable both within and between families. The nature of the major FD mutation makes it tempting to consider that this phenotypic variability might relate to the frequency of exon 20 skipping in specific tissues and at specific developmental stages, which may be governed by variations in many factors involved in RNA splicing. Even a small amount of normal IKAP protein expressed in critical tissues might permit sufficient neuronal survival to alleviate the most severe phenotypes. This possibility is supported by the relatively mild phenotype associated with the presence of the R696P mutation, which is predicted to permit expression of an altered full-length IKAP protein that may retain some functional capacity. To date, this minor FD mutation has only been seen in four patients heterozygous for the major mutation. Consequently, it is uncertain whether homozygotes for the R696P mutation would display any phenotypic abnormality characteristic of FD. The single patient with minor haplotype 3 and mixed ancestry, whose mutation has yet to be found, is also a compound heterozygote with the major haplotype. The existence of minor haplotype 3 indicates that *IKBKAP* mutations will be found outside the AJ population, but like the R696P mutation, it is difficult to predict the severity of phenotype that would result from homozygosity.

Since FD affects the development and maintenance of the sensory and autonomic nervous systems, the identification of *IKBKAP* as the *DYS* gene allows for further investigation of the role of IKAP and associated proteins in the sensory and autonomic nervous systems. Of more immediate practical importance, however, the discovery of the single base mutation that characterizes >99.5% of FD chromosomes will permit efficient, inexpensive carrier testing in the AJ population, to guide reproductive choices and reduce the incidence of FD. The nature of the major mutation also offers some hope for new approaches to treatment of FD. Despite the presence of this mutation, lymphoblastoid cells from patients are capable of producing full-length wild-type mRNA and normal IKAP protein; while in neuronal tissue exon 20 is skipped, presumably leading to a truncated product.

Investigation of the mechanism that permits lymphoblasts to be relatively insensitive to the potential effect of the mutation on splicing may suggest strategies to prevent skipping of exon 20 in other cell types. An effective treatment to prevent the progressive neuronal loss of FD may be one aimed at facilitating the production of wild-type mRNA from the mutant gene rather than exogenous administration of the missing IKAP protein via gene therapy.

FD Screening

With knowledge of the primary mutation and secondary mutation of the FD gene as disclosed herein, screening for presymptomatic homozygotes, including prenatal diagnosis, and screening for heterozygous carriers can be readily carried out.

1. Nucleic Acid Based Screening

Individuals carrying mutations in the FD gene may be detected at either the DNA or RNA level using a variety of techniques that are well known in the art. The genomic DNA used for the diagnosis may be obtained from an individual's cells, such as those present in peripheral blood, urine, saliva, bucca, surgical specimen, and autopsy specimens. The DNA may be used directly or may be amplified enzymatically in vitro through use of PCR (Saiki et al. Science 239:487-491 (1988)) or other in vitro amplification methods such as the ligase chain reaction (LCR) (Wu and Wallace Genomics 4:560-569 (1989)), strand displacement amplification (SDA) (Walker et al. PNAS USA 89:392-396 (1992)), self-sustained sequence replication (3SR) (Fahy et al. PCR Methods Appl. 1:25-33 (1992)), prior to mutation analysis. in situ hybridization may also be used to detect the FD gene.

The methodology for preparing nucleic acids in a form that is suitable for mutation detection is well known in the art. For example, suitable probes for detecting a given mutation include the nucleotide sequence at the mutation site and encompass a sufficient number of nucleotides to provide a means of differentiating a normal from a mutant allele. Any probe or combination of probes capable of detecting any one of the FD mutations herein described are suitable for use in this

invention. Examples of suitable probes include those complementary to either the coding or noncoding strand of the DNA. Similarly, suitable PCR primers are complementary to sequences flanking the mutation site. Production of these primers and probes can be carried out in accordance with any one of the many routine methods, e.g., as disclosed in Sambrook et al.^{sup.45}, and those disclosed in WO 93/06244 for assays for Goucher disease.

Probes for use with this invention should be long enough to specifically identify or amplify the relevant FD mutations with sufficient accuracy to be useful in evaluating the risk of an individual to be a carrier or having the FD disorder. In general, suitable probes and primers will comprise, preferably at a minimum, an oligomer of at least 16 nucleotides in length. Since calculations for mammalian genomes indicate that for an oligonucleotide 16 nucleotides in length, there is only one chance in ten that a typical cDNA library will fortuitously contain a sequence that exactly matches the sequence of the nucleotide. Therefore, suitable probes and primers are preferably 18 nucleotides long, which is the next larger oligonucleotide fully encoding an amino acid sequence (i.e., 6 amino acids in length).

By use of nucleotide and polypeptide sequences provided by this invention, safe, effective and accurate testing procedures are also made available to identify carriers of mutant alleles of *IKBKAP*, as well as pre- and postnatal diagnosis of fetuses and live born patients carrying either one or two mutant alleles. This affords potential parents the opportunity to make reproductive decisions prior to pregnancy, as well as afterwards, e.g., if chorionic villi sampling or amniocentesis is performed early in pregnancy. Thus, prospective parents who know that they are both carriers may wish to determine if their fetus will have the disease, and may wish to terminate such a pregnancy, or to provide the physician with the opportunity to begin treatment as soon as possible, including prenatally. In the case where such screening has not been performed, and therefore the carrier status of the patient is not known, and where FD disease is part of the differential diagnosis, the present invention also provides a method for making the diagnosis genetically.

Many versions of conventional genetic screening tests are known in the art. Several are disclosed in detail in WO 91/02796 for cystic fibrosis, in U.S. Pat. No.

5,217,865 for Tay-Sachs disease, in U.S. Pat. No. 5,227,292 for neurofibromatosis and in WO 93/06244 for Goucher disease. Thus, in accordance with the state of the art regarding assays for such genetic disorders, several types of assays are conventionally prepared using the nucleotides, polypeptides and antibodies of the present invention. For example: the detection of mutations in specific DNA sequences, such as the FD gene, can be accomplished by a variety of methods including, but not limited to, restriction-fragment-length-polymorphism detection based on allele-specific restriction-endonuclease cleavage (Kan and Dozy Lancet ii:910-912 (1978)), hybridization with allele-specific oligonucleotide probes (Wallace et al. Nucl Acids Res 6:3543-3557 (1978)), including immobilized oligonucleotides (Saiki et al. PNAS USA 86:6230-6234 (1989)) or oligonucleotide arrays (Maskos and Southern Nucl Acids Res 21:2269-2270 (1993)), allele-specific PCR (Newton et al. Nucl Acids Res 17:2503-2516 (1989)), mismatch-repair detection (MRD) (Faham and Cox Genome Res 5:474-482 (1995)), binding of MutS protein (Wagner et al. Nucl Acids Res 23:3944-3948 (1995)), denaturing-gradient gel electrophoresis (DGGE) (Fisher and Lerman et al. PNAS USA 80:1579-1583 (1983)), single-strand-conformation-polymorphism detection (Orita et al. Genomics 5:874-879 (1983)), RNAase cleavage at mismatched base-pairs (Myers et al. Science 230:1242 (1985)), chemical (Cotton et al. PNAS USA 85:4397-4401 (1988)) or enzymatic (Youil et al. PNAS USA 92:87-91 (1995)) cleavage of heteroduplex DNA, methods based on allele specific primer extension (Syvanen et al. Genomics 8:684-692 (1990)), genetic bit analysis (GBA) (Nikiforov et al. Nucl Acids Res 22:4167-4175 (1994)), the oligonucleotide-ligation assay (OLA) (Landegren et al. Science 241:1077 (1988)), the allele-specific ligation chain reaction (LCR) (Barrany PNAS USA 88:189-193 (1991)), gap-LCR (Abravaya et al. Nucl Acids Res 23:675-682 (1995)), and radioactive and/or fluorescent DNA sequencing using standard procedures well known in the art.

As will be appreciated, the mutation analysis may also be performed on samples of RNA by reverse transcription into cDNA therefrom. Furthermore, mutations may also be detected at the protein level using, for example, antibodies specific for the mutant and normal FD protein, respectively. It may also be possible

to base an FD mutation assay on altered cellular or subcellular localization of the mutant form of the FD protein.

2. Antibodies

Antibodies can also be used for the screening of the presence of the FD gene, the mutant FD gene, and the protein products therefrom. In addition, antibodies are useful in a variety of other contexts in accordance with this invention. As will be appreciated, antibodies can be raised against various epitopes of the FD protein. Such antibodies can be utilized for the diagnosis of FD and, in certain applications, targeting of affected tissues.

For example, antibodies can be used to detect truncated FD protein in neuronal cells, the detection of which indicates that an individual possesses a mutation in the IKBKAP gene.

Thus, in accordance with another aspect of the present invention a kit is provided that is suitable for use in screening and assaying for the presence of the FD gene by an immunoassay through use of an antibody which specifically binds to a gene product of the FD gene in combination with a reagent for detecting the binding of the antibody to the gene product.

Antibodies raised in accordance with the invention can also be utilized to provide extensive information on the characteristics of the protein and of the disease process and other valuable information which includes but is not limited to:

1. Antibodies can be used for the immunostaining of cells and tissues to determine the precise localization of the FD protein. Immunofluorescence and immuno-electron microscopy techniques which are well known in the art can be used for this purpose. Defects in the FD gene or in other genes which cause an altered localization of the FD protein are expected to be localizable by this method.

2. Antibodies to distinct isoforms of the FD protein (i.e., wild-type or mutant-specific antibodies) can be raised and used to detect the presence or absence of the wild-type or mutant gene products by immunoblotting (Western blotting) or other immunostaining methods. Such antibodies can also be utilized for therapeutic applications where, for example, binding to a mutant form of the FD protein reduces

the consequences of the mutation.

3. Antibodies can also be used as tools for affinity purification of FD protein. Methods such as immunoprecipitation or column chromatography using immobilized antibodies are well known in the art and are further described in Section (II)(B)(3), entitled "Protein Purification" herein.

4. Immunoprecipitation with specific antibodies is useful in characterizing the biochemical properties of the FD protein. Modifications of the FD protein (i.e., phosphorylation, glycosylation, ubiquitization, and the like) can be detected through use of this method. Immunoprecipitation and Western blotting are also useful for the identification of associating molecules that may be involved in the mammalian elongation complex.

5. Antibodies can also be utilized in connection with the isolation and characterization of tissues and cells which express FD protein. For example, FD protein expressing cells can be isolated from peripheral blood, bone marrow, liver, and other tissues, or from cultured cells by fluorescence activated cell sorting (FACS) Harlow et al., eds., *Antibodies: A Laboratory Manual*, pp. 394-395, Cold Spring Harbor Press, N.Y. (1988). Cells can be mixed with antibodies (primary antibodies) with or without conjugated dyes. If nonconjugated antibodies are used, a second dye-conjugated antibody (secondary antibody) which binds to the primary antibody can be added. This process allows the specific staining of cells or tissues which express the FD protein.

Antibodies against the FD protein are prepared by several methods which include, but are not limited to:

1. The potentially immunogenic domains of the protein are predicted from hydropathy and surface probability profiles. Then oligopeptides which span the predicted immunogenic sites are chemically synthesized. These oligopeptides can also be designed to contain the specific mutant amino acids to allow the detection of and discrimination between the mutant versus wild-type gene products. Rabbits or other animals are immunized with the synthesized oligopeptides coupled to a carrier such as KLH to produce anti-FD protein polyclonal antibodies. Alternatively, monoclonal antibodies can be produced against the synthesized oligopeptides using

conventional techniques that are well known in the art Harlow et al., eds., *Antibodies: A Laboratory Manual*, pp. 151-154, Cold Spring Harbor Press, N.Y. (1988). Both in vivo and in vitro immunization techniques can be used. For therapeutic applications, "humanized" monoclonal antibodies having human constant and variable regions are often preferred so as to minimize the immune response of a patient against the antibody. Such antibodies can be generated by immunizing transgenic animals which contain human immunoglobulin genes. See Jakobovits et al. *Ann NY Acad Sci* 764:525-535 (1995).

2. Antibodies can also be raised against expressed FD protein products from cells. Such expression products can include the full length expression product or parts or fragments thereof. Expression can be accomplished using conventional expression systems, such as bacterial, baculovirus, yeast, mammalian, and other overexpression systems using conventional recombinant DNA techniques. The proteins can be expressed as fusion proteins with a histidine tag, glutathione-S-transferase, or other moieties, or as nonfused proteins. Expressed proteins can be purified using conventional protein purification methods or affinity purification methods that are well known in the art. Purified proteins are used as immunogens to generate polyclonal or monoclonal antibodies using methods similar to those described above for the generation of antipeptide antibodies.

In each of the techniques described above, once hybridoma cell lines are prepared, monoclonal antibodies can be made through conventional techniques of, for example, priming mice with pristane and interperitoneally injecting such mice with the hybrid cells to enable harvesting of the monoclonal antibodies from ascites fluid.

In connection with synthetic and semi-synthetic antibodies, such terms are intended to cover antibody fragments, isotype switched antibodies, humanized antibodies (mouse-human, human-mouse, and the like), hybrids, antibodies having plural specificities, fully synthetic antibody-like molecules, and the like.

3. Expression Systems

Expression systems for the FD gene product allow for the study of the

function of the FD gene product, in either normal or wild-type form and/or mutated form. Such analyses are useful in providing insight into the disease causing process that is derived from mutations in the gene.

"Expression systems" refer to DNA sequences containing a desired coding sequence and control sequences in operable linkage, so that hosts transformed with these sequences are capable of producing the encoded proteins. In order to effect transformation, the expression system may be included on a vector; however, the relevant DNA may then also be integrated into the host chromosome.

In general terms, the production of a recombinant form of FD gene product typically involves the following:

First a DNA encoding the mature (used here to include all normal and mutant forms of the proteins) protein, the preprotein, or a fusion of the FD protein to an additional sequence cleavable under controlled conditions such as treatment with peptidase to give an active protein, is obtained. If the sequence is uninterrupted by introns it is suitable for expression in any host. If there are introns, expression is obtainable in mammalian or other eukaryotic systems capable of processing them. This sequence should be in excisable and recoverable form. The excised or recovered coding sequence is then placed in operable linkage with suitable control sequences in an expression vector. The construct is used to transform a suitable host, and the transformed host is cultured under selective conditions to effect the production of the recombinant FD protein. Optionally the FD protein is isolated from the medium or from the cells and purified as described in Section entitled "Protein Purification".

Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequences can be obtained by preparing suitable cDNA from cellular mRNA and manipulating the cDNA to obtain the complete sequence. Alternatively, genomic fragments may be obtained and used directly in appropriate hosts. The construction of expression vectors operable in a variety of hosts are made using appropriate replicons and control sequences, as set forth below. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to provide an excisable gene to insert into these vectors.

The control sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene. Generally, prokaryotic, yeast, insect, or mammalian cells are presently useful as hosts. Prokaryotic hosts are in general the most efficient and convenient for the production of recombinant proteins. However, eukaryotic cells, and, in particular, yeast and mammalian cells, are often preferable because of their processing capacity and post-translational processing of human proteins.

Prokaryotes most frequently are represented by various strains of *E. coli*. However, other microbial strains may also be used, such as *Bacillus subtilis* and various species of *Pseudomonas* or other bacterial strains. In such prokaryotic systems, plasmid or bacteriophage vectors which contain origins of replication and control sequences compatible with the host are used. A wide variety of vectors for many prokaryotes are known (Maniatis et al. *Molecular Cloning: A Laboratory Manual* pp. 1.3-1.11, 2.3-2.125, 3.2-3.48, 2-4.64 (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1982)); Sambrook et al. *Molecular Cloning: A Laboratory Manual* pp. 1-54 (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989)); Meth. Enzymology 68: 357-375 (1979); 101: 307-325 (1983); 152: 673-864 (1987) (Academic Press, Orlando, Fla. Pouwells et al. *Cloning Vectors: A Laboratory Manual* (Elsevier, Amsterdam (1987))). Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter systems, the tryptophan (trp) promoter system and the lambda derived PL promoter and N-gene ribosome binding site, which has become useful as a portable control cassette (U.S. Pat. No. 4,711,845). However, any available promoter system compatible with prokaryotes can be used (Sambrook et al. *supra*. (1989); Meth. Enzymology *supra*. (1979, 1983, 1987); John et al. *Gene* 61: 207-215 (1987).

In addition to bacteria, eukaryotic microbes, such as yeast, may also be used as hosts. Laboratory strain *Saccharomyces cerevisiae* or Baker's yeast, is most often used although other strains are commonly available.

Vectors employing the 2 micron origin of replication and other plasmid vectors suitable for yeast expression are known (Sambrook et al. supra. (1989); Meth. Enzymology supra. (1979, 1983, 1987); John et al. supra. (1987). Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes. Additional promoters known in the art include the promoters for 3-phosphoglycerate kinase, and those for other glycolytic enzymes, such as glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other promoters, which have the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization. See Sambrook et al. supra. (1989); Meth. Enzymology supra. John et al. supra. (1987). It is also believed that terminator sequences at the 3' end of the coding sequences are desirable. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. Many of the useful vectors contain control sequences derived from the enolase gene containing plasmid peno46 or the LEU2 gene obtained from Yep13, however, any vector containing a yeast compatible promoter, origin of replication, and other control sequences is suitable (Sambrook et al. supra. (1989); Meth. Enzymology supra. (1979, 1983, 1987); John et al. supra.

It is also, of course, possible to express genes encoding polypeptides in eukaryotic host cell cultures derived from multicellular organisms (Kruse and Patterson Tissue Culture pp. 475-500 (Academic Press, Orlando (1973)); Meth. Enzymology 68: 357-375 (1979); Freshney Culture of Animal Cells; A Manual of Basic Techniques pp. 329-334 (2d ed., Alan R. Liss, N.Y. (1987))). Useful host cell lines include murine myelomas N51, VERO and HeT cells, SF9 or other insect cell lines, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and later promoters from

Simian Virus 40 (SV 40), or other viral promoters such as those from polyoma, adenovirus 2, bovine papilloma virus, or avian sarcoma viruses, herpes virus family (such as cytomegalovirus, herpes simplex virus, or Epstein-Barr virus), or immunoglobulin promoters and heat shock promoters (Sambrook et al. supra. pp. 16.3-16.74 (1989); Meth. Enzymology 152: 684-704 (1987); John et al. supra. In addition, regulated promoters, such as metallothionine (i.e., MT-1 and MT-2), glucocorticoid, or antibiotic gene "switches" can be used.

General aspects of mammalian cell host system transformations have been described by Axel (U.S. Pat. No. 4,399,216). Plant cells are also now available as hosts, and control sequences compatible with plant cells such as the nopaline synthase promoter and polyadenylation signal sequences are available (Pouwells et al. supra. (1987); Meth Enzymology 118: 627-639 (Academic Press, Orlando (1986); Gelvin et al. J. Bact. 172: 1600-1608.

Depending on the host cell used, transformation is done using standard techniques appropriate to such cells (Sambrook et al. supra. pp. 16.30-16.5 (1989); Meth. Enzymology supra 68:357-375 (1979); 101: 307-325 (1983); 152: 673-864 (1987). U.S. Pat. No. 4,399,216; Meth Enzymology supra 118: 627-639 (1986); Gelvin et al. J. Bact. 172: 1600-1608 (1990). Such techniques include, without limitation, calcium treatment employing calcium chloride for prokaryotes or other cells which contain substantial cell wall barriers; infection with *Agrobacterium tumefaciens* for certain plant cells; calcium phosphate precipitation, DEAE, lipid transfection systems (such as LIPOFECTIN.TM. and LIPOFECTAMINE.TM.), and electroporation methods for mammalian cells without cell walls, and, microprojectile bombardment for many cells including, plant cells. In addition, DNA may be delivered by viral delivery systems such as retroviruses or the herpes family, adenoviruses, baculoviruses, or semliki forest virus, as appropriate for the species of cell line chosen.

C. THERAPEUTICS

Identification of the FD gene and its gene product also has therapeutic implications. Indeed, one of the major aims of this invention is the development of

therapies to circumvent or overcome the defect leading to FD disease. Envisioned are pharmacological, protein replacement, antibody therapy, and gene therapy approaches. In addition the development of animal models useful for developing therapies and for understanding the molecular mechanisms of FD disease are envisioned.

1. Pharmacological

In the pharmacological approach, drugs which circumvent or overcome the defective FD gene function are sought. In this approach, modulation of FD gene function can be accomplished by agents or drugs which are designed to interact with different aspects of the FD protein structure or function.

Efficacy of a drug or agent, can be identified in a screening program in which modulation is monitored in vitro cell systems. Indeed, the present invention provides for host cell systems which express various mutant FD proteins (especially the T-C and G-C mutations noted in this application) and are suited for use as primary screening systems.

In vivo testing of FD disease-modifying compounds is also required as a confirmation of activity observed in the in vitro assays. Animal models of FD disease are envisioned and discussed in the section entitled "Animal Models", below, in the present application.

Drugs can be designed to modulate FD gene and FD protein activity from knowledge of the structure and function correlations of FD protein and from knowledge of the specific defect in various FD mutant proteins. For this, rational drug design by use of X-ray crystallography, computer-aided molecular modeling (CAMP), quantitative or qualitative structure-activity relationship (QSAR), and similar technologies can further focus drug discovery efforts. Rational design allows prediction of protein or synthetic structures which can interact with and modify the FD protein activity. Such structures may be synthesized chemically or expressed in biological systems. This approach has been reviewed in Capsey et al., Genetically Engineered Human Therapeutic Drugs, Stockton Press, New York (1988). Further, combinatorial libraries can be designed, synthesized and used in

screening programs.

The present invention also envisions that the treatment of FD disease can take the form of modulation of another protein or step in the pathway in which the FD gene or its protein product participates in order to correct the physiological abnormality.

In order to administer therapeutic agents based on, or derived from, the present invention, it will be appreciated that suitable carriers, excipients, and other agents may be incorporated into the formulations to provide improved transfer, delivery, tolerance, and the like.

A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, (15th Edition, Mack Publishing Company, Easton, Pa. (1975)), particularly Chapter 87, by Blaug, Seymour, therein. These formulations include for example, powders, pastes, ointments, jelly, waxes, oils, lipids, anhydrous absorption bases, oil-in-water or water-in-oil emulsions, emulsions carbowax (polyethylene glycols of a variety of molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax.

Any of the foregoing formulations may be appropriate in treatments and therapies in accordance with the present invention, provided that the active agent in the formulation is not inactivated by the formulation and the formulation is physiologically compatible.

2. Protein Replacement Therapy

The present invention also relates to the use of polypeptide or protein replacement therapy for those individuals determined to have a defective FD gene. Treatment of FD disease could be performed by replacing the defective FD protein with normal protein or its functional equivalent in therapeutic amounts.

FD polypeptide can be prepared for therapy by any of several conventional procedures. First, FD protein can be produced by cloning the FD cDNA into an appropriate expression vector, expressing the FD gene product from this vector in an in vitro expression system (cell-free or cell-based) and isolating the FD protein

from the medium or cells of the expression system. General expression vectors and systems are well known in the art. In addition, the invention envisions the potential need to express a stable form of the FD protein in order to obtain high yields and obtain a form readily amenable to intravenous administration. Stable high yield expression of proteins have been achieved through systems utilizing lipid-linked forms of proteins as described in Wettstein et al. J Exp Med 174:219-228 (1991) and Lin et al. Science 249:677-679 (1990).

FD protein can be prepared synthetically. Alternatively, the FD protein can be prepared from total protein samples by affinity chromatography. Sources would include tissues expressing normal FD protein, in vitro systems (outlined above), or synthetic materials. The affinity matrix would consist of antibodies (polyclonal or monoclonal) coupled to an inert matrix. In addition, various ligands which specifically interact with the FD protein could be immobilized on an inert matrix. General methods for preparation and use of affinity matrices are well known in the art.

Protein replacement therapy requires that FD protein be administered in an appropriate formulation. The FD protein can be formulated in conventional ways standard to the art for the administration of protein substances. Delivery may require packaging in lipid-containing vesicles (such as LIPOFECTIN.TM. or other cationic or anionic lipid or certain surfactant proteins) that facilitate incorporation into the cell membrane. The FD protein formulations can be delivered to affected tissues by different methods depending on the affected tissue.

3. Gene Therapy

Gene therapy utilizing recombinant DNA technology to deliver the normal form, of the FD gene into patient cells or vectors which will supply the patient with gene product in vivo is also contemplated within the scope of the present invention. In gene therapy of FD disease, a normal version of the FD gene is delivered to affected tissue(s) in a form and amount such that the correct gene is expressed and will prepare sufficient quantities of FD protein to reverse the effects of the mutated FD gene. Current approaches to gene therapy include viral vectors, cell-based

delivery systems and delivery agents. Further, ex vivo gene therapy could also be useful. In ex vivo gene therapy, cells (either autologous or otherwise) are transfected with the normal FD gene or a portion thereof and implanted or otherwise delivered into the patient. Such cells thereafter express the normal FD gene product in vivo and would be expected to assist a patient with FD disease in avoiding iron overload normally associated with FD disease. Ex vivo gene therapy is described in U.S. Pat. No. 5,399,346 to Anderson et al., the disclosure of which is hereby incorporated by reference in its entirety. Approaches to gene therapy are discussed below:

a. Viral Vectors

Retroviruses are often considered the preferred vector for somatic gene therapy. They provide high efficiency infection, stable integration and stable expression (Friedman, T. Progress Toward Human Gene Therapy. Science 244:1275 (1989)). The full length FD gene cDNA can be cloned into a retroviral vector driven by its endogenous promoter or from the retroviral LTR. Delivery of the virus could be accomplished by direct implantation of virus directly into the affected tissue.

Other delivery systems which can be utilized include adenovirus, adeno-associated virus (AAV), vaccinia virus, bovine papilloma virus or members of the herpes virus group such as Epstein-Barr virus. Viruses can be, and preferably are, replication deficient.

b. Non-viral gene transfer

Other methods of inserting the FD gene into the appropriate tissues may also be productive. Many of these agents, however, are of lower efficiency than viral vectors and would potentially require infection in vitro, selection of transfectants, and reimplantation. This would include calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. A particularly attractive idea is the use of liposomes (i.e., LIPOFECTIN.TM.), which might be possible to carry out in vivo.

Synthetic cationic lipids and DNA conjugates also appear to show some promise and may increase the efficiency and ease of carrying out this approach.

4. Animal Models

The generation of a mouse or other animal model of FD disease is important for both an understanding the biology of the disease but also for testing of potential therapies.

The present invention envisions the creation of an animal model of FD disease by introduction of the FD disease causing mutations in a number of species including mice, rats, pigs, and primates.

Techniques for specifically inactivating or mutating genes by homologous recombination in embryonic stem cells (ES cells) have been described (Capecci Science 244:1288 (1989)). Animals with the inactivated homologous FD gene can then be used to introduce the mutant or normal human FD gene or for introduction of the homologous gene to that species and containing the T-C, G-C or other FD disease-causing mutations. Methods for these transgenic procedures are well known to those versed in the art and have been described by Murphy and Carter, Curr. Opin. Cell Biol. 4:273-279 (1992)

ILLUSTRATIVE EXAMPLES

The following examples are provided to illustrate certain aspects of the present invention and not intended as limiting the subject matter thereof.

Example 1

Identification of the *IKBKAP* gene and the mutations associated with FD were obtained as follows:

Patient Samples

Blood samples were collected from two major sources, the Dysautonomia Diagnostic and Treatment Center at New York University Medical Center and the Israeli Center for Familial Dysautonomia at Hadassah University Hospital, with

approval from the institutional review boards at these institutions, Massachusetts General Hospital and Harvard Medical School. Either F.A. or C.M. diagnosed all patients using established criteria. Epstein Barr virus transformed lymphoblast lines using standard conditions. Fibroblast cell lines were obtained from the Coriell Cell Repositories, Camden, NJ. RNA isolated from post-mortem FD brain was obtained from the Dysautonomia Diagnostic and Treatment Center at NYU. Genomic DNA, total RNA, and mRNA were prepared using commercial kits (Invitrogen and Molecular Research Center, Inc.). Cytoplasmic protein was extracted from lymphoblasts as previously described (Krappmann et al. 2000).

Identification of *IKBKAP* and mutation analysis

Exon trapping experiments of cosmids from a physical map of the candidate region yielded 5 exons that were used to screen a human frontal cortex cDNA library. Several cDNA clones were isolated and assembled into a novel transcript encoding a 1332 AA protein that was later identified as *IKBKAP* (Cohen et al. 1998). The complete 5.9 kb cDNA sequence of *IKBKAP* has been submitted to GenBank under accession number AF153419. In order to screen for mutations in FD patients, total lymphoblast RNA was reverse transcribed and overlapping sections of *IKBKAP* were amplified by PCR and sequenced. Evaluation of the splicing defect was performed using the following primers: 18F: GCCAGTGTTTTTGCCTGAG; 19F: CGGATTGTCACTGTTGTGC; 23R: GACTGCTCTCATAGCATCGC (Fig. 1).

DNA Sequencing

Sequencing was performed using the AmpliCycle sequencing kit (Applied Biosystems) or on an ABI 377 automated DNA sequencer using the BigDye terminator cycle sequencing kit (Applied Biosystems). The control sequence of the candidate region was obtained by constructing subclone libraries from BACs and sequencing using vector specific primers. The FD sequence was generated by sequencing cosmids from a patient homozygous for the major FD haplotype using sequence specific primers.

Expression Studies

Several human multiple tissue northern blots (Clontech) were hybridized using the following radioactively labeled probes: *IKBKAP* exon 2, *IKBKAP* exons 18/19/20, *IKBKAP* exon 23, and a 400 bp fragment of the *IKBKAP* 3'UTR immediately following the stop codon. Poly (A)⁺ RNA was isolated from patient and control lymphoblast lines, northern blotted, and hybridized using a probe representing the full coding sequence of *IKBKAP*. Cytoplasmic protein extracted from lymphoblast cell lines was western blotted and detected using ECL (Amersham) with an antibody raised against a peptide comprising the extreme carboxyl terminus (AA 1313-1332) of human IKAP, the protein encoded by *IKBKAP* (Krappmann et al. 2000).

To identify *DYS*, exon trapping and cDNA selection were used to clone and characterize all of the genes in the 471 kb candidate region: *EPB41L8* (unpublished data) or *EHM2* (Shimizu et al. 2000), *C9ORF4* (Chadwick et al. 1999a), *C9ORF5* (Chadwick et al. 2000), *CTNNAL1* (Zhang et al. 1998), a novel gene with homology to the glycine cleavage system H proteins (CG-8) (unpublished data), *IKBKAP* (Cohen et al. 1998), and *ACTL7A* and *ACTL7B* (Chadwick et al. 1999b). As FD is a recessive disorder, the *a priori* expectation for the mutation was inactivation of one of these genes. Consequently, each of these were screened for mutations by RT-PCR of patient lymphoblast RNA and direct sequencing of all coding regions. Although many SNPs were identified, there was no evidence for a homozygous inactivating mutation. Thus, it was concluded that the mutation would be found in non-coding sequence and the control genomic sequence of the entire 471 kb candidate region was generated using BACs from a physical map. Direct sequence prediction using GENSCAN and comprehensive searches of the public databases did not reveal any additional genes in the candidate region beyond those found by cloning methods. However, SNPs identified during sequence analysis enabled us to refine the haplotype analysis and narrow the candidate interval to 177 kb shared by the major haplotype and the previously described minor haplotype 1 (Blumenfeld et al. 1999). This reduced interval contains 5 genes, *CTNNAL1*, CG-8, *IKBKAP*, *ACTL7A* and *ACTL7B*, all previously screened by RT-PCR without yielding a

coding sequence mutation. A cosmid library was constructed from a patient homozygous for the major haplotype, assembled the minimal coverage contig for the now reduced candidate interval, and generated the sequence of the mutant chromosome.

Comparison of the FD and control sequences revealed 152 differences (excluding simple sequence repeat markers), which include 26 variations in the length of dT_n tracts, 1 VNTR, and 125 base pair changes. Each of the 125 base pair changes was tested in a panel of 50 individuals known to carry two non-FD chromosomes by segregation in FD families. Of the 125 changes tested, only 1 was unique to patients carrying the major FD haplotype. This T - C change is located at bp 6 of intron 20 in the *IKBKAP* gene depicted in Figure 1, and is demonstrated in Figure 2A. IKAP was originally identified as an I κ B kinase (IKK) complex-associated protein that can bind both NF- κ B inducing kinase (NIK) and IKKs through separate domains and assemble them into an active kinase complex (Cohen et al. 1998). Recent work, however, has shown that IKAP is not associated with IKKs and plays no specific role in cytokine-induced NF- κ B signaling (Krappmann et al. 2000). Rather, IKAP was shown to be part of a novel multi-protein complex hypothesized to play a role in general transcriptional regulation.

The *IKBKAP* gene contains 37 exons and encodes a 1332 amino acid protein. The full-length 5.9 kb cDNA (GenBank accession number AF153419) covers 68 kb of genomic sequence, with the start methionine encoded in exon 2. *IKBKAP* was previously assigned to chromosome 9q34 (GenBank accession number AF044195), but it clearly maps within the FD candidate region of 9q31. Northern analysis of *IKBKAP* revealed two mRNAs of 4.8 and 5.9 kb (fig. 3a and b). The wild-type 4.8 kb mRNA has been reported previously (Cohen et al. 1998), while the second 5.9 kb message differs only in the length of the 3' UTR and is predicted to encode an identical 150 kDa protein. As seen in figure 3b, the putative FD mutation does not eliminate expression of the *IKBKAP* mRNA in patient lymphoblasts.

A base pair change at position 6 of the splice donor site might be expected to result in skipping of exon 20 (74 bp), causing a frameshift and therefore producing a

truncated protein. However, initial inspection of our RT-PCR experiments in patient lymphoblast RNA using primers located in exons 18 and 23 (Fig.1) showed a normal length 500 bp fragment that contained exon 20 (Fig. 4A), indicating that patient lymphoblasts express normal *IKBKAP* message. The Western blot shown in Figure 4B demonstrates that full-length IKAP protein is expressed in these patient lymphoblasts. However, as the antibody used was directed against the carboxyl-terminus of IKAP it would not be expected to detect any truncated protein should it be present. The presence of apparently normal IKAP in patient cells is at odds with the expectation of an inactivating mutation in this recessive disease.

In the absence of any evidence for a functional consequence of the intron 20 sequence change, the only alteration unique to FD chromosomes, additional genetic evidence was sought to support the view that it represents the FD mutation. The 658 FD chromosomes that carry the major haplotype all show the T – C change. *In toto*, 887 chromosomes have been tested that are definitively non-FD due to their failure to cause the disorder when present in individuals heterozygous for the major FD haplotype. None of these non-FD chromosomes exhibits the T – C mutation, strongly indicating that it is not a rare polymorphism. The frequency of the mutation in random AJ chromosomes was 14/1012 (gene frequency 1/72; carrier frequency 1/36), close to the expected carrier frequency of 1/32 (Maayan et al. 1987).

In view of the strong genetic evidence that this mutation must be pathogenic, it was postulated that its effect might be tissue-specific. RNA extracted from the brain stem and temporal lobe of a post-mortem FD brain sample was therefore examined. In contrast to FD lymphoblasts, RT-PCR of the FD brain tissue RNA using primers in exons 19 and 23 (expected to produce a normal product of 393 bp) revealed a 319 bp mutant product, indicating virtually complete absence of exon 20 from the *IKBKAP* mRNA (Fig. 5, lanes 10-11). As additional FD autopsy material could not be obtained, intensive analyses of additional lymphoblast and fibroblast cell lines were performed to determine whether exon-skipping could be detected. Fibroblast lines from homozygous FD patients yielded variable results. Some primary fibroblast lines displayed approximately equal expression of the mutant and

wild-type mRNAs while others displayed primarily wild-type mRNA. In addition, extensive examination of additional patient lymphoblast lines indicated that the mutant message could sometimes be detected at low levels. An example of the variability seen in FD fibroblasts and the presence of the mutant message in some FD lymphoblasts is shown in Figure 5. In fact, close re-examination of figure 4a shows a trace of the mutant band in 2 (lanes 1 and 2) of the 3 FD samples. The absence of exon 20 in the FD brain RNA and the preponderance of wild-type mRNA in fibroblasts and lymphoblasts indicate that the major FD mutation acts by altering splicing of *IKBKAP* in a tissue-specific manner.

To identify the mutations associated with minor haplotypes 2 and 3, (Blumenfeld et al. 1999) we amplified each *IKBKAP* exon, including adjacent intron sequence, from genomic DNA. A single G – C change at bp 2397 (bp 73 of exon 19) that causes an arginine to proline missense mutation (R696P) was identified in all 4 patients with minor haplotype 2 (fig. 2b). This was subsequently confirmed by RT-PCR in lymphoblast RNA as shown in figure 2c for a region that crosses the exon 19-20 border. The PCR product, generated from an FD patient who is a compound heterozygote with minor haplotype 2 and the major haplotype, clearly shows that RNA is being expressed equally from both alleles based on heterozygosity of the G – C point mutation in exon 19. However, the RNA from the major haplotype allele shows no evidence for skipping of exon 20 which would be expected to produce a mixture of exon 20 and 21 sequence beginning at the end of exon 19. This confirms our previous observation that lymphoblasts with the major FD mutation produce a predominance of normal *IKBKAP* transcript.

The R696P mutation is absent from 500 non-FD chromosomes, and it has been seen only once in 706 random AJ chromosomes in an individual who also carries the minor haplotype. This mutation is predicted to disrupt a potential threonine phosphorylation site at residue 699 identified by Netphos 2.0 (Blom et al. 1999), suggesting that it may affect regulation of IKAP. Interestingly, the presence of this minor mutation is associated with a relatively mild disease phenotype, suggesting that a partially functional IKAP protein may be expressed from this

allele. No mutation has been identified for minor haplotype 3, which represents the only non-AJ putative FD chromosome.

Example 2- FD Diagnostic Assays

As discussed above, the allele-specific oligonucleotide (ASO) hybridization assay is highly effective for detecting single nucleotide changes in DNA and RNA, such as the T-C or G-C mutations or sequence variations, especially when used in conjunction with allele-specific PCR amplification. Thus, in accordance with the present invention, there is provided an assay kit to detect mutations in the FD gene through use of a PCR/ASO hybridization assay.

PCR Amplification

Genomic DNA samples are placed into a reaction vessel(s) with appropriate primers, nucleotides, buffers, and salts and subjected to PCR amplification.

Suitable genomic DNA-containing samples from patients can be readily obtained and the DNA extracted therefrom using conventional techniques. For example, DNA can be isolated and prepared in accordance with the method described in Dracopoli, N. et al. eds. *Current Protocols in Human Genetics* pp. 7.1.1-7.1.7 (J. Wiley & Sons, New York (1994)), the disclosure of which is hereby incorporated by reference in its entirety. Most typically, a blood sample, a buccal swab, a hair follicle preparation, or a nasal aspirate is used as a source of cells to provide the DNA.

Alternatively, RNA from an individual (i.e., freshly transcribed or messenger RNA) can be easily utilized in accordance with the present invention for the detection of the FD2 mutation. Total RNA from an individual can be isolated according to the procedure outlined in Sambrook, J. et al. *Molecular Cloning--A Laboratory Manual* pp. 7.3-7.76 (2nd Ed., Cold Spring Harbor Laboratory Press, New York (1989)) the disclosure of which is hereby incorporated by reference.

In a preferred embodiment, the DNA-containing sample is a blood sample from a patient being screened for FD.

In amplification, a solution containing the DNA sample (obtained either directly or through reverse transcription of RNA) is mixed with an aliquot of each of dATP, dCTP, dGTP and dTTP (i.e., Pharmacia LKB Biotechnology, N.J.), an aliquot of each of the DNA specific PCR primers, an aliquot of Taq polymerase (i.e., Promega, Wis.), and an aliquot of PCR buffer, including MgCl.sub.2 (i.e., Promega) to a final volume. Followed by pre-denaturation (i.e., at 95.degree. C. for 7 minutes), PCR is carried out in a DNA thermal cycler (i.e., Perkin-Elmer Cetus, Conn.) with repetitive cycles of annealing, extension, and denaturation. As will be appreciated, such steps can be modified to optimize the PCR amplification for any particular reaction, however, exemplary conditions utilized include denaturation at 95.degree. C. for 1 minute, annealing at 55.degree. C. for 1 minute, and extension at 72.degree. C. for 4 minutes, respectively, for 30 cycles. Further details of the PCR technique can be found in Erlich, "PCR Technology," Stockton Press (1989) and U.S. Pat. No. 4,683,202, the disclosure of which is incorporated herein by reference.

In a preferred embodiment, the amplification primers used for detecting the T-C mutation and the G-C mutation in the FD gene are 5'-GCCAGTGTTTTGCCTGAG-3' / 5'-GACTGCTCTCATAGCATCGC-3' and 5'-CGGATTGTCACCTGTTGTGC-3' / 5'-GACTGCTCTCATAGCATCGC-3', respectively.

Hybridization

Following PCR amplification, the PCR products are subjected to a hybridization assay using allele-specific oligonucleotides. In a preferred embodiment, the allele-specific oligonucleotides used to detect the mutations in the FD gene are as follows:

5'-AAGTAAG(T/C)GCCATTG-3' and 5'-GGTTCAC(G/C)GATTGTC.

In the ASO assay, when carried out in microtiter plates, for example, one well is used for the determination of the presence of the normal allele and a second well is used for the determination of the presence of the mutated allele. Thus, the results for an individual who is heterozygous for the T-C mutation (i.e. a carrier of FD) will show a signal in each of the wells, an individual who is homozygous for

the T-C allele (i.e., affected with FD) will show a signal in only the C well, and an individual who does not have the FD mutation will show only one signal in the T well.

In another embodiment, a kit for detecting the FD mutation by ASO assay is provided. In the kit, amplification primers for DNA or RNA (or generally primers for amplifying a sequence of genomic DNA, reverse transcription products, complementary products) including the T-C mutated and normal alleles are provided. Allele-specific oligonucleotides are also preferably provided. The kit further includes separate reaction wells and reagents for detecting the presence of homozygosity or heterozygosity for the T-C mutation.

Within the same kit, or in separate kits, oligonucleotides for amplification and detection of other differences (such as the G-C mutation) can also be provided. If in the same kit as that used for detection of the T-C mutation, separate wells and reagents are provided, and homozygosity and heterozygosity can similarly be determined.

In another embodiment a kit combining other diseases (i.e., Canavan's)

Example 3- FD Diagnostic: Other Nucleotide Based Assays

As will be appreciated, a variety of other nucleotide based detection techniques are available for the detection of mutations in samples of RNA or DNA from patients. See, for example, the section, above, entitled "Nucleic Acid Based Screening." Any one or any combination of such techniques can be used in accordance with the invention for the design of a diagnostic device and method for the screening of samples of DNA or RNA for FD gene mutations in accordance with the invention, such as the mutations and sequence variants identified herein. Further, other techniques, currently available, or developed in the future, which allow for the specific detection of mutations and sequence variants in the FD gene are contemplated in accordance with the invention.

Through use of any such techniques, it will be appreciated that devices and methods can be readily developed by those of ordinary skill in art to rapidly and accurately screen for mutations and sequence variants in the FD gene in accordance

with the invention.

Thus, in accordance with the invention, there is provided a nucleic acid based test for FD gene mutations and sequence variants which comprises providing a sample of a patient's DNA or RNA and assessing the DNA or RNA for the presence of one or more FD gene mutations or sequence variants. Samples of patient DNA or RNA (or genomic, transcribed, reverse transcribed, and/or complementary sequences to the FD gene) can be readily obtained as described in Example 2. Through the identification and characterization of the FD gene as taught and disclosed in the present invention, one of ordinary skill in the art can readily identify the genomic, transcribed, reverse transcribed, and/or complementary sequences to the FD gene sequence in a sample and readily detect differences therein. Such differences in accordance with the present invention can be the T-C or G-C mutations or sequence variations identified and characterized in accordance herewith. Alternatively, other differences might similarly be detectable.

Kits for conducting and/or substantially automating the process of identification and detection of selected changes, as well as reagents utilized in connection therewith, are therefore envisioned in accordance with the invention of the present invention.

As discussed above, through knowledge of the gene-associated mutations responsible for FD disease, it is now possible to prepare transgenic animals as models of the FD disease. Such animals are useful in both understanding the mechanisms of FD disease as well as use in drug discovery efforts. The animals can be used in combination with cell-based or cell-free assays for drug screening programs.

EXAMPLE 4- Creating Animal Models of FD

The first step in creating an animal model of FD is the identification and cloning of homologs of the IKBKAP gene in other species.

Isolation of Mouse cDNA Clones

The human IKBKAP sequence (GenBank Accession No. AF153419) was used to search the mouse expressed sequence tag database (dbEST) using the BLAST

program (www.ncbi.nlm.nih.gov/BLAST). A single 5' EST from a mouse brain library (GenBank Association No. AU079160) was identified that showed marked similarity to the 5' end of IKBKAP. The corresponding cDNA clone, MNCB-3931, was obtained from the Japanese Collection of the Research Bioresource/National Institute of Infectious Disease. In addition, eight EST's that were similar to the 3' end of the ORF were found to belong to UniGene cluster Mn.46573 (www.ncbi.nlm.nih.gov/Unigene). Examination of this cluster yielded several poly (A+)- containing clones, and we obtained the clone UI-M-CG0p-bhb-g-07-0-U1 (GenBank Accession No. BE994893) from Research Genetics.

RT-PCR Analysis

RNA (1 ug/ml from BALB/c mouse brain was obtained commercially (Clontech). Oligo-dT 15 and random hexamer primers were annealed to the template at 65° C for 10 min in the presence of 1X first-strand buffer, 2mM dNTP mix, and 4 mM DTT. The reaction mixture was incubated at 42° C for 90 min after addition of Superscript TM II RT (200 U/ul) and Rnase inhibitor (80 U/ul) (GIBCO).

DNA Sequencing and Analysis

DNA sequencing was performed using the AmpliCycle sequencing kit (Applied Biosystems) for the 33 [P]-labeled dideoxynucleotide chain termination reaction, using the following conditions: 30 sec at 94° C, 30 sec at 60° C, and 30 sec at 72° C for 30 cycles. The radioactively labeled sequence reaction product was denatured at 95 C for 10 min and run on a denaturing 6% polyacrylamide gel for autoradiography. Basic sequencing manipulations and alignments were carried out using a program from Genetics Computer Group (GCC; Madison, WI). The cDNA sequence generated throughout the experiments were aligned and assembled into a 4799-bp cDNA named Ikbkap.

Isolation of Full-Length cDNA

To obtain the full-length cDNA sequence, PCR was performed on the mouse cDNA template using primers designed from the sequence of the 5' – and 3' –cDNA

clones. The PCR conditions were as follows: 15 sec at 95° C, 30 sec at 54° C to 60° C, and 3 min at 68° C for 9 cycles; then 15 sec at 95° C, 30 sec at 54 to 60° C, and 3 min with increment of 5 sec for each succeeding cycle at 68 C for 19 cycles, followed by 7 min at 72° C. The PCR products were electrophoresed on a 1% agarose gel stained with ethidium bromide and were cleaner using a Qiaquick PCR cleaning kit (Qiagen) in the preparation for cycle sequencing. Successive primers were designed in order to obtain the full-length Ikbkap sequence, which was deposited in GenBank under Accession No. AF367244.

Northern Blot Analysis

Expression of Ikbkap was examined using both mouse embryo and adult mouse multiple tissue Northern blots (Clontech). The blots were probed with a 1045-bp PCR fragment that contains exons 2 through 11, which was generated using primer 1 (5' –GGCGTCGTAGAAATTGC-3') and primer 2 (5' –GTGGTGCTGAAGGGGCAGGC-3'). The probe was radiolabeled (Sambrook et al., 1989) and was hybridized according to the manufacturer's instructions.

Chromosome Mapping of the Mouse Ikbkap Gene

Several of the mouse Ikbkap ESTs belonged to the Unigene cluster Mn.46573, which has been mapped to chromosome 4 (UniSTS entry: 253051) between D4Mit287 and D4Mit197. To assess synteny between mouse chromosome 4 and human chromosome 9, we used several resources available at NCBI (www.ncbi.nlm.nih.gov/Homology).

Determination of Genomic Structure of the Mouse Ikbkap

The 37 human IKBKAP exons were searched against the Celera database to obtain homologous mouse sequences. Approximately 130 mouse genomic fragments (500-700 bp) were obtained using the Celera Discovery System and Celera's associated database, and these fragments were assembled into seven contigs. In order to assemble the coomplete genomic sequence, we obtained six mouse bacterial artificial chromosomes (BACs) from Research Genetics after they

screened an RPCI-23 mouse library using 4300bp human probe that contained exon 2. To verify that these BAC clones contained the entire *Ikbkap* gene, we amplified fragments from the 5' and 3' ends of the gene, as well as a fragment from the 3' flanking gene *Actl7b* (Slaugenhaupt et al., 2001). We designed primers at the ends of each of the seven contigs constructed from the Celera data and generated PCR products from the BACs. Subsequently, we sequenced and closed five of the gaps, with the resulting two contigs assembled and deposited to Celera (Accession No. CSN009).

Creating a Targeting Vector

After cloning and sequencing the mouse homolog of the human *IKBKAP* gene, a targeting vector can then be constructed from the mouse genomic DNA. The targeting vector would consist of two approximately 3 kb genomic fragments from the mouse *FD* gene as 5' and 3' homologous arms. These arms would be chosen to flank a region critical to the function of the *FD* gene product (for example, exon 20).

In place of exon 20, negative and positive selectable markers can be placed, for example, to abolish the activity of the *FD* gene. As a positive selectable marker a neo gene under control of phosphoglycerate kinase (*pgk-1*) promoter may be used and as a negative selectable marker the 5' arm of the vector can be flanked by a *pgk-1* promoted herpes simplex thymidine kinase (*HSV-TK*) gene can be used.

The vector is then transfected into R1 ES cells and the transfectants are subjected to positive and negative selection (i.e., G418 and gancyclovir, respectively, where neo and *HSV-TK* are used). PCR is then used to screen for surviving colonies for the desired homologous recombination events. These are confirmed by Southern blot analysis.

Subsequently, several mutant clones are picked and injected into C57BL/6 blastocytes to produce high-percentage chimeric animals. The animals are then mated to C57BL/6 females. Heterozygous offspring are then mated to produce homozygous mutants. Such mutant offspring can then be tested for the *FD* gene mutation by Southern blot analysis. In addition, these animals are tested by RT-PCR

to assess whether the targeted homologous recombination results in the ablation of the FD gene mRNA. These results are confirmed by Northern blot analysis and RNase protection assays.

Once established, the FD gene^{-/-} mice can be studied for the development of FD-like disease and can also be utilized to examine which cells and tissue-types are involved in the FD disease process. The animals can also be used to introduce the mutant or normal FD gene or for the introduction of the homologous gene to that species (i.e., mouse) and containing the T-C or G-C mutations, or other disease causing mutations. Methods for the above-described transgenic procedures are well known to those versed in the art and are described in detail by Murphy and Carter *supra* (1993).

The techniques described above, can also be used to introduce the T-C or G-C mutations, or other homologous mutations in the animal, into the homologous animal gene. As will be appreciated, similar techniques to those described above, can be utilized for the creation of many transgenic animal lines

To the extent that any reference (including books, articles, papers, patents, and patent applications) cited herein is not already incorporated by reference, they are hereby expressly incorporated by reference in their entirety.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modification, and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as fall within the scope of the invention and the limits of the appended claims.

WE CLAIM:

1. An isolated and purified nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:
 - (a) the nucleic acid sequence in Figure 6;
 - (b) the nucleic acid sequence in Figure 6, wherein the thymine nucleotide at position 34,201 is replaced by a cytosine nucleotide;
 - (c) the nucleic acid sequence in Figure 6, wherein the guanine nucleotide at position 33,714 is replaced by a cytosine nucleotide;
 - (d) the nucleic acid sequence in Figure 6, wherein the thymine nucleotide at position 34,201 is replaced by a cytosine nucleotide and the guanine nucleotide at position 33,714 is replaced by a cytosine nucleotide;
 - (e) the nucleic acid sequence in Figure 7;
 - (f) the nucleic acid sequence in Figure 7, wherein the guanine nucleotide at position 2397 is replaced by a cytosine nucleotide.
2. An isolated and purified nucleic acid molecule according to claim 1, wherein the nucleic acid molecule has the nucleic acid sequence shown in Figure 6.
3. An isolated and purified nucleic acid molecule according to claim 1, said nucleic acid molecule having the nucleic acid sequence shown in Figure 6, wherein the thymine nucleotide at position 34,201 is replaced by a cytosine nucleotide.
4. An isolated and purified nucleic acid molecule according to claim 1, said nucleic acid molecule having the nucleic acid sequence shown in Figure 6, wherein the guanine nucleotide at position 33,714 is replaced by a cytosine nucleotide.
5. An isolated and purified nucleic acid molecule according to claim 1, said nucleic acid molecule having the nucleic acid sequence shown in Figure 6,

wherein the thymine nucleotide at position 34,201 is replaced by a cytosine nucleotide and the guanine nucleotide at position 33,714 is replaced by a cytosine nucleotide,

6. An isolated and purified nucleic acid molecule according to claim 1, wherein the nucleic acid molecule has the nucleic acid sequence shown in Figure 7.

7. An isolated and purified nucleic acid molecule according to claim 1, said nucleic acid molecule having the nucleic acid sequence shown in Figure 7, wherein the guanine nucleotide at position 2397 is replaced by a cytosine nucleotide.

8. An isolated polypeptide comprising the amino acid sequence in Figure 8.

9. An isolated polypeptide comprising the amino acid sequence in Figure 8, wherein the arginine at position 696 is replaced by a proline.

10. A recombinant vector comprising a nucleic acid molecule according to claim 1.

11. The recombinant vector according to claim 10, wherein said nucleic acid molecule is operably linked to an expression control sequence suitable for expression of said nucleic acid sequence in a host cell.

12. A host cell comprising the recombinant vector according to claim 11, wherein said host cell is selected from a group comprising a strain of E.coli, Pseudomonas, Bacillus subtilis, Bacillus stearothermophilus, or other bacilli, other bacteria, yeast, other fungi, insect cells, plant cells, or murine, bovine, porcine, human or other mammalian cells.

13. A method of producing a wild-type IKAP polypeptide, comprising:
 - (a) culturing a host cell transformed with a vector of claim 10 containing a DNA molecule encoding for a wild-type IKAP polypeptide in a cell culture medium under conditions whereby the IKAP polypeptide is expressed, and
 - (b) isolating the thus-produced wild-type IKAP polypeptide.
14. A method of producing a mutant IKAP polypeptide, comprising:
 - (a) culturing a host cell transformed with a vector of claim 10 containing a DNA molecule encoding a mutant IKAP polypeptide in a cell culture medium under conditions whereby the mutant IKAP polypeptide is expressed, and
 - (b) isolating the thus-produced mutant IKAP polypeptide.
15. A method of screening a subject to determine if said subject has a mutation associated with FD, comprising:
 - (a) providing a biological sample containing the DNA of the subject to be screened;
 - (b) detecting FD mutations in said biological sample.
16. The method according to claim 15, wherein the FD mutation is a T-C mutation at position 34,201 in the DNA sequence of Figure 6.
17. The method according to claim 15, wherein the FD mutation is a G-C mutation at position 33,714 in the DNA sequence of Figure 6.
18. The method according to claim 15, wherein the FD mutation is a T-C mutation at position 34,201 and a G-C mutation at position 33,714.
19. The method according to claim 15, wherein the FD mutation is detected by an allele-specific oligonucleotide hybridization assay.

20. The method according to claim 15, wherein the DNA from said biological sample is amplified using oligonucleotide primers flanking the mutation.
21. The method according to claim 20, wherein the DNA is amplified with oligonucleotide primers 18F and 23R.
22. The method according to claim 20, wherein the DNA is amplified with oligonucleotide primers 19F and 23R.
23. The method according to claim 20, wherein the DNA is amplified with oligonucleotide primers 18F, 19F and 23R.
24. The method according to claim 23, wherein the amplified DNA is screened for FD mutations using an allele-specific oligonucleotide hybridization assay.
25. The method according to claim 24, wherein the hybridization assay is accomplished using probes that span the T-C mutation at nucleotide position 34,201 in the IKBKAP gene.
26. The method according to claim 24, wherein the hybridization assay is accomplished using probes that span the G-C mutation at nucleotide position 33,714 in the IKBKAP gene.
27. The method according to claim 24, wherein the hybridization assay is accomplished using probes selected from the following sequences:
- (a) 5'- AAGTAAG(T/C)GCCATTG- 3', and
 - (b) 5'- GGTTCAC(G/C)GATTGTC- 3'.
28. The method according to claim 15, wherein the FD mutation is detected by method selected from the group consisting of:

- (a) restriction-fragment-length-polymorphism detection based on allele-specific restriction-endonuclease cleavage,
- (b) hybridization with allele-specific oligonucleotide probes including immobilized oligonucleotides or oligonucleotide arrays,
- (c) allele-specific PCR, mismatch-repair detection (MRD),
- (d) binding of MutS protein,
- (e) denaturing-gradient gel electrophoresis (DGGE),
- (f) single-strand-conformation-polymorphism detection,
- (g) RNAase cleavage at mismatched base-pairs,
- (h) chemical or enzymatic cleavage of heteroduplex DNA,
- (i) methods based on allele specific primer extension,
- (j) genetic bit analysis (GBA),
- (k) oligonucleotide-ligation assay (OLA),
- (l) allele-specific ligation chain reaction (LCR)
- (m) gap-LCR, and
- (n) radioactive and/or fluorescent DNA sequencing.

29. A kit for assaying for the presence of an FD mutation in an individual comprising at least one oligonucleotide probe capable of detecting the FD1 mutation or the FD2 mutation.

30. A kit according to claim 29, further comprising primers capable of amplifying the region containing said mutations.

31. A kit according to claim 30, wherein said primers are 18F and 23R.

32. A kit according to claim 30, wherein said primers are 19F and 23R.

33. A kit according to claim 30, wherein said primers are 18F, 19F and 23R.

34. A kit according to claim 29, further comprising an oligonucleotide probe which specifically hybridizes to one or more additional mutant or wild-type genes, wherein said additional gene codes for a protein associated with an additional genetic disease.

35. A kit according to claim 34, wherein the additional genetic disease is selected from the group comprising: Canavan's disease, Tay-Sachs disease, Goucher disease, Cystic Fibrosis, Fanconi anemia, and Bloom syndrome.

36. A method of detecting a FD mutation in a sample, comprising isolation of RNA from a tissue sample, amplifying the RNA using primers in exons 19 and 23; determining whether said sample contains a mutant product or a wild-type product, wherein the identification of a mutant product indicates the presence of an FD mutation in said sample.

37. The method according to claim 36, wherein said RNA is isolated from neuronal tissue.

38. A method of detecting a FD mutation in a sample; comprising the utilization of an antibody capable of detecting a truncated protein product that is indicative of FD.

39. A method of producing a transgenic animal expressing a mutant IKAP mRNA comprising:

(a) introducing into an embryonal cell of an animal a promoter operably linked to the nucleotide sequence containing a mutation associated with FD;

(b) transplanting the transgenic embryonal target cell formed thereby into a recipient female parent; and

(c) identifying at least one offspring containing said nucleotide sequence in said offspring's genome.

40. The method according to claim 39, wherein said mutation is the FD1 mutation.

41. The method according to claim 39, wherein said mutation is the FD2 mutation.

42. The method according to claim 15, further comprising a determination of whether said individual is homozygous or heterozygous for said mutation.

43. An oligonucleotide for detecting a mutation associated with FD, said oligonucleotide having a sequence selected from sequences which detect an FD mutation or bind to a region flanking said FD mutation.

Fig. 1




Fig. 2a




Fig. 2b




Fig. 2c




Fig. 3A





Fig. 3B



b

FIG. 4A





FIG. 4B






FIG. 5

FIGURE 6

IKBKAPgenomic.seq Length: 66479

1 CCAGTGCTGC GGCTGCCTAG TTGACGCACC CATTGAGTCG CTGGCTTCTT
51 TGCAGCGCTT CAGCGTTTTT CCCTGGAGGG CGCCTCCATC CTTGGAGGCC
101 TAGTGCCGTC GGAGAGAGAG CGGGAGCCGC GGACAGAGAC GCGTGCGCAA
151 TTCGGAGCCG ACTCTGGGTG CGGACTGTGG GAGCTGACTC TGGGTAGCCG
201 GCTGCGCGTG GCTGGGGAGG CGAGGCCGGA CGCACCTCTG TTTGGGGGTC
251 CTCAGGTAAG CGATCCATCC AGGGTAGGGG CACGGGAGTG GACCTCTCCG
301 CCGGCGGTGT CCGGGTGAAG GAGACCCGGA GCCTCCTCTG CCTGCTGCGG
351 GCCGGGGACT GGAGTGCGGG CTGCACCACC TCTTTCCTAG AGCCTTAAAT
401 TCTTTTTGCA GCCTTGCCAC CTGCTCCATC GGGGGCGCTG GGAGGCGCGA
451 CAGCCCAGGG ATGCCTGCTG CCCCTCCAGC CGGACTTAAC CCAGCCTCTT
501 GATTGCTTGC AGGGGGTTGA TAATAACGCT GAAAGCGAGA GTATTAATTC
551 ACGATGGAAG GCGGCGGTTA ATAGAGGCTC GGGTGCTGTG GTGCGGGTCC
601 TTTCTCGCGT GTGAGACTTT TTCGTGGAGG TGGTGTCTC TGTGCTTCTC
651 CATCTAACGT GGTGTTTTAC GTGGCTTTCT CTCCCGTTAA CGATGATCTC
701 CGTGGAGACA GTGGCTGAGT AATCTTCAGA TCCAGTACT TAGCAAGTGC
751 TCAGTCGGTG TTGGATGTAG GCCACAAACC GGATCGTAAA GAATTCAACT
801 GTATATTGAC AGCCACGGAA CTAATCAATG AATAGATCCG TATGAAGAGT
851 AAGCAAAAAG GCAGCAAAGA CAGTTTTTCA GCTTGGGGAC ATAGAGTAGA
901 AATGGTCTGT CCCCAAATAG TGGGAACTGT CATTTGGGGG AAGAATAGCA
951 AGTTCTTTGC TTTCCAGGTC GCATTTGATG TGCATGTGAG ACATGCTTGT
1001 GATTCTATCA GGAGGTTGAA AATGTGGGTT TAGTGGAAG TTTGGGCTAA
1051 TTCAGTCAGG GCTAGGCATT TAGGCCTAAT CAGCGTATTG GTGATCTACC
1101 TGGTATATGT AATCATGCAT GTGATGTCTA GCCAAGAGGT GGA TAGTCGA
1151 AGGAGCAAGG GAAGAAAATG AAGCAGTTAT CAGGAAATTA AGAGAGAATC
1201 CACGATTGAC CTTTGGTGTG GAGGGATCTT TAGCACATTT AAGAACTGCG

1251 AAGAGTTTGA ATCAGTGGAG GCAGGAAGGT TGGAGGTTGC AGATG TCCAA
1301 GAAAGAGTAC TAATAGGCCT AGGTCCTGTG GCAATATGGA GGATATTCCT
1351 TTCCTAGCCT GGAAAGAAGT GGAGGGAAGT CTCCTCCGA GAAGA TAAGG
1401 GAATAAGGCT GATGGGTGTG AAATTTGAGA GAACTAGTT TTGAGGCGTT
1451 TTTATGATGT TTAAAGATGA AAAACGAGCA GGCACGGTGG CTCAGGCCTG
1501 TAATCCCAGC ACTTTGGGAG GCAGAGGCGG GTGGATCACT TGAGGTTAGG
1551 AGTTCAAGAA CAGCCTGGGC AACATGGTGA AACCTGTCT CTAATAAAAA
1601 TACAAAAATT AACTGGGCAT GGTGCCGCGC GCCTGTAATC CCAGCTACTC
1651 CGGAGGCTGA GGCAGGAGAA TCGCTTGAAC CCGGAAGGCA GATGTTGCGG
1701 TGAGCCGAGA TCGCGCCATT GCACCCAGC CTGGGCAATA AGAGCGAAAC
1801 TCCGTCTCAA AAAACAAAAA AACCTGCATG ATATGTTAGA GGTTCAGTA
1851 ATTTCTAGCA GTTCTTGAAT ATAATTGTCA CCAAACTTA CTAAATCAT
1901 TGTCTTCCTC ACTTCCATCA TATATAAACT TACCTTTCTC TTATCCACA
1951 TTATATATTA TATAATTCCT ATGACACTTG ACATTATCTT CTGTGTAATA
2001 TTAGGATTGA TTCATCTTTA TTCTTTCTAT GTCATACATA TGTGGGGTGC
2051 CAAGATGAGA GAAGTCTCCT TGGATTAAAG TGACAATAAG ACCGGTGTGG
2101 TCCTTGTAAT TGCTACCCCT AACATAAGTT AGGGACTTAC AATCA TAAGC
2151 CTAAAGGGA TCTGAATATA AATAACTAGC ACAGTAACAT TTTTTTCCCC
2201 TACTTAGGTA ATGTTATGCA TTAAAGCAAG CCTGATTTTG CCAGACCAAA
2251 GTAGATGTCT TGTTTAGCAC TCTTTTCTCA CGTTTTATAT TGTCTGGGA
2301 AAAGCCTGGC CAGAAGAACA AAGTTACTGG AAGTAGTTAT GTCAGGTCAT
2351 CAGGGTCCTT GAAATGTTGG TCATCATTTT GAAGTAAATT GTTGT CATGT
2401 CCCAGTATT TCTCTCCCC TTTAGAACAG TAAATGCTTT TCTATCTTTG
2451 ATTTAGTTT TTTTATGAAT GTATAAAACC AGTTTATAAA TGAATAGACC
2501 TGGTGAATAT TAAAGTCATT TCAGATTCTC TTCAACTGCC AGTATATAAA
2551 AATGGATTTT CAAATAGTGC TAATCAGTGG GATACCCTTT TGTTTTCTCT
2601 CATGATTTTA TAAAGATGTC CTAATATGCA AAAATAAAAT GTTCCCCAT
2651 TCATTTGTTT TTTCAACTTT CCCAAAGGAA TAACTGATAT TACATCTTTT

2651 TTGAAGAAAA CATTCTAAAG TTGAGAATCT TGCCTCTCCT AAAA~~G~~SAACA
2701 TAAAATAGGT TTCAGAATTC CTAATTTGTA GACCATAACT GTATAG~~A~~GTG
2751 GGTCAGGTTG CTGCTATAAT CCATACATGG GTGTGTACTC AGAG~~A~~GGTAA
2801 GTTTTTTCTT TTCTTGGTTA TTCTGATTCT GACTACCACT TCTTCA~~C~~CCC
2851 CTGAATCATT TCATTTAAAT AAATATGGTC ATTTATCACT ATTAAGCTAT
2901 TTATTTTTCT CTTAGAGATT AATGATTCAT CAAGGGATAG TTGTAC TTGT
2951 CTCGTGGGAA TCACTTCATC ATGCGAAATC TGAAATTATT TCGGA~~C~~CCCTG
3001 GAGTTCAGGG ATATTCAAGG TCCAGGGAAT CCTCAGTGCT TCTC TCTCCG
3051 AACTGAACAG GGGACGGTGC TCATTGGTTC AGAACATGGC CTGA~~T~~ATAGAAG
3101 TAGACCCTGT CTCAAGAGAA GTAAGTTACT GATGTAGAAT GCCA~~G~~CATGT
3151 GGGTATGACC CTTGATTTCT CTTCTTCCAA ATTTCTTTCC CCACA TGGTC
3201 TTTCTTTATA TCTTATTGAA TTTATATCCT CCCAAATAAA CATCTT~~T~~TGC
3251 TTCATATATA TGCCATGTTA GACATAGCTT AAATCGTAAT CCTTC~~T~~TTAA
3301 CTCTGCTGCT ATTTTAACT AAGTCAGTAG AACTCTGACC TTAC~~T~~TTTTTG
3351 AGTGTGTGCC GTACTTTTTA CCCTCTTTGT CATGCAAATT CTGTT~~T~~TATAA
3401 GAGTGGTTTT TTTTTTTTTT TTTTGAGAC GGAGTCTCGC TCTGT~~C~~ACCC
3451 AGGCTGGAGT GCAGTGGTGT GATCGTGGCT CACTGCAAGC TCC~~G~~CCCTCCC
3501 CGGGTTCACA CCATTCTCCT GCCTCAGCCT CCCGAGAAGC TGG~~G~~ACTACA
3551 GGCGCCCGCC ACCGCGCCCG GCTAATTTTT TGTATTTTAA GTAG~~A~~TGTGC
3601 GGTTTCACCG TGTTAGCCAG GATGGTCTTG ATCTCCTGAC CTC~~G~~TGATCC
3651 GCCTGCCTCA GCGCCCGGCC AAGAGTGGTT TTTAATTGGG AAT~~G~~AACACG
3701 AAAGTTGCCC ATGGAGCTTT CTAAAAGTTT GAGCCACAT CTC~~A~~TGTCAA
3751 CTAAATCAGA ATCTTTAGTG TTGGCTCCTA ACTATATGTA CTTT~~A~~AAAAAC
3801 CTCTGTGGGT TGGTTTTGAT ATGGTCCCTT GATTATGTTT TTCT~~A~~CTAAT
3851 ACATTTTAGG CAGTTACATC CTTTAGTGCC TTTTCCCCAT ACTA~~T~~AGAAA
3901 TCTTAGAAAA GCATAGCTAT TAGCATCATA TTTTAGTGGA CAAT~~T~~TTAAA
3951 GAGACCAGGC TTATTGTTTT TGTTTTTG TGTTTGGC AAAA~~A~~AGGTCA
4001 CATTACCTAT TTTTCTTGTT AGAGATGACA GAGTAGTGAT ATTT~~C~~TCAA

4051 TGAAAGTTTG GATTTTCATC TAGAAAAAAT ATTTTGGAA GCTTTTATGT
4101 AATAAAAGAA GCATTAAAA GTATTTCTGG AAATGTTATC AATTATCTT
4151 GAAAGTAGAC TGGGTTAATT TGCTTGTGTT TACTTTGGTG AAAGG TGAAA
4201 AATGAAGTTT CTTTGGTGGC AGAAGGCTTT CTCCCAGAGG ATGGAAGTGG
4251 CCGCATTGTT GGTGTTGAGG ACTTGCTGGA TCAGGAGTCT GTGTGTGTGG
4301 CCACAGCCTC TGGAGACGTC AACTCTGCA GTCTCAGCAC ACAA CAGGTA
4351 AGTGGAAGAC TCCAGTGAGG GGGGAGTCTC AAGCATCCTC AAATAGGTTA
4401 CTTGCTATTT GTGGAAGTTT TCAAATCAGT AGCCATAATA GTTACACTTT
4451 TGCTAATTAA TTTTGCATT ATATATTTCT TTATTTAAAA AATTGTTAAC
4501 ATGGCTTTAT CTATATGTTA AGATTCTTCT AAAACTGAGT TTTGCTTGCT
4551 GCATCTATTA ATCAGAGTGA TCAGAATGTT CCAAATGAGA ATATA TTTT
4601 TTAAAAGTTA AAAGTGGCTA TTCTTATGTG GTGTAGATCA CCTCTTATCA
4651 GACCCCTATC TTGAGTTGCA ACCTTTGTTT CTCAATTTAG GAAGTCTTGG
4701 TTTATCTGAC TTAGATTTTC TGTTATGAAT GTTGATTGGC TAAATTTAGA
4751 GTCCCTGAAG TCTAGGCACT AAAGTAAATA CATTGTCATT ACCTGCACAT
4801 GTGATGACTG CCAGTAGAGC TAGACTTCAA GCAATTGCTT CTTTCTCTAC
4851 TTTAGTGTAT AGTTGAGTTT CTGATTCTA TCCTCACCTT CTTAACAGCA
4901 AGGGTTTCAA ATTACACTTG GCTGATTCTT TAAATCTTCT TCCATTACTT
4951 CATTAGTTGT GATCTCCTTA ACATTGATTA TGTCACAGAA GTTAGAGTAT
5001 TACTAATAGT AGGATAATGA TAGCAGCTTA CATTTATTAA CTATCATGTG
5051 CCTGGCACTT TTAAAGTGC TTTTCATGCA AATTATTTA ATCTTACCA
5101 TGACCTTATG CAGTAGGTTG TTGTTTCTA TTCTTCAGAA GAGGCAGTTA
5151 AGGCACAGAG TGCTTAAGTA ATTAGACCAG GGTCACACAG TAATCAAATG
5201 GGGTTTGACC CTAGCAGTCT AAATCTGGCA CCTCTGCTCT TAA CATTCC
5251 ATTTAGTACA ATCATAAACC TTTACTTGCA GTTCATGGTG GGAAATATCA
5301 AACTTGTCAT ATACAGCTTG TTTTTTTTTC GTATTTGAAA GATAGATGCT
5351 TTTACTTTCC AAACATTTTG TAGCATTGTT TCCTGGTTAC TGAGCTCTTC
5401 CAGTCTATTT ATCTTCATTT AATGGTGCTG ATTCTGCCCT TTAGTGGCTT

5451 CTCAATTGTC TGAAAGGTAG AGCCCACTAT TGTGCCTTAT AAGCCCCTTT
5501 CACTATCTGT TCCCCACATT CCTTTTTAGC CTCATCCCCC CATTGTTCTT
5551 GTGTGTACGT AAACCTTATG TTTTAGTTGC AGCTGATTTT TAACTGCTCT
5601 TTTTCTGGC TTTGTGCCTC TACACTGTGT TTTCTTCCTG GTCTCTCTTT
5651 CCTGTCCTTA TTACCACTCT TTGAAACACG TCAGAAAAAC TTTTCTGGA
5701 CTTTGGGCCA CTTGTCATTC CCTGTGCTGA GACGCATTTT GCTTCCAGA
5751 GATCTTGGTC ATTGCTGTTA TCCTCTGTAG GGTCTTCTTT TATCTCCCTC
5801 GTGAGACAGC TCTGGGAAGA AAAAGATATT TATTTCTAAT CCCTGTGCCT
5851 AATAACAGGT CTATTCTCTT GATATCCATT ACTGAAGAAA TGTGTTGA
5901 GTAAGTTCTT GTTTTAATTT TTAAATATAA ATTTTAATT TTTATGAGTA
5951 CATAGTAGGT ACATATATTT ATGGGCTACA TGAGATGTTT TGATACAGGC
6001 ATGCAGTGCA AAATAACCAC ATCATGGAGA ATAGGATATC CATCCCATCA
6051 AGCGTTTATC CTTTGTGTTA CAAACAATCC AATTACAGTC TTTAGTTAT
6101 TTTAAAATGT GCAATTA CTG TTGACTGTAG TTACCTTGTT GTGCTATCAA
6151 ATAGCAGGTC TTATTTATTC TATTTTTTTT TGTACCTATT AACCATCCCA
6201 ACTTCCCTCA GCCCCTCACT ACCCTTCCCA GCCTCTGGTA ACCATCCTTG
6251 TACTCTCTGT GTCCGTGAGT TCAATTGTTT TGATTTTTAG ATCGCACAAA
6301 TAAGTGAGAA CATGTGATGT TTGTCTTTTT GTGTCTGGTT TATTCACCTT
6351 AATGTAATCA TCTCCAGTTC CATCTATGTT GTTGCAGATG ACAGGATCTT
6401 ATTCTTTTTT TATGGCTGAA TAGTACTCCA TTGTGTATAG TACCACAATT
6451 TCTTTATCCA GTCATCCATT GATGGACACT TAGGTTGCTT CCAAATCTTA
6501 GCTATTGTGA ACAGAGCTGC AACAAACATG AGAGTGCAGA TATCTCTTCC
6551 ATATACTGAT GTCTTTTCGT TTGTTTTTTT TAATTGTTTT GATTGAAGTT
6601 GCAGTCAGTT TTTACTGAGA TGCTAGTGTT TGAATCTCTC TTTTCAATTT
6651 TCTCTGTCTC AGCTGGAGTG TGTTGGGAGT GTAGCCAGTG GTATCTCTGT
6701 TATGAGTTGG AGTCCTGACC AAGAGCTGGT GCTTCTTGCC ACAAGGTAAGC
6751 TTGTTACTGG TGCCTCACTG GCTTTTTTAA AACATTATTC CAGATGTCTT
6801 ACAGGCTTCA TCAGCTTTAG GCTGCTTGAA TTTCAAAAAA TTCTTTGAA

6851 CCAGTATAAT ACCAATTATG AACCAGTATA ATACCAATTA TGTATGTGTG
6901 TGTGTATATA TATATAAAC GTAGAGTGAT TTTTTTTGG TGA CTGAAGT
6951 TTTGCCTCTT AGTCTATCAT TATAAAAGT TGTTTCATGT AACTTTTAA
7001 GTCTTTGGGA GTAAGAAACA AAGTCATAAA ACTTGGGGAG GCTGCTAAGT
7051 CCCCAGTTAG AGTTAAAAAT GTCAGCAATA TGTATTTTAA CTTATTCTAA
7101 GAGTTGCTGT ATGGACACAT TCTAAAAGCC CTTCTGGGT TCTGTTGCTG
7151 TTTTCCCCT TTAAGTCTCA TCATTCCAGA TGAGTTTAGT AAACCAGCTC
7201 CACTGATGAC ATTTATATT AGAGGTATCT TGGGGACAAG GAGTGTGAA
7251 GTTAGTGGAG GAGGGCTTG TGGACTTTA AGTTCAACTG TACACACATT
7301 AATAGCTGAG CATAAGCACC AGGTGACTTA TCTAGGGAAA GCTTTTGGG
7351 GTTTTTGTC ATTGTTGTT TTTAAGTCA AAGCATTTG GATGAATTCT
7401 GTCTGCTCTG TTCAGACTAA CTCCAGCTCC TTAGCTTACA GTGC CATAGG
7451 TACTTAGGAA TGGCAAATTT GTTACATGAA AACAAAATCA TTTT GTTG
7501 TGTTTCTCTA AGGTCAACAG ACCCTGATTA TGATGACAAA AGATTTTGAG
7551 CCAATCCTGG AGCAGCAGAT CCATCAGGAT GATTTTGGTG AAAGTAAGTA
7601 TAGCTTTGTG CAATATTTTG TGACCTACGT TTCTCCCAT TTTGACCAT
7651 TTCCTTGTC ACTAATAGCC ATGTCATTAG GCCAAAGAAC TGTGAAAGTT
7701 AAACCCCAG CTATTAAATG TCTATTAGCC CAGTTCCTC AGCCCATCCC
7751 AAATCTTAA AGGCCTACTG ATGCCTCTCC AGGTCTGAGG GTTTAAGGTC
7801 ACTTAGATAG TTATTACCA AACCTAGGA AAGTCTTAGG CTGGGCTTTC
7851 AGTGAAAGGG ACTGTACAAG GTAGTATTC TGGGATACAG TTTTAGGGAG
7901 AAGAAAAGAA GAAAGATGGA ATAGAAGGCT GGTTTTGTT ACTACGATTA
7951 GATCCAATCT GCATTTCCAT GGAACAATC AGATTATTT CTTGCTAAAA
8001 TCTAGCCAAG GTCATCTGGG CATTAAAGCT GTGGGGGTAT TGAAGGGCAG
8051 TGCAGGAGAA GAGAGACGCT TATTAAGCAT AAGCTTTGGC CATCTGAAG
8101 TCACAAAGTA GCTGGCCTGA TTGAAGAGGG ATGGGGAAGA AGATGTTCCA
8151 ACTTCTGTTA TGGTCTAACT TCCTGCCTTC TTGCTCCATC AACTCTGAGA
8201 AATCATTTAG ACAACTTCTA CCCATTTATT TACAAATAAT GTATTTGTTT

8251 AGAAATAATT TTGGAGGGCT GGGCACAGTG GCTCATGCCT GTAATCCCAG
8301 CACTTTTGGG GGATGAGGCA GGAGGATTGC TTGAGCCCAG GAGTTTGATA
8351 CTAGCCTAGG CAACGTAGGG AGACCCAGCA TCTACAAAGA ATTTAAAAAT
8401 TAGCTGGGCT TGGTGGTATC AGCACAGTAA TGACATGATG TGCAGGTACT
8451 GGGGTAGCAT AAGGGAAGGA AACGAGTAAC TAGAGAGGGA TGATTTATTT
8501 CCCCTAGGAG GCCAACTTGA GCTGAGTCTC AGCTGAATTG GTGTTGGGTA
8551 GGTGAGGGAT AAGGGTGGGG AGTAGTCAGC TGAATTGGTA TTGGGCAGGT
8601 GAGGGATAAG GGTTCGGAGT AGTCAGCTGA ATTGGTATTG GGTAGGTGAG
8651 GGATAAGGGT GGGGAACAGT CCAAGCAAGT GAATGTGTCC ATTCAAGTG
8701 TCCATTTCAA GGGAGGGTTA TTTCATAGAA ACATTGTGGG TTA CTCAGGG
8751 AACTGTGAGT AATTCAGCAT TGCTGAAGTG GCAGAATGTG AGTGTAGAAT
8801 GAAATAAATG GAACAGATTT GATTGAGTTT GTAGTAGGGA ATATGGACAT
8851 TGAGTTATAG TTGATCAGCC ATTACAAGTT TTGATGATAA GAGGTTTAA
8901 GAGATTTATT TAATAGAAAG ATGGCTCGTG ATGGCATATT TTGTTGTTT
8951 TTGTGTGTGG AGAGGGAAGA GATGAGAGGC AGGGTGATCA GG TAGGAGGT
9001 TGCTACAGGA ATCCAGATGA AAGATAAGGA AGGTTTGTGT GGGGCTAGAA
9051 GCAGGAATCA TTCAGGAAAA AACTTGATTC ACAATGAGGA TGGGAGTACA
9101 TTTTITAGAA TTAGCTGGGA AACTTTTTTA GAATATATGT GCATGATTCC
9151 CCTTCTGCCC TAGGCCAGTT TGAGAAATAC CAATTTAGAA AGTGAAATAA
9201 ATAGGCTTTG CGTATGTAAG GTGAATAAGA AAAAGTTGAG CAGGACTCCA
9251 GCCAGAACCT CAGGTGTTGG GAATAAAGAT GCCAGTAACA GGGAAGATGG
9301 AGAAGTGCTG GTCTGTAAGG GGTGGGTGGT GAGATCTGTT TTGGATTTGT
9351 TGAAGGACCA TATGTGATTG CCATGTGGAG TATGCAAATA TAAGGCTGAA
9401 GCTCAGGAGA GGCCAGAGCT ATGGACTGAG AGTAGTGGGT ATGTAGGAAA
9451 TTCTGACAGT TTTGGGAACA GATGGACTGT CTCAGGGAGC AGATGCTGTA
9501 CAGGAAGAGT CTAGAATCCA GGGTGGAACCT CTGGGGCATC CAGCTTTGAG
9551 GACAGTCAGA GAGAGAGTAA CAGCACACAG TATACTTTGG GATGGGAAAG
9601 TGCTCTGGGC CTGGTGTTC CCACTGACTT TTTCACACAA ATCCTAATGC

9651 AGTAAATCAA AGGAAATGTA GGCCAAGTTA AGATCTTAGG TCTCAGAAAT
9701 GTGTTTCTCA GTACAAAAA AAAAAAATCA TTCTATGGAG TGATGAATAT
9751 TTTTCCTCTA TCCTGGGGTC AGTAGACTTG TTCTGAAAAG GGCTAGGTCA
9801 TGAATATGTT CAGCTTTGCA GGCTGTATGA TCTGTGTTGC AGCTGCTCAA
9851 TTCTAATGTT GAGGTGTGAA AGTTATACAT GATACATAAG CACATCTATG
9901 TTCCAGTAAA CGTTTGTTTG TAAAAGCAGA TGTAGGCTGT AGTTTTGCAA
9951 ATCCCTGCTG TAACCCCATC ATTTCTTGTC TTCCATTGGA AAAGTTCTCT
10001 TTCTTCATTC CTTGGTCCTT AATCTTTCTG TGGAACTTG CAGATAGAAG
10051 CCTGGGGGTT TGCACCAGGA TAGTCACTAC CATTTGTACG CAGCAGCAAT
10101 TGAGGTACTG TAGCACTTGG ATGTGAGCAG ACAGGAAATG GTCATATGGA
10151 CCCATAATTT ATAGGAATTG CAAACAGCCC TGCTTCATCA GAATCAGAAT
10201 CAATGGCAGG AGGAAAGTAT TGGGTCCTGG ATTAGGTGAT GTTTTCAGGA
10251 CCATCTTTAT TGTGCTTCTT GCAAATGGAT CCTACCTCCA GGAACAGAAG
10301 GGTGTGTGTG TTTCAGCAAC TCTGCCTAAT AGTTTATATA AGAGAAGTGT
10351 TACGATCTAG AAAGAACCCC AGTCAGCCTG GAAGGCAGAA GACCTGTGTT
10401 CTACTTTTTG GCTCCACCAT TAGGGAGGGT CTCAATCTCT AAGTCTATGT
10451 GAGGAGCTGT TTTGTGACCT GCAGCCCCTC TATCACCAGT GAGAGCTTGC
10501 AATCAGAATT TTATTCCCAG TTCTCATCTT GGGGTTTTAT GTTCCGGACA
10551 TATTTTGTA ACTCTTTATG TTTCATTCTT CTTACTTATA AGGTGAGGGT
10601 GAGATCGCTG ACTTGTGTCA TCAAAGAAAC TTGGAATATG TAAGATGGCA
10651 GTAAAATGCT TTCCAAAATA AGGAAGGGCA TTTCAAATTC TTCAAAGTCA
10701 CTGCTGCATA TAATATGAAA TGGGTTTTGT TTGTTTGTGTT TGAGATGGGG
10751 GTCTCGCTGT GTTACCCAGG CTAGAGAGTG CAGTAGTACA ATCAGGGCTC
10801 ACTGCAGCCT TGAACCTCTG GGTTCAGTG ATCCTCCTAC TTTAGTCTCT
10851 TGAGTAGCTG GGACCACAGG TGTGTGCCAT CATGTCCAGC TTATTTTGTA
10901 TACTTTTTGT AGAGATGGGT GTCTCCCTAT GTTGCCCAGG CTGGTCTCGA
10951 ACTCCTGGAC TCAAGTGATC CTCCTGCCTC AGCCTCCCAA AGTGTTGGGA
11001 CTATAGGCAT GAGCCACCAT GCCCAGCCTG AAACATAGGT TTCTCAAATA

11051 TTGACTGCTG GTCAATTTAT TGAGAGGCGT TAGAGGACCT GAGT AATTGC
11101 CAATGACTAA CTTTCATGAAG AATAGCAGTG AAAGTGTGTTT TGTTT CATT
11151 CATGTGGCTT ATTAGTTGTC TTGCCAATTG TTCTGTAGGC AAGTTTATCA
11201 CTGTTGGATG GGGTAGGAAG GAGACACAGT TCCATGGATC AGAAGGCAGA
11251 CAAGCAGCTT TTCAGATGCA AATGGTAAGT TTGGTTTGAT GGATAAAAAG
11301 CCTTGACTGG AACAAATGTA AGTTTGCCAC CCACCAGGAA CTCTTTGGTG
11351 TCCACTTAGA TGCCAGTAAT GAACAGTTCT CTTCTGCTTT AGTAAACTG
11401 CCTAGAACCT TCAGGAAATG AATCCCTCTA GAAAGATCCT TTTTTCCT
11451 GTTATTGCCA AGTTGCTTG TGATTTATTT TCATAGTAGC AAATAATTAT
11501 AACCAATATT CATCACCCAG TTTAAAAAAT AAAACATCAC AGACAAAGGA
11551 AACCCCTGT GTATCCCGTC CCGATGTCCC TCCCCTTCCT CTC CAGAGAG
11601 AGCTGCCATC CTTCAATCAC ATGCATGTTT TCATACTTTT CCCATATATG
11651 TGTATATTAG ATATTTTCT TTTTCTGTTG GATGAACTC TTTGTTTCC
11701 TTAATTCTGG ATTGGAAAAT TCTGAAGACC ATATAATGAT GTCTTGATGA
11751 CTCAAGGCAG GACTTTTTAA TCTTCTAATG TAGGCGGGGC GGC CCCTGAA
11801 GGCAGAGGTG TGTGGACACA AGAAGAGTGC AGACTCTTG GGCACCTGGG
11851 GAAGTAGTGT CCGTGTCACA TTAAATTCAT TTAACTCTT ATATTTTATT
11901 TTAATTTATA CAATATGAAT ATTTTTTAA ACTATGAATT GAAAAGTATT
11951 ACCCTTGAGT AAAATTAATG CCCCAAGAAG ATGTGCCATA TTAACCCTCT
12001 GGCACACTAC CAAGTACCCC CAGGGGCATT ACAGATCTCT GTTAGAAAAG
12051 TACAGATTAC ATTATCCTCA TAACATTTAG AAGCTATGAG ACCTTGGCAG
12101 GGAAGTTTCC TAATGTTTCT GAGCCTCAGT ATTCTCTGTA AAGTGGACAA
12151 CATAATGTCT CCTTACAAGG GTTGAGATGG GCAGGTAATA GCATATATAA
12201 AACAGCTATC ATAGCATCAG CACAGTGTAG GCACTCAAAT GGTAGTTGCT
12251 GCTTTTGTTT TAGTAGACAA ATAATTTTGG AAAGTTTTTA AAGCGTAGTT
12301 TTTATTTCAA AACAACTTTA TTGTGAGTAA AATATGCATA GTGGGTCTAA
12351 TTTAACATTC TGAAAGCTAT TGACTTATTA GAACAGTAAA GGATTATTAG
12401 AGGGCAGAAA CATGGAGTAA GTACTCTGAG ACACAACCTT GCTTCTTTGG

12451 GGGTGATCCA CTACAACTGC CCAGCTTTGG ACAAGTGGTT TTCATGTTCC
12501 CCTGATTTTT AAGTGATTTT TTTTTTTTTT GGCAGGACTT AAAAGGTATC
12551 CTTGACTAAA CAGGAACTTG ACCAAGTAAA TAGTTGGTGC AATTTGAATA
12601 TTCTTTCTTG CTATAAGCAA CAAGTAAATT ATGGTACAGC TTTCTAAGAC
12651 CATATCTTTT CGATTTAAAA ATAGCACTTT ACTCATACAT GTTATGACAT
12701 GGGTAAACCT CATAAAGATT ATGCTAAGTG AAAGAAGCCA GTCATAAAAG
12751 ATCACATATA ATATGATCCC ATTTGTATGA AGTGCCCAGA AGGGGCAAAT
12801 CCACAGAGGC AGAAAGTAGA GTAGTGGTTG GGTAGGGCTG TGGGGTGGGG
12851 TGGGGAAGGG GTGACTGCTA ATGGATATGG GGTTTCTTTT GGGGATGATG
12901 AAAATGCTCA AAATTTAGAT TATGGTGATG GCTATTCAAC TTTGTAATA
12951 TACTTTAAAA ACATTGATTC TTACCACTGA GTTTAAACAA CCAAAAAAAAA
13001 ATCCCAAGGT GCATTGAATT GTGTACTTCA AATGGGTGAA CCTTAATAAT
13051 ATGTAAATTA TATCCAGTA AAGGTGTAA AAAATAGTAC TTAAAGGAA
13101 TCTATGGTAG TTTTGAAAAT AAGGCAGTTT TCCATACTTT GTTAAACTCT
13151 GGAGAAGATG ACACTTTACT ACTGGTACCT GCTAGAGTAA GACTTATCTA
13201 GTATTAACAA AATTAGGGTT TATTAATGGT ATAGGATGAT CCAGGTAATG
13251 GGGGAAAAAA ACCGAGCATC CTGTTATCTA ATGTACTATC CAGTAAACTA
13301 CTCTAGCTTT TTTTCATGAA CTTTTCTAA AGGCTTTCTA GGGCCTCGTC
13351 TTGGTTTGAA AGTTCACAGC TACCCTTCAG AAAAGAAAAC AAAAATCCAT
13401 GGAGTAGGCA GATACAAGTA CTCATGTGAG CATAATTTAC TTTGATTTTT
13451 TAAGTTGTGT TATTCTAGCC CTCAGCCTGT TCCCTGCCTG GGCTCTCCTA
13501 GTGCCCAGTA ACACTGATTC AAGAGGTTGC ATTTAGCTGG GCACAGTGCC
13551 TGATGCCTGC AATCCCAGCA CTTTGGGAGG CCAAGTTGGG CAGATCACCT
13601 GAGGTCAGGA GTTCAAGACC AGCATGTCCA ACATGGTGAA ATCCTATCTC
13651 TACTAAAAAT ACAAAAATTA GCCAGGCATG GTGGCAGATG CCTGTAATCT
13701 CAGCTACTTG AGAAGCTAAG GTAGTAGAAT CACTTGTACC TGGGAGGCAG
13751 AGGTTGCGGT GAGCCAAGAT TGTGCCACTG CACTCCAGCC TGGGCCATAA
13801 AGCAAGACTC CGTCTCAAAA AAAAAAAAAA AAAAATTGGG TGAGAGGGAG

13851 GAATTGAGGA GGATACCAAG GGTTGGGCCT GAACAAATGG AAGCATAATT
13901 ATATGTAGAA ATTTCTATGA GCTACTCTTC TAGAATAGAT GACTCAATAA
13951 TACCCTGCTT GCCATCTACG TTTTCTGTCC TTAATTATTT CCAGTTCTAT
14001 TTCATATAAT GCCTATTTCA GGCCTTAACC CTTCAAGTAA GGAGGTTTGG
14051 TTTCTATACC CTAGGACAGT TTCATTGAGA ATAAATTTTG TTAGGC TACC
14101 TATGTATTCC CTA CTGTGCA GACTACAGTA CAGTACTAGC AGAATTCTTA
14151 GGCTGTTACT AGAATATGAT GATGAATGCC CGGGTGGTCA TCTGTCTCCC
14201 ACCCGGTAGA GTTGGCTTCA GGATTGAGAT ACACGTGGCC CTGGAGGAGA
14251 TTTTCTTCC CGTCATGCTG CAGAATGAGA ACATTTCCAT GTTTT CGTCA
14301 TTGTCTGCTG CTGCCTTTAC CACCTCTGTG GCTCCTCCCT ATTACCTTG
14351 TTCACATCTT ACTCATCTG TGCCCTGTTG TGAAGCTTAC ACAATATGTA
14401 AACAAACTC TACCCTGTTG GACAAATGGA ACACTTGTTT CCTTGTTGTA
14451 GTTACCTGAT AGGTTCTTA GCTCATTATA TTCAGGATCT AGATCTGTAG
14501 CTCTTTTCCT CTTTGCTGT TCTCAGAGGC CACTTTTTT TTTTTAATG
14551 CCGAAAGGAG GATTTTGTT GTTTTACATT TTTTCTTCT TTTGATGAT
14601 TTCTGCGTTC TAAGAACCAA CCCTTGGATG GTTTCTGATT CTAGAGGCAG
14651 GCTTTCAAAG TAGCTTAAAC CTCTTAAAAA ACATCTGTAT CTAGTGGTCT
14701 GAGGCTTGTT TGATTCTGGG AACTTAAGG TCCCCCAGTA ATATTGGTGT
14751 TTGTTCCCCT TTTAGCATG AGTCTGCTTT GCCCTGGGAT GACCATAGAC
14801 CACAAGTTAC CTGGCGGGGG GATGGACAGT TTTTGCTGT GAGTGTGTT
14851 TGCCCAGAAA CAGGTATGGA AATATATTGC AGTTAAACAA CAATAAAAAA
14901 TTTTATCTT ATTAATAA AGGAAAATTT TCTTTCTTT GCTTGAGTA
14951 GGGTATTAAT TATACATATG AGGCAAGGAT GTGCTGCTTT AAATGTGAAA
15001 TGAGGTTAGA GTTAAGAATT AGAAGAGTCC TTTGAGGCCA TTTGGTCCAT
15051 CCTCCTACCT GGTGGACACA AATTTGTAAC AAAATTAATC TAATTGGCTA
15101 TGTAACCA TGGCAGTTTT TATTTGTAAG GAAGGTGTTT GAATAGTTCT
15151 GAATTGACAA CTTTATCAT AATGTTTTAA GTGTGTATGT GTGTTTGA CT
15201 CCACTCCCGC ACAGGGGCTC GGAAGGTCAG AGTGTGGAAC CGAGAGTTTG

15251 CTTTGCAGTC AACCAGTGAG CCTGTGGCAG GACTGGGACC AGCCCTGGCT
15301 TGGAAGTGAG TGGGAGAAGA AACCTTAGAG AAATTCTTGG AACCAGAGTA
15351 GAGGTGGTGG TACACATGGA TACAGATGAT ACAGATGTTT GTGTAACACA
15401 AAAGGATTTT TACGTTTCTT CATTTGGTTA TAAGGCTGTA TCTATCTTTG
15451 TTTCTTCTTT TTTTTTTTTC TTATTCCCTG AAGTCTGAAT TCAACTCGAA
15501 TAGTAGATTT TACGCTTCTT CACAGATTTT ATTGTTCCAA GGCCGCATAT
15551 ATTTTGCATT CCTAACTCTT AAAAGGCTGT GGTTTAAAGG CAGGGTATAT
15601 ATGAAGCCAT TGTACAGAGC AGAAAATGGT GTTTAGAAGG GAAGGCCCCAG
15651 TTTGCAAGGC TCTGTGGGGC AAATGGTGCT TTTGTGGAAA TTAGGGAAAAG
15701 AGCCTCCTTC CTTGGCACAA AATTCCTACA GCAGAGGATC TGCTTGCCAA
15751 GGAGCATGCA GGCTGGATTC AGACCCTGCT CTTTCCTTCC ATTC TCCTCC
15801 TTGGCCCAGT ACCCTTGTGC AGGTTACAAT TTGCCTGTCA TATGTGGCTG
15851 CCTGATTTTA GATAGAAGAT GTATCTCCTC TGTTTCGGTG ATATCTGTTG
15901 TATGTAGACC TCTTGTTTCC CACCAGTATC TGAATGGTAT TATATGATAG
15951 AGCAGAAGAG AAATGTATTT GAATTAAAC CCTAGAGACA AATATGAATA
16001 AGATGAGGCA ATTAAGATGT TTTCAACATT TGGTGAAGTC TTAAAAAAGA
16051 CCTACTGGAG CATAGAATAT TTGCTGAAGT TGTATAATGG AAGGAGAAAT
16101 AGATTTTGAT TTTTAGGACA TTATACCTGG AATGGTTTAG ATAAC TTATT
16151 ATTTTAAAG TCATCCAAAT GCAATGTAAA TATGTAAGGT TTTGTGGGCA
16201 AATGGAGCCT CTGTGTAAAA CAGGAAAAGG CACTCTTCC TCTGGGCAAG
16251 TACAGTCCCA CAGTGGGATG AACCGCTCGC CGAGAGACAA GG GACACATG
16301 GGATTTAAAA CTTCTTGGA TAAAGATATT CATTAATTCG TTCA TTCATT
16351 CATT CATGTT TGCTGGAAAA AAACTCTTC TGGATTTTAT CTAT TCTTTA
16401 GTTAGGTGAG CTTTCGATAT TGTAACACTC TGAGTTTGCT TTAAGACCCT
16451 CAGGCAGTTT GATTGCATCT ACACAAGATA AACCCAACCA GCAGGATATT
16501 GTGTTTTTTG AGAAAAATGG ACTCCTTCAT GGACACTTTA CAC TTCCCTT
16551 CCTTAAAGAT GAGGTTAAGG TAAGTGCCTG AGTTTGTTTC ACC CTCGAAT
16601 GTAGAGGACT TTCCATAGCT ATAGAGGGAA TTTTTTTTTT TTT TTTTGA

16651 GATGGAGTTT CATTCTTGTT GCCCAGGTTG GAGTGCGATA GTGCAATCTC
16701 GGTTCAC TGC AACCTCCGCC TCCTAGGTTT AAGTGATTCT CCTGCTCAG
16751 CCTCCCGAGT AGCTGGGATT ACAGGCTTGC GCCACCACAG CCAGCTAATT
16801 TTGTATTTTT AGTAGAGACG GGGTTTCTCC GTGTTGGTCA GGCTGTCTC
16851 AAACCCCTGA CCTCAGGTGA TCCACCCGCC TCTGCCTCCC AAAGTGCTGG
16901 GATTACAGGC GTGAGCCACC ACGCCTGGCC TATAGAGGGG ATTTATATT
16951 GATATGGATA TATAAATAGT AGCTTTAGAG TAAATAGTAA TAAAAATGGT
17001 GGCTTCCTAG AACTGATTTT TATTTAATAA AATATTGTTT TTCCAGTGAT
17051 TTTGCAAATA ATAGCATTTG TCCCCCACCT TAGATAAAAC AGAAGTAGGA
17101 AATAAAAATG CTAGTTTTTA TTGTTTATTT TGACAAAAGC ATAATTTTTC
17151 CAGTAATGAA GATGTTTTTC ATTTATAACA TTAAATCTT AAGTGGTTTG
17201 TATACCATTA AGATTCTTGC TGAAGTGAGA ACACATCAAA TGGTATCTCT
17251 GTGTAAATTT TAAACATCC TAAGTTGAGA GACGAGTTTA ATGAACTCCC
17301 ATGTAACAT TACTCACTTT CAGTAGATAC CAACATTTTG CAAACTATT
17351 TTCATCGGTC CGCAACTCTT TGGCCTATAC ATATATATAC TTACATATAT
17401 TTTTATTTCC TGGAGTTTTA ATTCTAGAAA TCATATTTTC AATATTTATT
17451 TATAACAGTT AAGGACATTT TTCTTTACAT AACCATAATT CTATTATTAC
17501 ATCTTATCTC TGTGTTGTCT AACACCCAGT CCATATTCCA GTTCTCTGA
17551 TTGTCTAAAA ATGTCACCTT GTATTTGGTT AAGTTTCTTA AGTCTCTTTT
17601 AATCTTTAAG CATAATGTAT TTCTTTTTTT TAAGTCCTCT ACATAATAAT
17651 GACATATTTT ACAGATTTGT TTAATGCCTC TGTAGGTTAG TGATTTACAG
17701 CTAGGGATGA GCTCAGGTAG TGGGATTATT TGATTTGAGA GAGGAAATAC
17751 AGCTATTATA AAGATTTGGA AGTAAATCCA TAACTGAAAG CCAATGACAG
17801 ATCTTTTTTC CCTTCTAGGT AAATGACTTG CTCTGGAATG CAGATTCCTC
17851 TGTGCTTGCA GTCTGGCTGG AAGACCTTCA GAGAGAAGAA AGCTCCATTC
17901 CGAAAACCTG TGGTAAGACA GCTGTAGTAC CCCAGCCTTC TGCCCCATAA
17951 AACGTAGTTG AAAGTAGACA GGTATGGGAT TTCCTTCATC CCTTCTACTT
18001 AGTCCCTTAG TAGAATCAAA GATGCTGAAG TGGGTAGGTG GAAATGGGGG

18051 TGGTTAGGTT TTGATTGATT GTGGATTTC A GTCATGTATT GGTGGG GGT
18101 CTCTAGAGAA ACAAATAATA CATATATATA ATTCGTCCCT CAGTATTCTC
3151 GGGGGATTAG TTCTAGGATT GCCCATGGAC GCCAAAATCC ACACATGGTC
18201 AAGTCCTGCA GTCAACCCTG CAGAACACTC AGATATGAAA AGTCAGCCTT
18251 TTGTATACTT GGGTTTTGCA TTCCTCAAGT ACCATATTTT TGATGTGCGT
18301 TTGGTTGCGG GTATAGAATC CACAATATGA AGGGCCGACT GTATTCATTG
8351 AAAAAAATAC GAATATAAAT GGACCTGTGT AGTTCAAGCC TGTGTTGTTC
18401 AAGGGTCAGC TGTA CTTACA TAGAGAGACG GTGAGAGAGG GAATAGGGTG
451 GGGCGGGAGG GAGAGAGAGT AATAGAGTGT GGATAGATTT ACTTTAAAAG
18501 ATTAGCTAAT GTAGGGGATG GCAAGTTTGA AATTTGTGGG GGCAAGGTTGG
18601 CAGGCTGGAA ATTCAGGTAA GAATTGATGT TGCTGTCTTG AGTATGAAAT
18701 CTGTAGGGCA GGCTGGAAAC TTAGGGAGGA TTTCTGTTAC AGCCTTAAGG
18851 CAGAATTTCT TCTTTTCTGC GAAGCCTCAG TTTTGTCTT TAAGGTCTTC
18701 AGCTGAATGA ATGGGACCTT CCCACATTAT GGGGAATAAT CTGCTTTCTT
18751 TATAGTCAGC CGATTATAAA TATTAATCAC ATCTACAGAA TACCTTCACA
18801 GCAACATCTG GAGTTTAGCA GATAGCTGGG TGCCATAGCC TAGCCAACCT
18851 GACACAATAA AATTAAGTGT TGTAAGTCAT CACGTGCTTT CCCTAGTGCA
18901 TGGTATTACC ACAGAAAAAA CACTAACCAA AGGAATTCTG TGGACGTGAA
18951 AGAAGATTTA GATTAAGCGT AAAAGTAAGA ATATTTTTAT AGCTTTTAAA
19001 ATGTATAAGT GTGTGGTTTT AAGTATTAAA TAATACTTGA AATGTTAGA
19051 AAATAAGATG AGAAAAAAT CTCATAGTTC TACCACTTCG TAATAATCAC
19101 TATTCAAATT TTCTTGCTT CTAGGTTTTT CATGTATATA TCTCAGTATA
19151 GCTATCATCT TGTTTTTGTT AAAAGTGTAG TAGGTATGGG CCAAGGTGCGG
19201 TGGCTCATGC ACTTTGGGGG CCCAGCACTT TGGGAGGCCG AGGCGGGCGG
19251 ATCACGAGGT CAGGAGATCG AGACCGTCCT GGCTAACACG GTGTAACCCC
19301 ATCTCTACTA AAAATACAAA AAATTAGCTG GGC GTGGTGG CAGGCGCCTG
19351 TAGTCCCAGC TACTCAGGAG GCTGAGGCAG GAGAATGGTG TGAACCTGGA
19401 GGAGGCGGAG CTTGCAGTGA ATGGAGATCG TGCCACTGCA CTCCAGCCTT

19451 GGCGACAGAG TGAGACTGTC TCAAAACAAA ACAAAAAAAAA GTGTAGGTGT
19501 GATACATCTG CATCATTTTA AATTGCTGTA TAATACTCGT TTATTC TCGT
19551 TCATTAAATC TCATGCTGTT AGACATTTAC AGTTTTGTCA TTCTC ATTA
19601 TTGTAAACAG CAATGCATGG TACATTTTTG TTCATAAATC TTTTACTTG
19651 ATTATTTTCT AAGTAGCTTT CAAACTCTTT AATCAGTAGA ACCCCCCCCCC
19701 TTTTTTTTTT TTTTGGAGA CGGAGTCTCT CTCTTTCCCC CAGGCTGGAG
19751 TGCAGTGGCC CGATCTCGGT CACTGCAAGC TCTGCCTCCC GGGTTCACTC
19801 CATTTTCCTG CCTCAGCTTC CCGAGTAGCT GGGTCTACAG GCGCCCGCCA
19851 CCAAGCCTGG CTAATTTTTT GTATTTTGG TAGAGGCAGG GTTTCACCGC
19901 GTTAGCCAGG ATGGTCTCGA TCTCCATCTC GTGATCTGCC CGTCTCGGCC
19951 TCCCAAAGTG CTGGGATTAC AGGCGTGAGC CACCGTGCCC GGCCTCAGTA
20001 GAACCCTTTT AACTGCAATG TTAAGAACT CATTATTCAT TCAACACAAT
20051 AGTTCCTAAC CCTGGCCACA CCTTTAGAAA AAAAATGATA TTCAGGCTTC
20101 ATCTAAGAGT TCAGTTCAGT GTGTTGGAAT GGAGATTATA CGTAAGTATT
20151 TAATTAAAAA CCAAAGCCC CCAAGTGATT TTAAACAGCC GCAGTTGAGA
20201 ACCACCGATT AACCAGTGTG TCAAGGGATG GCACTGTGAT ATGCTGAGCA
20251 TAAAAATATT GCACAGGATG AAACCCTGTC TCTACTAAAA ATGCAAAAAT
20301 TAGTCCGGCG TGGTGGTGCG CGCCTGTAGT CCTAGCTACT CGGGAGGCTG
20351 AGACAAGGGA ATCGCTTGAA CTGGGAGGCA GAGGTTGCCG TGAGCCGAGA
20401 TTGAGCCACT GCACTCCAGC ATGGGTGACA GAGTGAGACT CCATCTCAAA
20451 AACATGTATA TATATATATA CACACACACA CACATTGCAC AAGAACAGCC
20501 ACAACATCTG TGCTCACAGA ACATCAGCAT GTGGTCTAAC TTCAAAGTGT
20551 TGTAATAATG CGGTTTGAGA CTAGGTTATG TTTGCTGTGA TCACTAAGTT
20601 AAGCATTAGT GAGCAAGGAG ATTGAGAAAA TCCTTAATAT AAATAATATT
20651 TCTTAATATA ACTATAATTC CTAATATAAC TAAGGTCTTA ATTTATATGT
20701 CATCTGTTTA GTAAAGGTTG GTTTTGGCAT GATTAAGTCT TGC TTGCTTA
20751 ATAGATGTTG GAAGGATAAT TTCATGCTTA TCTTCTTTGG ACAGCTGAAT
20801 CAGGATTAAT ACCCAGATAG CCTTGAACAT AAGTGCTTGC AAAGCACCTG

20851 AAAGAAAATA AGCATCTTAA GCCCAATACA ACACAATGAT GCTAGTCTAG
20901 ATCTTGGATT AAGTGTTTTA ATACTTTTAC TCTAATTGCC AAGTTATCTT
20951 CTTCTAAAT CTTTCATGAGA AAACCCACTA AAAGAATGCT TTTCTTGGT
21001 AGCCTTCCAT TGTGATCATA AAGTTTGGAA GTAAAGTTGA AAATAACAT
21051 GTGGGCCAGG CACGGTGGCT CAGGCCTGTA ATCTCAGCAC TTGGGGAGGC
21101 CGAGGCAGGC GGATCACAAG GTCAGGAGAT CAAGACCATC CTGGCTAACA
21151 CGGTGAAACC ATGTTTCTAC TAAAAATACA AAAAAAAAAA ATTAGCCGGG
21201 TGTGGTGGTG GGCCTGTA GTCCTAGCTA CTCGAGAGGC TGAAGGAGGA
21251 GAATGGCATG AACCCGGGAG ATGGAGCTTG CAGTGAGCCG AGATTGCGCC
21301 ACTGCACTCC AGCCTGGCCG GCAGAGCGAG ACTCTGTGTC AATAAAAA
21351 AAAAAAAAC GAAAATAAAC ATATGAATAA AAGTTAAAA TAGAAAAA
21401 ACAAGAAAAT AACATATAT TTCTGACCTT ATTGATTCTT GATATTTAT
21451 CTGCATGGAA AGCTATTTT TGGCAGTTAT TATTGTTCTT ATTTAGAGA
21501 CGAGGCTGAG CAGGAAGGGT CCTTTGAAAA AGAAAAGATT GCCCTTGAAC
21551 CCCTCTGGCA AGTGGGATGA AGTCTGCTTC CCAGCCTCTA ACGGCCTTCT
21601 TTTCATTTTC CCTTGCAGTT CAGCTCTGGA CTGTTGGAAA CTATCACTGG
21651 TATCTCAAGC AAAGTTTATC CTTCAGCACC TGTGGGAAGA GCAAGATTGT
21701 GTCTCTGATG TGGGACCCTG TGACCCCATTA CCGGCTGCAT GTTCTCTGTC
21751 AGGGCTGGCA TTACCTCGCC TATGATTGGC ACTGGACGAC TGACCGGAGC
21801 GTGGGAGATA ATTCAAGTGA CTTGTCCAAT GTGGCTGTCA TTGATGGAAG
21851 TAAGCTCCTG GGAAGTGTGT CCATGAGCCT GCAAGGGGTC CTGAGCCTAG
21901 GGCCTGCAGA TGTGGTGGTT TGACTGGAAC AGTGGGGAAT CTTTATTTGT
21951 TTTGGCTGTT TGGGTTACTT GTTTTTTTAT TGAATGGGAT ATAAGGTGGG
22001 GTATGTTCTC TCCTGAGAAC CATTGTCCCC CCTCCCCAC CAGTTTCCTG
22051 TTATACTGCA TCTGTGGCCT TCACACGTTT ACTTGCCTGG CCTTTGAAGA
22101 CACTGAAAAC TTGACTCTA GGTAGAGAGG ATGACAACAG TACAGTCTTG
22151 TGGGATTGGG TGTGTTAGCT TTATCTGTTT GCCCTGACAC AGATTTATAA
22201 TTGACCCTTA TACCACCCCA CTTGTGTTGC TTTGTTTCCT GATACAAATG

22251 CTTGCTGATA TATACCTCTC CAGTATGTTT AGTTCATGCA TAAACGTTTG
22301 CCTAATATGA AGATTAGGTT TATATTTTAT AATGAGGTAG AAGGTTTTTT
22351 TAGGGGGTGG GGTGGGAAGG GCAAGACTGA AGAGTGAAGT AGT CACCTTA
22401 ATGAATAGTT TCATTGCTGA TATGAAAGGG AGCACTGGCT TCTAAGATTG
22451 TAATGTGAGG TGGATATTAA TTCATATTCT GTGTAATATT CTACATAATA
22501 CTGATTTTAT AGTCATGTAT TCTATATAGA GAACTTAATC AGATCTGCGT
22551 TATTACCAA TCCACACATA GGAAAGTGCT TTAAGGATTT TGAAAGTATT
22601 AATTCCTTG GTTTAGTGTG GCTTGGTTGC AGGCCAGGT TTAAAGCTAG
22651 AGGTCTGACC TCTGGCCTT TTTGCCTTAG TCCCTGGCAC CTGAAACTCC
22701 AGGTACTGAG ATGGACTCCC CTAGGCCTAG AGGTGACAAT AGCCAATTAT
22751 GGACAGAACC CATGACATTT CCCCATCCCA CACTGTTTTT AGACTTGTTT
22801 CTGAGAAAAA CATTGAAAGT TATTTTTTTG TGAATTGCCA TTATTGTTA
22851 GATATACTGT GATGTTTCTG TGGCTTATCT TACAAATTGA ATATCCCTAG
22901 GTCTAATCCT CTTCTTTCTT TTTCACTGCA GACAGGGTGT TGGTGACAGT
22951 CTTCCGGCAG ACTGTGGTTC CGCCTCCCAT GTGCACCTAC CAACTGCTGT
23001 TCCCACACCC TGTGAATCAA GTCACATTCT TAGCACACCC TCAAAGAGT
23051 AATGACCTTG CTGTTCTAGA TGCCAGTAAC CAGATTTCTG TTATAAATG
23101 TGGTATGTTA TAAACTTTT GCCAAGATGT TCTGAATCAA GTCCCTTCTA
23151 CTCCTACATA AAAGCAAATT ATAGTTTGGT GTTGCCATAG GTCTAGTGTT
23201 TCTCAAAATT TTAAAGTCTG CAGTTGATAT CATTATCATT ATGATATTTA
23251 ATTGCCTTGG GTTTTTGTTT TTTTTTTTTT TAATCCTATA CTGGTTTGTA
23301 CGAGCCATTC CTTTCCCTT ACTGACTTGA AGAGTCAGTT ATTTAAGAAT
23351 AACATTGGAC TCTGGAAATA ACATAGTATG TTATACATTG TTAACATGTT
23401 TTAATCTTTT CATAGCCTTT ACACATATTT TCAGTTGATC TCATCCCTCC
23451 TAGGAGCTGT GTCAGAGATG GGGTTTTCTT CTTTGTAGA TGAGGGAACA
23501 CAGTGTCTGA GGTGTTGTAA TTTGTTGTAA CAAGAATGGA CAAAGGACCTC
23551 AACACAGGTG TTCTAGCTCC TAATCCACTT GTCCTGCCAC AGCCCCATTG
23601 CTGTCAGTTC TTCATTACTT TCCTGATGTG CTGGAGAATC TGAATTTGT

23651 TTTTACTTGT GAGTTCTGTG GTTATGTCAT AAATTCTGCT GGCATATGGC
23701 AGTGTTAGCC TTGTTTTCAA ATATCTTTTG AATTCTCAGA AAAAGCCTAG
23751 ATAGTTGCCA AGAGAGAATA ATCAAAATTA ATTAATTTAA ATGGGAAGTC
23801 CTTACTTTCA TATCAGCTTT TCTGTTAAGT CAGCAGCCCA CTGTGTACAT
23851 GGATCCTATC TGGATGTATC ACCAGTTTCT CTGATTATAG TTTCAGTGTG
23901 TAAATGCTG TTACAGTCCT CCTTAACTT TTCAAAATAG CTTTAAAAAA
23951 AAGTGCAAAT ATGTTTCATTG TCAAGGCAAA AAGAATCAGA TGTAAGCTTT
24001 TGTGGGACTT AACTGTATGA TGCTAATGAG TTTATATGTC ACTTTATGAT
24051 GTATGGTATG TTTTGTCTG CATTCACTTA AAAAATAGCT TTATATCATT
24101 CATCTATTTA AAGTGTACAA TTCAATGGTT TATATGTGTG TGTATGAATA
24151 TATATACATA TGTATATGTA TATATATGTA TATTCACAGA GTTGTACAGC
24201 CATCACCACG ATCAATTTTA GGACGTTTTT ATCTCCTCAG AATGAAACCC
24251 TGTACCACCC TGCATTCATT TTA CTGAGA GAAACTCCC TGTGATGAGA
24301 TAGGACAGGT TGAGAGCTCC ACTTTTGAAA GATTGTTCGG CATCAATATG
24351 TGGGGTTGGC CATAGGTCAG GGGCACCTGG AGGCAGAGAT TCTAGTTAGG
24401 AGAAGCTGTT GTCAAGTGTC CAGGCAGGAG CTAGCAAGAG CTTGAGCCAG
24451 AGCAGTGTTT ATAGAAATGG AAAGAAGAGA AAGATCATAA CAAATCCATG
24501 AAGTAAAAAC CCTGAGAAGT TAAAGAACCC ACTGGGGAGA GTTTGGATAT
24551 AAGAGAATCT GGAAAAAGAG ATCTTGGACT GGAACAGGTC AGGGCTCCGT
24601 GCCCAAGTGG AAGGGAAATT AAGAACTTGG AGTCAAGTGG TAGACATTTG
24651 AGTGGTGTGG AGACAAGTTC GTTGCCAAAG TTTCAAAGA TGGTGTTTGA
24701 TGCATCCTGA GTATCACTCC TTTTCCCCC TCATTGCTTC TTGATTGTTT
24751 ATTATATGCC AGGCTTTTTT CTAGTACTTG GCTTGTGTA CTAGAAAAT
24801 AGTTGTACTT TGTCTACAAC TTGTTGTTCT AGGTGTAGAC AAAAGATATC
24851 AATTAAATAT GATCTATCAG ATGGCAAGTG CTGTGGAGAA AAATTAAGCA
24901 AAATAAGGGG TAGGGAGAGC TTAAGGATAA GGGTTTACAG GGGAAGGTG
24951 TCTTTCCTAT TTAGTGTGAT CCCAAAGGCC TCTCTGTGAA GGTGACATTG
25001 AAGCAGAGAC CTGGTGAGAA TCACAGTGGG AGCCACGCAG ACATCTGGGG

25051 TAAGAGCGTC CCAAGCATTC TATGCTTGAA GGCAAAGAAG AAAAAAGAAA
25101 GAGCGTTCCA AGCAGAGTAA AAAGCAACCA CCGAAGTGCC TGTTGTGTTT
25151 AGGAAATAGC CAGGAGGCCA GGGTGGCTGC AGCAGAGCAA AGGAGGGGAA
25201 GGTGGTGGGT GAGTTCAGAG TGGTGATGGG AATCTGCTCT TGTAGGGCCT
25251 TGC GGCTTTT ACTCCGAGTG AGATAGGAGC CACCAGAGGG CTTAGAACAG
25301 AGGAGTGCAG TGTCTGGCT GAATTTTTTA AAGGCTTGCA TTGGCTGCTG
25351 TGCAGTGAAT AAAGTGGATG AAGAATAGAA AGAAAATGTC TTTAAGCAG
25401 GTGCTTAGGA CTTTGGAGAA TTTGAGGATA TTGAGAGGTG GTTGAAGACA
25451 GTGGAGGAAA TTGTCCACAG CACTGGGCTG AGAGGGTAGC CCCTTCACCT
25501 GGTCTTGCTG AGATGTGGCC TTTGTCAGGG AAGATTATGA CTGATGTGTT
25551 CTTAAGAGGA AAGCAGAGAT TTTAAGGAGG TTGAGATGTG ATTATTTTCT
25601 AGATTGCTGT TTGCCTTCTA GAACTCATTA ATTGCAGACA CCATCCCCTT
25651 AGTATTAGGT GAAATCTTAT AATTACGAT GATAATATTT GCATTTTGT
25701 TTTCCAGGTG ATTGTCCAAG TGCTGACCCT ACAGTGAAAC TGGGAGCTGT
25751 GGGTGGAAGT GGATTTAAAG TTTGCCTTAG AACTCCTCAT TTGGAAAAGA
25801 GATACAAGTA GGTTCTTAAT TATCTTGGGC TTCTGGGAAC AGAATCAGCC
25851 AGCATGCAGT CCTAAATTCA GCCATCTGAT AACAGTTCTA TGCTGTGTC
25901 TGAGTGGAAC AAGAAATAAA GACAACACCC AGGCCCTGAC TTTGCGATCT
25951 GATTGGAGAA GCCAGTCATG TAGTTTGTCT GAATGCCATA TAATTTGATA
26001 GGTAGCAGGA GAGCATGAGT TGTAAGCCAG CCTAGGACCT ACTCCCAATA
26051 GCGCTTGGTT CTCCAGGAAA AATCATGTGG GAAAGATGGA GATGACAATG
26101 ATAAGGCGGA GCTGCATTCT CTTACATAAA TGGGGATGTA TGGGTTGTTA
26151 ACATGGATGA CCTAATGCAG CCTCTGTCTT TGCTCCATCC CAGAATCTAG
26201 AACTTCTGGG TGCTGTGCTT TGAGGCTCCT GGGATGGAAA TCAGAATGCA
26251 TTCTTCCATT GAAACAGTAT TGTAACAAT TGGATGTTAT TGAATACCTC
26301 AGGTACACTA TAGGCATTTG CAAAATGACC TAGAAACCAA ATTATAATGC
26351 CACATCTGTG AGAGAACTTT TTTAAAAAGT ACCACTTATT GAGTACTTAC
26401 AGATTAAAAA AACAAAGTGT AGAGGTTAGG TAACTTACCC AAGGTCATGG

26451 ACCTGGTAAC TAGAGAATTT AGGGTTTGAT TCTATTCTGT TTGATAAGTC
26501 CATGTTCTTC ATTACTAAAC TACTCTGCCT CCAGGGAACA TTTATTGTTA
26551 GATTAATAGA AATAATTAAC TGAGTACAAC AAATAGCAGA ATTTAATAAA
26601 TAATGTTTCT TAAATATATG TGATATATTT AATAAATACA GCAGAAGTGT
26651 TCAACCTCTG TATGATTTTG AGGCTGCCTG TATAATGCTT AGTAGTTTTT
26701 AAAGAGCATT TACATGCATT ATTTCACTTC ATAGACTTGA AACCAC TAGA
26751 GTAGAGATAG AGGACAAATT AGAAAGTATG AGGCAGTTTA GAATATAGTT
26801 TCATTTAAAA AAAATTGATG GGGATAATGC CAATTCGTCT GAGATTTTAC
26851 AGAAGACATG AGTACTCATC GTGATCTTGG GGAAGGGATA GGTTTGGGGT
26901 TGGCAAAGAA TTGGGAACAT TGGGTCTGGT GGGGAAGAAA GTGTCAGTGA
26951 AAACCAGAGG TGGGACTGAT CCTCCATGGG ATACTCTATG TGAATGCAAT
27001 GGAGAGCCTG AGTCCGGGGA GAGATGTTTG AGGAGGAAGA TCAGGCTAGT
27051 GACCAACTTC TTCAGTGGA GCTGCGGATT TGCCACCTGA TCTAAAAGGC
27101 AGGAAGTAGC CATTGTCGGT TCCTACGTGA GGTGACAAGA ACAGTGCGCT
27151 GGTCAGGTGT ATAAATGCTA CCAAAGAATG CATTAGAGAC ATGGAGACCA
27201 TCTCTCAAGC TAGTCAGTCA GTTTAATGTG AGGTGCTTAG GAAAGGACCC
27251 ATTCTACTGC AAGTGACATA CCTGCCAGAG CCTGGTTTGA ATGCTGGTAA
27301 GTCATGGCAG TGGAAAAGCT CTGGGGTTCA TTAGTGTAGG GACTAGGGCT
27351 GGTAATTTTC TTGTGTAGTC AGTTTCCTCA AGTGTTCTCT TCAAATTTAA
27401 AGATTTTCAGG GTATGAGAAA TTAGGGAAA ATATAAAAAC GTATTCTTAA
27451 GCCAGACAAA GATTAATTTT AGATTTTGTA GTATTTGGTA GTATCTCAGG
27501 TTTTGTCCCT CCAAATAATT AGGAGTGGAC TGTATACAAG ATGCTTCAGT
27551 CTTCTTCAT CCAGGAACGT CTCAGTGGTT TTTAAGTTTT ATTCATGTCT
27601 TGGATATTCT TCAATATTTA CAATAGAATC CAGTTTGAGA ATAA TGAAGA
27651 TCAAGATGTA AACCCGCTGA AACTAGGCCT TCTCACTTGG ATTGAAGAAG
27701 ACGTCTTCCT GGCTGTAAGC CACAGTGAGT TCAGCCCCCG GTCTGTCAAT
27751 CACCATTGA CTGCAGCTTC TTCTGAGATG GATGAAGAGC ATGGACAGCT
27801 CAATGTCAGG TATTGCAGTT TTTCCCTGTA CTCCACATGT TAAGCAAATG

27851 GAGTTAGGTT TTTGTCTTTT ATGAGCATAC AACTTTTGAC TTCTATT GAT
27901 CAAGGTTGAG GAGCAGTAGC TTTCTTGTTA GACACACTTA ACAAGAAGGT
27951 TAAGTCTAGT TATGAGCCAT GTCAAAATAA CAGACCAAAA ATATAT CAAA
28001 AAGTGGTGAA AAATAGGATA AATATTAGTA GATGAAGCAA CTTTTT AAAG
28051 ATATGTTAAA TATTTTAATT TAGCATCTAC CCACATTTTT CCAGCGT GAT
28101 TGTTATATGT TATAATTGAT TTTAATAACT GTCAAGCATA ATTAGAGTGG
28151 CTAATTCTCA TGGGCTAATG TGATGGGAAG AAATTTTGTA TAAATGCAGT
28201 CATGCGCATA TATGTGTGTG TGTGTGTGTG TGTGTGTGTG TATACATACC
28251 TTTTCTATGT TTAGATACAC AAATACTTGA CATGGTATTA CAATTGCCTG
28301 TAGTATTCTG TAAAGTAACA TGCTGTCCAG GTTTGTAGCC TGGTAGCAAT
28351 AGGCCATACC CCATAGGCTA GGGGTGTAGT AGGCTACACC ACCTAGGTTT
28401 GTGTAAGTAC TCTATGATGT TTGCACAATG ATGAAATCAC CTAACAACAC
28451 ATTTCTCAGA CGTATCCCCA TCGTTAAATG ATGCATAATT GCACATATAT
28501 GCTTTGTTTT GATGTGGTGA CTTCAAATG CTTCTTCCAG CCTCCTCTTC
28551 TATATATCCT ATTTTGTACC TGACTACATT TACCATTAGA AAGTCTCTAT
28601 TCTTCTTGC TGAAATTCA CTGTTCTCTG GGCCTGAGTT TTGTTTGGAT
28651 TCCTGACTAT ATCTTCATTA TGTAACAGGT TTCAGTTAAT GAATGCTCTT
28701 CTGTGTAATG TAAGCCCTGT TGTATAGTTG ATAGCATTTT CTAGCCAGTT
28751 CCCAGAACTC CTTGTTTCCA GTGTCAATAC TTGGCACCTT TGTCCACTGA
28801 CACTAATCCC CAGATTAATT TGTAATTAAA GCCCTACTGG TGAGATTTCT
28851 GAGAAACGTT GTTGCAAAAT TAGGAACCTT TCCTTTATAT ATATACATTA
28901 CATAAATTTA TAGACATAAA ACATTTTAAT GCAGTCATTT GCTGCTACTC
28951 TTTGACTCAT AGTCTTTCGT GATATTTTGA AAAAGCCTTT TGTTAACATG
29001 TCTAAATGCA GAATATGTTT TAGAAATATG TAGCACTTAA AGTAAGCCAT
29051 TAGATTACCT TTTGAAAAGC GGAGCAATTT ACTAAGTTTC TACTTCTTCA
29101 GATTTGAAAT TCTTCATCAT TAGCTTGTAG AGGCAAAGC TTGATGCAGT
29151 CATCTCATTT GCTGTAAAGG AAATGAGAAG TCATTTACAG TATATTTCTA
29201 CTGCTTTGAC TTTTATTTCT CAAAAGACT GTTTTGTTCATAATAAATAT

29251 TAATGCTTTT GAGGACTACA AAGTCCCTCG ATTTAGTTTA CATTACTTT
29301 AGCTTATACT TTGTAAAAA TACTCTTCTA AATGCTTGT CTGTTT TAGC
29351 TTA CTATTATTT CTCATAATAC CTCTGTAAAG TATATGCCAT TTGCACCATC
29401 ATTTTACAGA TGAGACAACT AAGACATGGA GCAGTTAGGT AACTT GCCTG
29451 AGATCATGCA GGTGGAGCCA GGATCAAATC CCAGCGAGTC TAGCTCCAGA
29501 GTTTGTTCTC TTCTTGACAG ATAATTTATC CTCACAAAAT TTGAAGCATT
29551 TG TAGAGGAA TTCCCTATTG TTATAATGTT TAGTTTTTT GTAGATTGGT
29601 TAAAACTTT GAATTAAATG TTAGCATTAA CATCATTTGC TTTATCACT
29651 ACTTCTTTGT CTCTTTTTT TTTTTTAAT CACTACCTCT TCCTCCTCTT
29701 TTGAGAAATT CTGCTTCCGT GGCTATGGTC CAAGCTACTT GAGAAGGTGA
29751 GGTGGGAGGA TCACTTGAGC CTAGGAGGTT GAGATTGCGG TGAGCTGTGA
29801 TTGTGTCAAC TGCATTTCAA CCTGGGCAAC AGAGCAAGAC ACTGTCCAAA
29851 AAAAAAAAA AAAATAGTGA AATTTTACTT CGCTCCATTG ACTCAGGGAA
29901 AAAATGTAAT GGTGATAACA AATCCCTTC ATCTCATTAG TGAAAATCCA
29951 CAATTTTCCA TCAATCGATA TGATAGTGAT AGAGATATTG AGTGTGCTCA
30001 TTTTCTACA GACCAGCTGC TTAACTATT TTAAGCAGAC AGAAATGATA
30051 TTGGTACCAT CCATGTCTAA TGAAGGCAAT ACTTTGTAAT AAGTTGCAGT
30101 AAGTTGTGGC CAGAAGAGGA ATGATGACTT CACAGTGTA ACAACTACCT
30151 TATTGGGTTT GTGGAAAATG GTGTCATGTA GCAGATGTGG CTTTATCTGG
30201 GCTTTGGTTT GGAGTAGTTT TATCTATTCA TCTAACCGTC TGTC TCTAAG
30251 TGTATAAGTG TGTGTGTGTG TGTGTGTATA GTATTGGGTG TGTATATATG
30301 TATTTTGTCT ACATTGTATT GAAGTAGGTA GTGCAGCATC AAAAGGAAAT
30351 TGTTGATTTT CAAAATCAGT GAAATGTCAC TATTTTGTAG AAAAATGGTC
30401 TGTTTACACT CCCTTCTCCT TTTTTTGTG AGTTCATCTG CAGCGGTGGA
30451 TGGGGTCATA ATCAGTCTAT GTTGCAATTC CAAGACCAAG TCA GTAGTAT
30501 TACAGCTGGC TGATGGCCAG ATATTTAAGT ACCTTTGGGG TGAGTATCAA
30551 GGTGTTAGGA AAGCATGTTA TGA CTTACAT AGATGCTTAG TTC TTAAGAA
30601 CATGTACTTG TATCTTGTCA GTTCAATATT GATTGTCAGG TCTTTTAACT

30651 ACCCTGGAAA ACCCTAAGCT TTAGAGTGGA ATTGGCAAGT GTATTCTACT
30701 CCTGTTTCCT CTTTAAATGA ACTAACGTAC TCTTAAAAA GTGATTGATG
30751 ACTATCGCAG GGACAAAAA CGAAACACCG CATGTTCTCA CTCATAGGTG
30801 GGAAGTGAAC AGTGAGAACA CTTGGACACA GGAAGGAGAA CATCACACAC
0851 TTGGGCCTGT CGTGGGGTGG GGGAGGGTGG AGGGATAGCA TTAGGAGATA
0901 TACCTAATGT AAATGACAAG TTAATGGGTG CAGCACACCA ACATGGCACA
0951 TGTATACATA TGTAACAAAC CTGCACATTG TGCACATGTA CCCTAGAAGT
101 TAAAGTATAA TAAAAATATA TATATAAATA AATAATGCCA GCATTAGAGA
1051 AAAAAAGTGA TTGAAATTGC ATGTTAAGTG TTTTAGCAAA TGTGATGTT
1101 GATGGTTTTT TGCAAAGAGC GCATCAGCTA TTTGTGAACT AGATCTGTGA
1201 ATCTTGCAGA GTCACCTTCT CTGGCTATTA AACCATGGAA GAACTCTGGT
1301 GGATTTCTTG TTCGGTTTCC TTATCCATGC ACCCAGACCG AATTGGCCAT
1401 GATTGGAGAA GAGGTAGGTG AACACGGAGC AGGAAATTTA CTTAAAGTAG
31301 TTACCCAGGG ACTGATGGCA TTAAGTAGAA AGAGCGTGGG CTTTGGAGGT
31351 GGACTTGGGT CTCCACTAAA TGCCTAGACA ATAGTGGGAA ATGATCTCAC
31401 TTTCATAAGC CACACCTTAT TCATCTATAA AATGGGAAAA TCAGTATCTG
31451 TCTATCAGGG TTCAGAAGAC TAAATGAGAT AATATATGTG ATTAGCAACC
31501 TTTTATCCCT AGTTGTACAA ATCATTCAAA GTTAATTTTA TTAGTAGGG
31551 GAAACAGAAA TGTGATCTTG AGAATAGTTT TAGTAGATTT TTATTCAACA
31601 CATACTAGAA TGCCTATAAT TGTGGTGGAT GGTAGAATGC AGTGGCTGGA
31651 AAACAAAACC GCTTGACTAA TTCCTGCTCT TCTGGAACTT GTGATCTATT
31701 AATTTCAATG TAATGATTCC CTTTGTTGGG AGTGTGATGG AATGGACAG
31751 AGTATACTGG TAGAGAATAC TGAGATGTTT GAGGGGTAAT TTGAGGATGG
31801 TGGCTATGAG AATGGGAGTC CTGCATCTGG TGGTCCAGGA AGGCCTCTCG
31851 GAGGCAGTGA TGTGTGTGCT GAGATGTGAA GAAAAAGAAG GCTCTGTCTC
31901 CAGGCAGAAG GAACAACAAA CTCCTTGAGC TTAGCAAGAG CTCATCTTAT
31951 TCAAGGGACT GGATGGAAGT ATTGTGGCTG GAGCTCAGTG ACAGTCATAG
32001 GAGGGAATTT GGGTTCTTTA ATTGAACAAA GATTAGAAAC TTC TTGTGAT

32051 TTTTAATAAC AGAGTAATGT GTTCTGCTTC ATGGTTTGGA CAGTGATTCT
32101 GGCTGCCCAG AAGAGACTTG ATTGGAGAGT GACGAGACTG GAA TATGGGA
32151 TCAACACCGG TTGAGTGGAG TTAGTGAGGG GAAAAAGGAG ATGGGTTTGA
32201 GATATGTGTA GGAGATGGAG ATGTCAGGGC TCACTGATGG ATTGGATGGC
32251 TTCACATTCC GTTTTGCACT GGACCAGCCA CGTCTTAGGT ATCTATCTTT
32301 AGTCCTGATT ACAGGAACTT AGGTGTGAAA TCATAGGGTG GTAGAACTAT
32351 GTGATAGAAA AGGTAGGTTT AACTGATTTG AGATAGAATT GCTTGTGATT
32401 TCAGTTTTAT TTCTTTGCAG GAATGTGTCC TTGGTCTGAC TGACAGGTGT
32451 CGCTTTTTCA TCAATGACAT TGAGGTATCA AGGCTTGGTT TGGTGTGGA
32501 TCCTTTTCAC AGTGTTAGCT CCGAGTAATC TAGCTAGCTT TCACCCATGC
32551 CTCTCTGGCC TTCTCTTGCA GGTGCGTCA AATATCACGT CATTTCAGT
32601 ATATGATGAG TTTTATTGT TGACAACCCA TTCCCATACC TGCCAGTGTT
32651 TTTGCCTGAG GGATGCTTCA TTTAAAAGTA AGTTTTCAAT GTATAAAACA
32701 GAAATGGTCC CTTCTCCAAT GTCTTTTGGA GTCTTGATGA CTTTTTGAAT
32751 TCTTCATTTA TTTTGGCTTT TTATCAAGGA GTCCTAGGCT GGAGAAAATC
32801 TTTAGAGTTA TTTTACTTAG ACCCTAATCT CAACATAATA TCTCAGTTAA
32851 ATCATTCTGC ACTTTAGTAA AGACATCCAA GGAAGGGAGT TCC TTCCTTA
32901 AGCAGCACAT TCTAAAGTTA AAAACTTTTC AGGAAATTTT ATTA TGTAAC
32951 TGATCTAATA TTTTATTTGG AATTACTATG TAGATCCCCA ATGTTTACC
33001 TTCTGTGTAG TCTTTTCCCA CTGTGCCAC CCTCCACTGT ACATCTGCGC
33051 TCCATCTAGT GGTTTGTAGG ATATTGGCTG CATTTTGTCT TCTGTTCCAT
33101 GCCCTATCTA TCTCTGTGTG TGTGGCGTGT ATGTGTGTGT GGC GTGTATG
33151 TGTGTGTGGC GTGTATGTGT GTGTGGCGTG TATGTGTGTG TG GCGTGTAT
33201 GTGTGTGTGG CGTGTATGTG TGTGTGGCGT GTATGTGTGT GT GGC GTGTA
33251 TGTGTGTGTG TGTTCTTAT TCTAAAAGC CAACTATTT TCTTTGCTTC
33301 CAACTTGGA ATAGGGAATC TTTCTTTCAT TGATATGATT ATAGTACACT
33351 GATAATGCTA AGAAATAGAG AAGTTGCCCC AATTCTTAAC TGT GTTTCTC
33401 CACATCATTT GAGAAGCTGT GTATGTGAAT GTGCATGAGG GC TCTGTAAG

33451 AGAGAGGGCA AGTCCAGGG ATGAGCGTGT TCATCAGCAG GGCTGATAGT
33501 CTTGAGGTTT AGTGGGAGAG CTAAGGCACA TGGTTGTTAT TTGTTCTCTT
33551 CTATTTTACA TAATGTGTGC GGTTCATTT GCAGTTAATG GAGAGTGGCT
33601 TGTGTGATA ATTAAGGCTT ATTAGTTAAT GGTGTGTTTA GCATTACAGG
33651 CCGGCCTGAG CAGCAATCAT GTGTCCCATG GGGAAGTTCT GCGGAAAGTG
33701 GAGAGGGGTT CACGGATTGT CACTGTTGTG CCCCAGGACA CAAAGCTTGT
33751 ATTACAGGTA AGCTGGTTTT TCAGACAAGA TAGATAGTCT GATTGTCATT
33801 CAGCCAAGTA CCAAGCATAA TTCTTGACAGG TTGTATTTTA GGCTTTCTTA
33851 TTCTTTGTAT CGTTTATTGT AAACCTTTCC TTGATAGTTT TCTGTTAGCT
33901 TTATTCAAAG GAGTGTGAT ACAGGCTGTG ACCATAAGGC TCAAAGCGAA
33951 ACTTTTCTTG AAAGTCAAGA TAAATATAGA GAACAACAAG ATTCTGCTAA
34001 AAGTGTGCTG ATTTTAGAGA GTTGTGGTAA TTCTCTGTGA AGAGTTAGGT
34051 AAAATGGTGT ATCCTGGCTA TTAAATGTT TTCTACTTAA TTAATAATGT
34101 TACTGCTTTA ATTTATTTAA GATGCCAAGG GGAAACTTAG AAGTTGTTCA
34151 TCATCGAGCC CTGGTTTTAG CTCAGATTCG GAAGTGGTTG GACAAGTAAG
34201 TGCCATTGTA CTGTTTGCGA CTAGTTAGCT TGTGATTTAT GTGTGAAGAC
34251 AATAAGTATT TTATTACAAT TTCGAGAACT TAAATTATG AAAAGCCCTC
34301 ATTACCTATA TCATCAATCA GATTCTTAGA GGCTCTTTTT TTTTTTTTA
34351 ACTTTTTTAC TTTAATGCAG TATTTGTAG TGGAGATTCC TAGCAGAAAG
34401 AATCGTGACA CTCATCATAT AAAGGAGGGC TTCTCTTAAC CTGAGGGAAC
34451 ACATGTGGGT TTAGGTGGC CTGTGAACCC AGGGAGATTG TACACACCAA
34501 ACCTTGTCTT TGTGTATTTA TTCAAGTAGA AAGCCCACAG CTTTCAATAG
34551 ATTTACAGCG GGGCCTATGA CCCAGAAAAG CCTGAGCTAC TC TTGTGAAG
34601 GAAATGACTG ATTTTCTGAA CCTATTTGGA GGAACTTTG TATTGGAAG
34651 ATCTATACTA ATGTTTTGTT TAAAAAGTAG ACCTGAATTC CATGATGATT
34701 TTCTTTGTTT TTTTTTGAG ACAGAGTCTT GCTCTGTCAC CCAGGCTGGA
34751 GTACAGTGGC GCAATCTCGG CTTACTGCAA CCTCTGCCTT CTGGGTCAA
34801 GCAATCCTCC CACTTCAGCC TCCGCGATAG CTAGGATTAC AGGTGTGCAC

34851 CACGCCTGGC TAATTTTTTT TTTTGTATTT TCAGTAGAGA CAGGGTTTCA
34901 CCATGTTGGC CAGGCTGGTC TCAAACCTCT GACCTCAAGT GTTC TGCCCA
35001 CCTCGGCCTC CCAAAGTGCT AGGATTACAG GTGTGAACCA CCGTGCCCGG
35051 GCTTCTGTAA TGATTTTCTG TTGTATGTAT GTGAAGATGT AGTTCTCAGA
35101 CAGTCATGAT GACTAAATTA CACCTTTTAA GAAGGTAAAT GAATG TGGTA
35151 CCTGATTTTT TTATTCTGTA ATTCAGAGT AGAAATCCAG TGATAGTAGC
35201 TTGGCATTGG GGCTGTAATC TGATTATAAC TGGTTTGTAT CATAA TGAAA
35251 ATATGCTGGG CCCATGGAGC TCAGTTTTTG TGAATATCTT TTCTATTCTT
35301 TCTCTGTCTT CTCACAGACT TATGTTTAAA GAGGCATTG AATGCATGAG
35351 AAAGCTGAGA ATCAATCTCA ATCTGATTTA TGATCATAAC CCTAAGGTAA
35401 CTTTCTAAGC TGTCATTTAC TCTAGCTTAC TTTGTACTTA AACTAATATG
35451 ATCTGAACGA AGATGTTTTG TCCTTTTTTT GGTAGGTGTT TCTTGAAAT
35501 GTGGAAACCT TCATTAAACA GATAGATTCT GTGAATCATA TTAAC TTGTT
35551 TTTTACAGAA TTGAAGTAAG TATTTTGAAT AATTCATGTG TATCTTTTCC
35601 ATAGTTTTCT CTCTTCTGT TAAGGAAATC AAGCATAAAT AGCTAGAGAA
35651 GAAAAATTCC TTAAGTTTCA TTTTAAAAA TTGCTATAAC TCTTAGATGC
35701 CAGTTGGTTT TTGCTCTTT TCCGTTCTTT TAAAACAGC CTGTTTAAAA
35751 CTATGTCCTT AAAACATGTC ATTCAGAATT ATTATTTTAC TTGATTTTAA
35801 GGTATACATA TAAACTACT TGTTTTTCCT AGGAGACTGA AATCAAATGG
35851 CATCTTTCTC TCTGATGATC TTTCCCTCA ACTTTTAAAT GAAACACTTT
35901 CAAAATAGAG AAAAGTTGAG AGAATTGTCC AGTAAGCAAC CTA TATATAC
35951 CCCACCTGGA TCGCCAGTT TATATTTTTT TGTATACACA TTCTCATTCT
36001 CTATAATCTG TCCATCCATC ATTCATCTTG TTTGTAGACA AATTGCTAAG
36051 TGAGTTGTAG ACATCAGTCC ACTCTACCAC CTGTACTTCT CCTTGATAT
36101 CATTAAGTAG AGGGCATTCT TTGTGTATGG GTTGGTTTTG TTGTGTTTTT
36151 TCAGGTCATA TTTATCTACA GTGAAATGTC CAAATCTTAA GTGTGCCACT
36201 TAGTGAGTTT TGGCAAATGT AACTTCATG TAACCTGAAC CTC TGTCAG
36251 TTAGAGGGCA TTAATCCTT TTAGAAAGC TGCTTCAGAT TCC TTTCAAT

36251 CAGTCCCTGT CCCATTCCCC AGGCAACTAC TCTTCTGAAT TTTTACCAT
36301 AAATCAGTTT TGCCTGTTCA AGAACTTCAC CTAAATGGAA GCATACAGTA
36351 TTA~~CT~~CTTCT GCATAAAGCT GTTTTCATTC AGCATATTGT CTGAGATT~~C~~
36401 ATCTGTGTTT TTATATGTAT CACTAGTTCA TTCTTTTTTT ATTGGT~~C~~AGT
36451 AGTATGCCGT TGTGTAAATA CACCACTATT TGCTTATTCA TTCCCCTGTT
36501 GCTGGACATG TGGATTGTAC TACCCTGTTT GGGGCTAATG TGACTAAAAC
36551 ATCTACAAAC ATTTGTATAA GTCTTTTGTG GACATGTTTT ATTTCTCAAT
36601 ATTTTATAA TTCAACTCTT TTCCAAAGT CATTTTTATT TATCATCATC
36651 AGCATGCCAG GTGTATGTTA GTAATTTGAT CGCTGGGCTA CATGTTCTGT
36701 TGATGACCAT TCCATACACA CCTGTTCTTA GAGAAGAAGA TGTCACGAAG
36751 ACCATGTACC CTGCACCAGT TACCAGCAGT GTCTACCTGT CCAGGGATCC
36801 TGACGGGAAT AAAATAGACC TTGTCTGCGA TGCTATGAGA GCAGTCATGG
36851 AGAGCATAAA TCCTCATAAG TATGTATGCT GTCACCAGGT GGCATCCTTT
36901 GAAAAACCGA AGTGTGTAGT TGTCTTGTC CAGCCTACTT ACCTTTCTCA
36951 TTCTGGTGTT CTTCACTTAT TACCTCAGAT ACTGCCTATC CATACTTACA
37001 TCTCATGTAA AGAAGACAAC CCCAGA~~ACT~~G GAAATTGTAC TGCAAAAAGT
37051 ACACGAGCTT CAAGGTAGAG ATCCGCTCAC AGAGAAAGTG CTTAAGGTGG
37101 CCGTGACTGC TACTAGTCTT CTGCAGGTGA CAATCACCAT GTCATTGCCA
37151 CACCACAGAT TTAACATGTG ACTTTTTAGT TGCCATTTTA AGACCCTTGT
37201 CAGTTTTTTT CAGTGCTGCC CTCTAAAGCA TATATAAAAG TATCAGAAGT
37251 ATATATTCTT CTGATGTCCA GTTCTATTGA GAAAAATTA TTGCTTTTT
37301 GGTTATGTTG TTAGGTCTGT GGATTTTTTC CCCAAATGAT TGTGTTCTGT
37351 TTTGTTTTCT AAACACTGTT AGGAAATGCT CCCTCTGATC CTGATGCTGT
37401 GAGTGCTGAA GAGGCCTTGA AATATTTGCT GCATCTGGTA GATGTTAATG
37451 AATTATATGA TCATTCTCTT GGCACCTATG ACTTTGATT GGTCTCATG
37501 GTAGCTGAGA AGTCACAGAA GGTATGTGGA GTTCTTACTT TATGCCATT
37551 TGGTTCTTGT TTATATAATG ATAGTGTGAA ACCCTGCTTC TGGTAGTGCA
37601 GTAGCTTTTC TGCTATCACT CTGTGAGTGC AGGGCTGGAG ACAGATCTGT

37651 GAGTTTCTAG GGCCACATT CCTAAGCCCC TGTGCTTATG AAAGTGTTTT
37701 GATTGTGAGG TTGAAGAAGT GAAGTAAAT TGCATGGCTT TTTTGTGTT
37751 CTTTTTTTTT GAGACGGAGT CTCCTCAGT CGCCCAGGCT GGAGTGCAGT
37801 GGTGCGATCT CGGCTTACTG CAAGTTCCAC CTCCCGTGTT CACGCCATTC
37851 TCCTGCCTCA GCCTCTCTAG TAGCTGGGAC TACAGGTGCC CATCACCACG
37901 CCCGGCTAAT TTTTGTATT TTTAGTAGAG ACAGGGTTTC ACTGTGTTAG
37951 CCAGGATGGT CTCCATCTCC TGACCTCGTG ATCCGCCTAC CTCAGTCTCC
38001 CAAAGTGCTG GAATTACAGG TGTGGGCCAC CATGTGCGGC CTAATAATTAC
38051 ATGGTTATTT TTAAGATGAT GGGCATATGT GTGAGCTAAT TTCTTCTCTT
38101 ATAAAGGAAA TGTAACAAGT GGTTTCATGTT CCACTCCGGT TCTTCTCAC
38151 ATGGCTCTTT TTTCTAGTGG AGGGTGGGCA CATGGAGCAC AGAAGGCTCA
38201 TGGCCTCCTT TCCTATGTTG GTACATTTGC TATGATCAAA AACTTTGAAC
38251 ACCACTGGTA TGCATATTTT TTATTTATTT TTTTGCAGCC TCAGTCTCTT
38301 CCCCATGACC TCTCCAAAAA TGAAAATCGG ATCCTTCATC TCTCTGCTTA
38351 AAATACTTCA TGAGCTCCCA TTGTTCCGAG GATATAATTC AGAAGCCATA
38401 ATACTGCTTA AAAACCCTTC CTTGACCTGG CCTCTGTGTA TCTTTCCATT
38451 CTCATTCTT GGTATTGTCT TTTTTCCTC TGCCCATGGA GGAAAGACAA
38501 TGCTTTTGTG CCCCTTCCCT TGCCCCTCAC CACCACATGC CTTGGTGGGC
38551 AGCATTACTT CTGCCATCCA TGGGCTTTGA CTGCTTCCAC CCTCACCATT
38601 CCCCTGGCTA ATTCTCACTA ATCTAGGTTA AAGGATGCCA AGGTGGCCTC
38651 TTCCAGTAA GCCATTCATG CTTCCCTCCA GGGACTGGGT GAGGTGACCC
38701 TCCTATATGC TTCTGTTGCA CACAGTGCCT ACCCCTGCAG ACTACAGTGT
38751 GTCTTTATCT AGAGTGCGGT ATTTATTTAT TTATTTTGA GACAAGGTCTG
38801 GGCTCTATCA CCCGGGCTGG AGTGCAAGTGG CACCATCTTG GCTCACTGCA
38851 ACCTACGCCT CCTAGGCTCA AGCAATCTCA CCTCAGCTTA CAGGCGTGCA
38901 CCACCATGCC TGGCTAAGTT TTGAATTTT TTTGTTGAGA CGGGGTTTCG
38951 CCATGTTGCC CAGGCTGGTC TCAAACCTGT GAGCTGAAGC AATCCATCTG
39001 CCTCGGCCTC CCAGAGTGCT GGGAATGAGC ACTTAATTAT TTGTTGTCTT

39051 GGGTTTTCTT CCTATGTTGT TCTTACATGT ATTTATCCTG TCAGCC CAGG
39101 GAAATTGCAT TAAAAACAGG AAACACCTCT CCATTAGGAA GAAAAACAAT
39151 TTGCTTACAG GGCATGGCAT AGAGCTGGAG ATGATAGTGC CAATAAATAC
39201 TAGGTTGGCA GGGTCTCAGA GTTTTGTGTC CAACTCAGTA TAATTTTATG
39251 TTTGTTTTAA TGTGATCATT TCAGGAGAGC ATGGAATGTC ATGAAACAG
39301 CACCAAGAGC AATGTCTTAG ACTTTTAGGA GAACTTAGA TGCATTTGTT
39351 GAATATCTTC TAGACTGAAA CCTTATTTCC CTTATTAGCC TATGAAATAA
39401 ATGATACTGT GAGACTTAGT TAAGGAAGTT ACTATTATTC CAAGTGTAAC
39451 TTATTAATAT CCGTATGTGA AAGCATTTTT GCCAAAGCTT GTTTGATGTT
39501 CAGCTGACCC TTGCACAACG TGAGTTTCAA CTGTGCGAGT TTGAACTGTG
39551 TGGGTTTATC TAAATGTGGA TCTCTCTCAA ACACAGTTGG CCCTTTGTGT
39601 CCACGGCTTC TGCATCCACA ATCAGTGTGG ATCAAAAGTA CAATATTTGC
39651 AGGATTTGAA ACTTGCAGAT ACAGAGGGCC AACATTTTGT GTATCCAGGC
39701 TCCATGGGGT CAAATGTAGG ACTGGGGTAT GCTTGGATTT TGGTATCCTT
39751 GGGGTGTCCT GGAACCAATT CCCCATAGAT ACTGGGGGAC AACTGTAGTT
39801 TGATTTTATA TATTATATAA TATGCAGTTA ATATATAATA CACATTTAAA
39851 AATTATGTAG CTTTGGGTTT ATTGCTATAT GTAAATGCTA GTTTC TATTC
39901 CTATATATGA ATATCACAAG TAATAAAGTT CTCATTAATC ATTTT TTTAG
39951 GATCCCAAAG AATATCTTCC ATTTCTTAAT ACACTTAAGA AAATG GAAAC
40001 TAATTATCAG CGGTTTACTA TAGACAAATA CTTGAAACGA TATGAAAAAG
40051 CCATTGGCCA CCTCAGCAAA TGTGGTAAGT GTGGGGATTA GTATGTTTAT
40101 CTCTACTTCA GATCTTCTTT GGAAGTAGGC AAGGTATAAA TTAAACTGTT
40151 AGTTTAGACA GTGACTGATT TCACTTCCCA CTCCTGAAAA CTCTAACAAT
40201 TATGTATGCT CACGTTATTT TGTCTGTGT TCTGAAAAGC TGAAGGTAAT
40251 CACTTTTAAT GAACTGGAGG AGCTCCCTAG GTAAGAACGT CAAGTAGATC
40301 CTTTTTTGGT TAAGAATGAG CACCTGTGAA GTTAACTTCA GTGTCTCAGA
40351 ATCAAAATTG GTTGACAGTT CTTCTTCTC ATGCTGTTTG CAGACATGTC
40401 AGGGAAACTC TGCTTGTCTG GAGAGAGTGA TGAGGCCACC TCCCCGTGCC

40451 CTGCAAGACG CAGTTTAAAT TGACAGTGAT GGGGTGCCAG TTGTTCTTCC
40501 CATGCTGGAA CAGTTGTGAT TCTTTACTGA GGACTGATGG GGGAAAGGAA
40551 GAATCACCTG GGGTGCATGT TAAGCCTTCA GCTGCTGGCA TCCTTGGAGA
40601 ATCTGATTCA GGTGGTCTGG GATAGGACTG AGGCGTGCAT GTGTCTAATA
40651 AGCTTCCCAG GTGATGTCTT TTCAAGGAGG CTGAGAAAAC ACTGGGCTGG
40701 AAAGCTGGGA CTCTTAAGTA GGATGCTGAT CCCAATCAGT GCTGCTCTTG
40751 CCTCAGAATC TGCAGTGGTG CTCATTAAAA ATTCAAATTC CAGGATCCCA
40801 TTCTTCAGAT TCTCTGATTA TTTAGGTCTT AAAAAGTTCC TCATTTATTT
40851 TGTTTGGTGA CCATTGGTAT AAATGAAGTC CATTATGCTT CCCATGTCTT
40901 AAGCCTGTCT TTGTGTGAAT CTTTTTCCTG CAGGACCTGA GTACTTCCCA
40951 GAATGCTTAA ACTTGATAAA AGATAAAAAC TTGTATAACG AAGCTCTGAA
41001 GTTATATTCA CCAAGCTCAC AACAGTACCA GGTATGTGGT ATGTGAAAAT
41051 GAGGCTCTCC TGGTTTTGCT TTTTGCTTTA GTAGGAAAGG AGTGAGGATC
41101 CTAAGTTCAT AACACCATCC TTGGCTTCAA AATTTATCTT AAAACTAATT
41151 AGCCTCAATT TGAACCTCTT ATCTGGGAGA ATGGTCCTGA CCTGTTCTCT
41201 GATTCCTCAT CTGGAATACC ACAGCACCTT CCTCGTGGGG TTCCCTGCTT
41251 CTTTCCCACC CCTCCTCTAG CCCAACCTTA CTGCTGTAAG TCTGATTATC
41301 CTAACAAGTA CAGATCTTTC CCATATATTT CAGCATAAAG GGAAATTTTT
41351 GTTTGCTTGA AAAAGCATCC CTTTAGCTTT TTTTATATAC CACACACTTT
41401 GCTTCTAAGT TAAATGTGTT ATATGATCCT CTTAACAGCC TCATAGGGTG
41451 CTGTACACAA TTTGTAGATG AGGAAGCAAC TTGCCTGAGG ATCCAGAGCT
41501 ACAAAGTGCT GGACCTGGGA TACAGAGCCC AGGCTGCCTG ACCACCCTGC
41551 CCATGCCATT AACCACCACT CTACCATGCC ACCAGCATCA CCATTTTTCAG
41601 TTTGTCCTCA GACAATATAC ACATCTTTCT TTGATCAAGC CCCTGCCAGC
41651 TTCTTTAGCA CCAGCTTCTG CCACTGTCCA CATTCCCAGT TACTTGTAGG
41701 TAGTTCTACA GATGTCACAT CGTGTGATTC CTCTGTCATT TCTCTACCCA
41751 CCAGCCTTCC TTTAGCCCCA TTTGTCCATC AGAACCCTTG GGTTACTCCT
41801 GAATGCCATT CCTGGACCAG GCGCCAAACA CTGAGCCCCC AGAGCAGCCT

41851 GCCCTCGCCT TGGTGATTGC ATTTGTCAAA CTGCTGATTA GCTGGTTTGT
41901 CACCTCCACC AGGCTGTGGG CTCCTTAAGG GCAGGGACTC CATGTTGSTAT
41951 TCCTCTCTGA ATCTCTGGCT AACATCCAGC CTGGAGAATC GAGGATTTGG
42001 CCAGTGGATA CCTCTTTGCC CTGTGTTTCT GTTCTCTTCC AACTCTCTC
42051 TGCTCTAGTC AACTGGCCG TCCTGTACT CCTCAGACCT GCTATACACA
42101 TTCCTGCTGC ATGGCCATGG TGCCTTCTGT GCCCTCTGCC TGGTGCCCCC
42151 TATCTCATCA CGTGGTTTAT TCTCCTGACA GCCATTAGAG CTCACACTCC
42201 CTGAGAGCTG CAAGGAGACT GTCCTCTGTC CCTTTACTCA CGTTTGCCAT
42251 TATGCTATAG ACTATATTTT GTCCCTAAGT CCATCCTCTG TTAATAAAG
42301 AGCAGCAACT TGGTGGTGGT TCTTATATGG TTTTTCATTT GTTGGTTTT
42351 ATTTTTTGCC TTGCTGTAGT ATCCATACTG CCCAGAATGG TGCATATGTA
42401 GTTAAGAGTA ATTATTTGTT GAGTGAATAA ATGGCACATC CTCAGTAAGG
42451 TTTTGAATGA AAAAATGACT GTACTAACTG ATCAACTGTA AGATTTCCC
42501 AGGTAATTCT TTCAAGGGAG TTCCAAGTAT AGGAACTAAG GCAGCTACAC
42551 TGGAGCTTTA GAGAAATGAT TGTCATATTT CTCCTCAGT CCTAAATCTC
42601 CTCTTGTCAC AGGATATCAG CATTGCTTAT GGGGAGCACC TGATGCAGGA
42651 GCACATGTAT GAGCCAGCGG GGCTCATGTT TGCCCGTTGC GGTGCCACG
42701 AGAAAGCTCT CTCAGCCTTT CTGACATGTG GCAACTGGAA GCAAGCCCTC
42751 TGTGTGGCAG CCCAGCTTAA CTTTACCAA GACCAGCTGG TGGGCCTCGG
42801 CAGAACTCTG GCAGGTAAGT ACAATCATTT ATATGTTTAC ATCTACAAAG
42851 GTTTTAAAAA ATTTATTTCT TTTGTTTGGT AATTTTGCAA ATAAATTTAG
42901 GGCAGAATAC TCTGAGACAG TCTTGTTCTC ACTGATAAAA ATTAATTTAG
42951 AATGCTTTAA AGGATAAGCT ACTACAGCAA GAGTCCCAGA ATGCAGTGGC
43001 CCAATATGGA AAGAAGTTA TTTCTCTCTC CCATAGGGAT TTATAGGCCC
43051 TTCCGTTGTG TGGCTCTGCA ACCTTTTAGG CAGATGGTTG TAGCTGGGTT
43101 ATCTCCACAG CTGTGGGGAA GGAAGGAGAG TGGGGAGAAG TTAGAATCAT
43151 GGTAAAACAT TTACCTTTAA GTTGGAAATG ACCTGGATGG AAGTTAAACT
43201 ATCACCTTCT ATTCCATCTC GGCCACGCCA TG TAGCTGGA TGGGCTGTGC

43251 CCTGTAAGAA GGTAAAGATG AATTTTGGGA TGGGTCCATT CTGTTATAGA
43301 CAGTAGGTTG TTGGAATAGC CAGGAATGAG GTGGGGAAAA TAAAAGGCCA
43351 AATGTCGAAG CATTCTGAAA GCAAAGGCAG TTTAGCTGCG TCAGGGACAA
43401 GGGTTGCCCCG AACCAGAGGC GAGGCTGGTA CCAGGGGCTC TAGTACCAGA
43451 GTGGAGGAAA GGGTAAGGAC ACCTATGAAA AGAGATGAGC AGAAGCTCTG
43501 GTCATCTCAG CAGTGCTTGA AGTAAAGCAA TGA CTGGTAT ATTTT TTTCC
43551 CTA ACTTGTA AATATTGTTG AGATCTCAA GAAAAAATA AAAAGCAGTC
43601 CTAAAAAAT TCCAACTCT ATCCTGTAA ATTTTGTTAA ATTTATGTAC
43651 CAGTCCTTCT TTGTCATTTG CAGTATTCTT TTTTCTTGG GATTATACCA
43701 GTGTATGGGA TTATCACTTT TCTTTTCTG GTTATTAGCC TTTCCCAAAT
43751 CCCTCCGTTT CCATGCTGGC CTCTTTTAC AAATGTCGAG AATCCTTAT
43801 TTCAGGCCTT TTAGTTATTC GTTCGGTCTC CATTGTTCTT TCTGCTTTA
43851 GAAATTTATG ATATTGGTTG TTTATACCTT CTATCTCTGT TCTGGATCT
43901 CTTCTATTCT TTACAGCTCT TAGCTTGCTA TTTCCCATGT CTTATGAGGG
43951 AGTATTTCTA GTTTTCTCA GATGTTTAGC AAAAGTAGGT GGGGAGGGCA
44001 GTGGTCAAAG ATGTTTGAGA AATGTTACAC ACTGGAGTCA CTCTGTGTGT
44051 ACATTTAACG TAGGCAGTTT ACACAAGAGA GCAAAGAAA GGTAACTATT
44101 TAAATAGTGG AGGTGATTTT ACCTACTTTT TTAGTGATA TATGCACTGG
44151 AGTGAGCATG CAATGAGAGA CCGGAATCTA CCAGCTCCTT CGAAAGCCTT
44201 GGGTTCTCTG TGCCTCTCAT TGTGGTTTAT CTCAATTGGG CTGAGAGTGA
44251 TTCTAGGATC TAAAGACACT GCATGACTCA AACATAAGTC AGCTACCTCC
44301 ATCTAGTGCT CAACCAAAGA AATAGTGGTC TCTTACTGTT AAGGGACGAA
44351 GTGGTTTAGT GAGAGATACC AGGTCATTTT CCCATATACA TGC TTTGGAA
44401 GCATCTTTCA AGGCTAATTT TGGCTGTATA TGATTTTCAA TTCC TGTGCT
44451 AAATTTAGAT TCTAGCTGCC ATTTAAGATA GGACTCTGTG GTGTATATAC
44501 CTATTCCCTC ACAGAAATTC AGAAAGTACA TAGTTTCATA CATAATAAAG
44551 ACATATTAAA GAAGCACTTG AGCTAAAGTA TCTGTTTAAAC TTTGTAGTCA
44601 ACTGCTGCTT ATTGTCTCTA CAGGAAAGCT GGTTGAGCAG AGGAAGCACA

44651 TTGATGCGGC CATGGTTTTG GAAGAGTGTG CCCAGGTAAA CTCAATTCCT
44701 CCCTTCTAAA CCCCCAGTC AGCAAGAAAG GTCTTCTCAA TTGTATCTTA
44751 GTGATCATGA AAGTTAAAGG AACTGTGCAT AATTGTTAAG TCCAGAGATA
44801 GTGTTTGCCC CAGAGGTCTT ATCTTGCTGG CTTGACTTGG AAATCTAAAT
44851 TTAGTACATC TCTAAGTTTG GTGAGGTAGA ATATGAAGGT GCTCTACTTT
44901 AACATACCAC TGGTTTGACC TTGGTAGAAA GTACTTAATT ACATCTCAAG
44951 GTAGCTGTGC TTTTAAAT TGAGTTTGCC AAAGTAGAAA CAATGAGAAA
45001 GGACCATTAT AAAACAGGAT CATTGAAGGC TACATACTCT TGGCTTTTAC
45051 TCTCATTCTC CCTATTGGAA ATGTCTCTTT TACCTCAGGG ACCTGGAGGT
45101 ACAGCAGATT ATAAGGATAA GTACCCATAT GAGCATTG TAGTATTATA
45151 GGATTTATTA TGAAAATAAT AAAACTGCAG TAACACTGGC CACAGACTAA
45201 CAGTACACAG GTGCACAGTT GACACCAGGG ATTATTGCCT TGTAGAGTTT
45251 TGACCTTTGA TGAGAGAGTG TTTTACAG TTGTTACTGA TAGCACATT
45301 ATGTAACCTA ATTGTGCTTT AAAAATATTT AATTGTCTCT TGTGTAATAA
45351 CAGTAAGTGA AAGACGATAA CTAAAATTTT ATATAATTAG ATCCTGGAGA
45401 GAATATTTGT TGGGTGATTG AATTGAAAAT ACCAGTGAAT GAAACATACC
45451 TAAAAGGGTA GATAGGTTGG GTTGGAAGA TATACCACAT CGAGGGTTAA
45501 TTAAATGGAT AAGATGTCAT TATCTTTTTT TCTTTGTAA GGAAGATTAA
45551 TGCATAAAAT TATTTGTGT AATTACATA CAATAAAAT ATGTGTTGTA
45601 CAGTTGTATA ATTTACATAT AATAAAGCTA ATTCACCAAT TTAGATGAA
45651 GAATTCAGTA CATTTGGACA TATGTTTGTA GCTGTGTAAC CACCATTGCA
45701 CTCATGATCT AGAACATTC TAACACCCCC AAAAGTTCCC TACTTCCCCCT
45751 TTTGCAGTCA GCCTTCTCCC TCCACTGCCA GCCTTTGGCA AACTGATCAG
45801 TCAGTAAAGT TTCACATTAT CTAGAAATTC ATATAAACAG AACCATATGG
45851 TATGTAGTCT TTTAATCTG GCTCCTTTCA CTCACATAGT GCATTGGAGA
45901 TGCATCCATG TTGTAGTTTA TTCCTTTGTA TTGCTGAATA GTATCCCATT
45951 ATATGTATAT GTCAGAATTT GTTGATTAC CAGTTGATGT ACATTTGGAT
46001 TGTTTTCACT TTGGGGTTAT TATGAATAAC GCAGCCATGA ACATTCTAGT

46051 GCAGGTCTTT ATGGGGACAG GAGTAGGAAT GCCACATCCC GTG~~G~~TAAGTG
46101 GATGTTTAAC TTTT~~T~~AGGAA GCTGCAGAAC TAATCTGCAG TGGCC GTATC
46151 ATTTTGCATT CCCCTCAGTG ATATGTGAGA GTGCTTCAGT GACTC~~C~~TATA
46201 CTCACCAACA CTGGGTGTAT TACTGTGACA CTAGATGTAT TATCT~~A~~TTGC
46251 TACGTAACAA CTTACCTTAA AAGCTGGCAG CTTAAAACAA CAGAC~~C~~CCTAT
46301 TATCCCACTT TTTCAATGGG CCAAGAATCT TGGCTGGGCT TAGCT~~T~~GGGGC
46351 CTCTGGCTCA GGGTCCTTTA CAAGGCTGCA ATTAAGGTAT TGGC~~C~~CAGGGC
46401 TAGAGTCATC TCAAGGCTTG ACTAGTTTTT AATTTCA~~T~~TTT TCTAAT~~G~~TTT
46451 TATTACTAGT ATATAGAAAT ATAGCTGAAG TGT~~T~~TTTGCAG GGAG~~G~~CTGTA
46501 TAATTGACCT TGTATCCTGC AACCTTGCTA AACTCATTTA TTAGT~~T~~TCTAG
46551 AAGCTCTTGG GTGTATTCTC TAGGATTTTC TACATCAACA AACAT~~G~~GGTTT
46601 CTATAAATAT AGTTTTATGT CTTTCTTACA ATCAATACTT TTTTCTATCT
46651 GTATTGCATT TTCTAGGGCT TCCAGTGTGG TGTGAATAG AAGT~~G~~TTAAG
46701 AGTGAACATC CTTGCCTTTT TCCTGATATT GGAGAAAATT CACTTGTCTT
46751 TTAGCATTAA GTGTCATGTT TGCTTTTTTA AAATTTTATT CTATATTATT
46801 TTATTTTTGA GACAGAGTCT TGCTCTGTCA CCCAGGCTGG AGTGCAGTGG
46851 TGTGATCTCA GCTCACTACA ACCTTGACCT CCTAGGCTCA AGC~~G~~ATCCTC
46901 CCACCTCAGC CTCCTGAGTA GCTGGGACTG CAGGAACATG CCACCATGCC
46951 TGGCTAATTT TTGTATTTTT TG~~T~~AGGGATG GGGTTTTGCC ATGTTGCCCA
47001 GGCTGGTCTT GAACTGTTGG ATTCAAGCAA TTCGCCTGTC TCAGCCTCCC
47051 AAAGTGCTGG GATTACAGGC ATGAGCCTCC GTGCCTGGCC TGATATTGCG
47101 TTTTTTTTTT TTTT~~T~~TAATG CTCTCTATTG CAGAGTTGGC AACTACAAC
47151 CTGTGACAAA TCCAGCATGC CACCTGTTTT TG~~T~~AAATAAA GCTTTATTGG
47201 AGCATAGCCA TGCTCATTAG TTTACATCTT GTGTATGGCT GCTTTAACAC
47251 TACAGCAGCA GAGTTAGAGT TGTGACACAG ATAGTTTGGC CCATAAGGCC
47301 TATATTTACT GTCTAATCTT TTACAGGAAA AATTTGCCAA TTCTGCCCCT
47351 CTTGGTTTGA GGAAATCCC TTCTGTTCCCT TGT~~T~~CTGAGA GTTTGTATCA
47401 TGAATGGGTG TTAAATTTTG TCAAATGCAT TTTCAACTAT GAAGGGTTTT

47451 GTTTTTAGAC GAGTGATATG GGGGACTAGG TGATTGATTT TCTACTGTTA
47501 AACCAACCTT GCATCTCTGG GTTCAACCCC ACTTGGTATT ATAGATTTAT
47551 TACCCTTTTT CTCTTGTCAG AGATTAGATC TACTAAAATT TTCTTGAGGA
47601 TTTTGTGTT TGTGTTTCATG AGGGATATTG TAGTTTTTTC GTGTCTTTGC
47651 CATGTTTTGG GTATCAGGAT AATGCTGCTG TCATTGAGGG GTGACAAAAA
47701 TGAGGGGTGG TGTCTTTTAC ACTTCTGTTT TCTGGAGGAT TTCATGTAGA
47751 ATTGGTATGA GAGTCTAGCT TATGGTTAAA AACCTATGTG TGATGTTTCA
47801 GACCTGACCA TAAACAATTA CAGACTTTAC CTAGGAGGCC ACATGGGGAA
47851 AAGCTGCCCT CCCTACACCA GACTTGCGT ACTGCCAATG CATTACAGTT
47901 TCTAAAGGGA GTTGCAGTCA AGGACTCAGG GCCCCCTGTT AGTCATGCTC
47951 TTGTAACAGT ATTTGCATTG AGAGTCCTGG CACTTTCATT CTTAGGTCTC
48001 TCTATCTGAG GACATGGGCC AAGGTCTTCT TCAGGCACCT CTGCCAAGGC
48051 CTGTTTATGC AAGAAGGAGT GGAAAAACCT TGACATTTTT TTCCACTGTG
48101 ACTCACTACC CAGTACTTTT CCACCCTTAG CCCCCTTCCT TTGCACCCAT
48151 ACCCCCAAGA TCCATCAAAC TGCTAAAGCC TTTTTTCCA AGCTCCTTCA
48201 ACAGTGAACC AACCTCATG TCTGTGTGGA TCCAGCTGAC TCTTGACTAG
48251 TGAGTTGTTT CTTGGGAAAA AATGGAACAG AGAGAGTTGG TGC TTTCCTT
48301 GGTTTTAGCC TCTTGCTTAT ACCAATGCAA TGCCTGAAGG CTTAATTCAT
48351 TTTTGACTTG TTGCTTTGAT CAGCTACTCC AACACCTGAC AGCTCAGCTC
48401 TTTCTCCCAG CTCTTGGGAG ATATTTTTTT CTTTAAATGT TTAGTAGAAT
48451 ATACCAGTAA GGCCATCTCG GCCAGGAGTT TTCTTTAATG AAAGTTTTTC
48501 ACTATTAGTT CAGTTACTTT AGTAGACATT AACCTATTCA AGTTTATCTG
48551 TGTCTTCTGG AATGAGCATT GGTAGTTTAT GTCTTCAAG TAATTTGTTT
48601 ATTCATCTA AATTGTCAGA TTTATTGGTA TGAAGTGTTT ATAGTATTCT
48651 CTTATTTTAC TGTCCGTAGG GTCTATGGTG ATGTCCTGTC TTTCAATTGA
48701 GATATTGATG TGTCTTCTTT TTTCTGATTA TTCTGGCCAG AGGTTTATCA
48751 ATTTATTGA TCTATTAAA GAATGAACTG TTTCAATTGT TTTCTCTATG
48801 ATTTTCTGT ATTCTATATC ATTCTTTTTT TATTATTTTA TTATTTTATT

48851 TGCTCTTTAT TTTTCTAGTT TCTTAAGGTG ATGGCTTACT TTTATTTT
48901 TCTTATTTT TTCTTTGTT GTTGTGTTT TTTAAAGAA ACAGGGTCCC
48951 ACTCTTGCTC AGGCTGGAGT GCAGTGGCAC GATCATGGTT CACTGCAGTC
49001 TCAAACCTCCT ACATTCAAGC TGTCTCCCC CCTCAGCCTC CAGAGTAGTT
49051 GGGATTACAG GTGCATGCCA CCATGCCTGG CTAATTTTAA ATTTT TTTG
49101 TAGAGATGGG GTGTTACTAG TTGCCACGC TGGTCTGAAA CTCTGGCCT
49151 CAAGTGATCC CTCCACCTCT GCCTCCCAA GTGCTGGGAT TCCATGTGTA
49201 AGCCACTGTG CCTGGCCAAG GTGATGGCTT AAAGCTATTG ATTTGAGATG
49251 ATTCCTTACT TTATAGTTTA AGCATATAAT GCCATAATT TCCTCAAGCA
49301 CCGTTTTAGT TACGTTATAC AAATTTTGAA ATGTTTGTGTT TCAATTCCT
49351 AATTCCTT GTGATTTCTT TATTGAACCT TGGCTTATT AGAAGTATGT
49401 TTAATTGCA GATATTGGAG ATTTGCCAGC CATCTTTTG TTATTAAAT
49451 CTACTTTAAT TTGTTGTGA TTAGAGAACA TACATTTTAT TAATTTAAAT
49501 TTATAATTTA TTTAATTTA TAATATGGTC TGTTTTACAG AATGTTGTGT
49551 GTGTATTTGA AAATAATATG AAAGCTACTA TTATTGGATG GAGTGTCTA
49601 TAAATGTCAG TTAGATTAGG TTGATCATGC TGTTCTAGCT TTTATATCC
49651 TTATTGATTT CCTCACTACT TGCTCTATCA ATGACTGGGA AAGTGTGAA
49701 GTCTCCCAGT ATTTGTCTAT TTCTCCTTG ATTCTACCAG TGTTGCTTA
49751 ATGTATTTTG AAGCTCTGTT ATAGGTGCAT ACATGTTTAT GAGTATGTTA
49801 TAGATGTATT CATTTTGATA TCCTTCTTC TCTGTTACTA TTCCTAATC
49851 TGAATTTGAC TTTAATGTTA TTAATATAAT TCTCCAGCC TTCTTTGGT
49901 TAGTCTTTC ATTGCATATC TTTTCTATC CTTTACTTT TAATCTAGCT
49951 GAATGTAGTC TTTATTTGA AAGTGCGTTC CTGTTGATA GCATTATTGG
50001 TTCTTTTTT TTTTAAATC TAATTTGACA ATCTCTGTCT TTTAATTGGA
50051 GGGTTTAGAC ATTTGCATTG AATGTGATTA CCAATATAGT TAGATTTAAA
50101 CCTACAGTCT TGCTGTTTGC TTTTGTTTG TTTCATTGAT CCTTTGTTTC
50151 TTGTTTTTT CTTTTTGC TTCTTTGG ATTTAGTATT TTTCATAAT
50201 CCATTTTACC TCCACTGTTG GCTTATTAGC TATACTTCTT CATTTAGTA

50251 TTTTAGTGGT TGCTGTAGGA TTTATAATAA ATATCATTAA CTGACCATAT
50301 CTTCAGATAA TCGTATACTA CTTCATATAT AGTGTAAGAA CCTTACAAGA
50351 GTATTCACCT CATAATACTT TGTTATTGCT TTTGCTTTAA GTGATCAATG
50401 ATTGTTTAAG GAAATTTTTT AATGACCTTT CATGTTTATT CTTTTTTT
50451 TTTTCCAAA AGATTGAGTA TTTCCGAGT TTTCAAAAAC TGCTGGCCAC
50501 TCAAAGTGGA TCAACAAAAA TTTAAGAGCT AAAACTGTAA AACTCTTGAA
50551 GGCTGGGCAC AGAGGTTTAT GCCTGTGATT CCAGCACTTT GAGAAGCTGA
50601 GGTGGGACAA TCACTTGAGC CCAGGGGTTT GAGACCAGCC TGGGTAACAT
50651 AGAAAGACCT TGTTTCTACA AAAAATAAAA ACACAATTAG CCAGG CATGG
50701 CGGTGTGCAC CTGTAGTCCC AACTTCTTGG GAGGCCAAGG TGGCAGGATT
50751 TCCTGAGCCT GTAAGTTTGA GACTGCAGTG AGCTGAGTTC ACGCCACTGC
50801 ACTTCAGCCT GGACAACAGA ACAAGACCCT GTCTCAAAAC CAGAACGAAA
50851 CTATAAACT CTTAGAAGAA AACAGGGGCTA AATCTTCATG ACTTTGGATT
50901 TGGCAATGGA TGGTTAGAAT TAATACCAAA AACACAATCA ATAAATTGAT
50951 AAATTGGATT TAATAAAAAT TAAGAAGCTT TGTGTATCAA GGACA TTGTC
51001 AAGAATGTGA AAAGACAGCA TATAGAATGG AAGAAGATAT TTGCAAAATCC
51051 TATATCTGAT AAAGGTTTAA TATCCAGAAT ATGTAAGGAA CTCCTGCAGC
51101 TCAACAACAG AAAGCCAGTT AAATCAATTT TGAAATGAGC AAACGCCTGT
51151 AAACCCAGCT GCTTGGCAGA TTGAGACAGG AGGATTGCTT GAGGCTAGGA
51201 GTTCAAGACC AACCTGGACA ACATAGTGAG ACCCTGTCTA AAAACATTTT
51251 TTTAATTAGC TGGGTGTGGT GGCATATTCC TGTAAGTCCA GCTACATGGG
51301 AGACCGAGGC AGGAGGATCA CTTGGGGCCA GGCAGTCAAG GCTGCCGTGA
51351 GCTGTGATTA TGCCACTGCA TCCAGCCTG GCGACAGAG TGAGACCCTG
51401 TCTGAGAAAA AAAAAAAAAA AAGAACAAAA AAAAATTTAG AAGATTGCTA
51451 TTCTAGTCTA CTATTTTTTC AAAGGGTGGT CTTGTTAACA ATTCTGGAGC
51501 CCACCTAAAC CTGCTAAATC AACTTGGTA GTAAAGCTGG GGAGATGGGC
51551 ATGTCTAACA GACGTTTCTG GTGGTTTTGA TGTCCAGGCG TGCAGAGAGA
51601 TGATGCTTAC CTTGTGTTTT GTCATTATTT TCAGGATTTA CACCCTTCC

51651 TTGTCTTTTG TATCAATATT TATGGAGTCA TGAAGTCTAG GATAGG CATG
51701 ATGTTGAGAA CTAGGAGTTC TCCCCTGGCC AGGGAGATAG AGGC AGGTCT
51751 GTGGTTAGTT TTGTAGTTGG CTGTGATGAC ATCTGACATG CTCTC TTCAC
51801 TTGTTGTCTT CTTCCTGTTT CCTTGTGAGG ATTATGAAGA AGCTGTGCTC
51851 TTGCTGTTAG AAGGAGCTGC CTGGGAAGAA GCTTTGAGGC TGGT AAGAAT
51901 CTTGTAAATC CTCTGGATGT TGGGTGCTAA GCAGAGAGAG CAAG CAAGGG
51951 ATTCCAGGTC AGTTGGAATC TCTTGTCTTC TGAGGTTTCAAT GAAAT AAGTA
52001 GAAATAGGTC AGGTTCTGCT CTTAAGGAAA AGCGGTGTTA CTAA AATCAT
52051 TTTTATCATT CTTGATAATA ATTTGAAATA TTAAGTCTT TTAAGTAAAT
52101 GAATTGAATT TCCTTGGCTG CTTGTAGGA GGCCTGTTTT TCAGG AAAAT
52151 ATTCTGATTA CCTCTGAAAG TAATCCATGT CTTTCTAAGT ATCTTAACTC
52201 TCCAGTGACT AGAAGTTTTT CTTCCTAAAA TATCGTGTTT TTCCTTCTAG
52251 GTATGCAAAT ATAACAGACT GGATATTATA GAAACCAACG TAAAGCCTTC
52301 CATTTTAGAA GGTGAGGGTT CCATTTTAGA TAGAATTCCT CATTTGGAAG
52351 AAGGTGAGGA GAGAGAGATG AGAGAGTCTC CTCCTATTTA CTGTGTTTTT
52401 TTAATAATAT GTCATGTAGA CTCAATCAAA ATTACCACCT GGATA TAATA
52451 TTTAATTCTC ACTAGAATTT TAAATATGC TGAAGTATTA AATGGTAAACA
52501 AAATATTTAA ATGTTAGAAA CCTGTGATCA AATATGATTA AGAATCTTTG
52551 TATTTGGAAA TAGTAACTT GAATATGAAC TATATTAGAT AATAATATAA
52601 CACTGATAAA TTTCTGGCAT TTAATAATCA TGTGTGGTT ATATAAGATA
52651 ATATCCTATT ATTCTCAAGA GATAAATGCT GAAATATTTA GGAATGAAGG
52701 ATCATATCTC TGCCTTACTC TTAAGAGTT CCACAAAAGT ATTAATGAAT
52751 GTGTGTATGC ATGCAGAGAA ACAGGAAGCA AAAAAATGTC AAAATGTTAG
52801 TAATTGGTAA ATCAAAGTGA AGGGTATATG TGTGTTTCAAT GAAGTCTTAC
52851 AACTTTTATG TAGGTTTCAA CGTTTCAAAG TATTTTTTAA AAGTTACCTT
52901 TTCAAATGAA GTTTGTGGTT CTTAGAGAAC ATATGAATAT TACCAGTTCT
52951 AGAATACTCA GATGGTCACT GTGACCTCTT AAAAGCAAAG TGGAGAAGGA
53001 CATCAGTTTG ACTTATAGAA ACCTTAGGGA GTGGTTGATT TTAAGTTCTG

53051 CATT TTTTATG CACATCTACC CTGTAAGTAA CGTCTGGCCT TTCTGACATT
53101 TACATGTATG CACATTCTTA CCTTGTCTGC ACCCCCTTCC TCCATCCTAA
53151 TTAAAACGTT GCTGGGGTAC TTTTATGTC ATTCACTTTA GGTACCTCTA
53201 ACTGGGTACT GAAAACATCA TTCCTCATCT ATAATAATCT AACCAGCTCT
53251 TACTTAGATT TTCACCACTA ATGAGAACCT TTCTTAGATA AATGCCGATA
53301 ATTCATCTAC ATAGGCCCAA AACCTATTAA TAAAATGCAT CCTTGGATAG
53351 TAGTATTTTG CTTTTTAAA ATGTATTCTA CTAGTGTTAT TTTCTCTTG
53401 TGTATTTTTC CATTGGACAA TATTATTAG ATACATTTT TCCACA TCCA
53451 TGGGCATTTT GATGGATGTT TAGCCAGAAA CATTTAGGTA ATTTCTTCT
53501 TATTTTGTG AACTGAGCTC CCCTCCCCTA CCCCCCTT TTTGTTTGT
53551 TTGTTTGTG TGTGTTTGTG TTTTGCCAAT CCTCCCTTGC TTAGGSTATC
53601 AAGTCTTCGT TCAGGTGATT TTACAAGTTC AGTGGTAGCG CATA TTCTGG
53651 GATAATGTTG ATGAACTCTA AGATCTGGAA TCTCAGTCTC TAATTTGTTA
53701 ATGCTTATTA AGGAAAAAGA GCTCGCTTGG AAAACCTAGT AACCTCTTTC
53751 TTTTGCTGA ATTTTAACCC TCCTTCACTG CTCCCCGCCT TTAGTTTTT
53801 CTCTTTGCTT AAACCTCATG CTCAAACAT TTTCCATTCT GCATCTCCAG
53851 CCCAGAAAAA TTATATGGCA TTTCTGGACT CTCAGACAGC CACATTCAGT
53901 CGCCACAAGA AACGTTTATT GGTAGTTCGA GAGCTCAAGG AGCAAGCCCA
53951 GCAGGCAGGT CTGGGTGAGT ATCTGCGTGA AGGCCATCGA CGTGCGGGGG
54001 CAGTGGGGTT GGGTAACGCC ACACATTGTC TAGATTGCTT GGTGATCCGC
54051 CTGCAATCTG ATTA CTGTGC CATGGGCAAG TGTGAGGCTT CTGTGGAGCC
54101 CCTTCAGGGC CCTCTGTGTC TGTGTTTGTG TGTGGTGAA GGGCAGGACC
54151 AAGCATGAAT GGGGAGAGCT CTGCCAGACA TTCCACCTA CCCCCATTCA
54201 CCCAGAGCAG CTGACCACTT CCGTGTCTAA CAAAATGAGT TTCCTCATTT
54251 CCAGAAAAAA GTTCAGGAAA CTACTGATTT ACATTAGTAA TTA CTGTATT
54301 TAATATTATC TCATTCATTT TGAGATCAAC TTTGCAATCA TTTTCATCCA
54351 TCCTTTGATA TGCACCAGTT GACTCTAGTT AGTTCATTTA CCGCCCTGAA
54401 AGTAAACCCA CACATTAGCA GGCAGTGTTT TCATCGGCTT CTGGTTCTTC

54451 TTTTCTAGAT GATGAGGTAC CCCACGGGCA AGAGTCAGAC CTCTTCTCTG
54501 AAAC TAGCAG TGTCGTGAGT GGCAGTGAGA TGAGTGGCAA ATACTCCCAT
54551 AGTAACTCCA GGATATCAGC GTACGTATCA CATTGATTCA GCACATTGAC
54601 TATATCCTGG GCATATAGGG AAAGTGGAAG CAAATAGATT GGTTTCTAC
54651 TGGGACGGTG TAGTGGGAGT GGGGAGAATA TTCTTCAGCG CTGTGTGGAA
54701 GTTGTT CAGA CACTTTCCCA GCATATCTGA GACATTAAAC TTGGCATTGG
54751 AAGGTTTTCT TCCTCAGCTT TGTGGCTTGT GTGTTTTCCC ATTCC CCACG
54801 AGGCAGTTCC TCCCCTGAAT GCTCAGTTTA TATTAACATC TGATTTTATT
54851 TTTTGAACAA ATGTTGTGAC TAAATTATAG GCACTGAAAA AATGAAAAGA
54901 TAAGCTTCTT CAATTCAAAA TCAGGATTGG AAGAGACCAT AATGTAAAA
54951 TAAGTCATAA CACTTTTACC AAATATAGTA ATTTGTCAGA AATATTTATT
55001 CAGCACTCAT ATGGTAGGTG CAGTAGATGT TACCAAAAAC TTATAAGGAG
55051 ATATGAGTTA TAAGAGTTA TAGTCTTGCT TGGGATGTGT AAAGCAATGC
55101 AAGATTATAT ATTCAAAC TG AATTTTGCTT TAGGAATTTA AAATGGAGAT
55151 CTGTGAAGTT GTGTGGGGTC ATCAGCAACT GCAAGAAAGT AGC CAGGCAA
55201 GG TAGCACAT GCCTGTAGTC CTAGCTACTC AGGAGGCTTA AAAATATCTG
55251 TGTAATTTCT AACAGGAGAT CATCCAAGAA TCGCCGAAAA GCGGAGCGGA
55301 AGAAGCACAG CCTCAAAGAA GGCAGTCCGC TGGAGGACCT GGCCCTCCTG
55351 GAGGCACTGA GTGAAGTGGT GCAGAACACT GAAAACCTGA AAGGTATATT
55401 CTCAGTCCTG ATGATGATTC CTGACCACAA ACAATAGTGA ATAGGCAGTA
55451 CAGACAGGCA GAGTTCAGTA GGTGATTAAG CTACCATTTT CCCAATTTGA
55501 GGAAAGATGA GAACTTTTAG CAGGAAGGGT CATGTCTGCA CACATTCCTG
55551 AAGCAGCCCT TCTTAGCTGG TAACTGAGAA GCCTTCCTCC ATTTGGCATC
55601 CCCCTAACTG AACTGGGAGA GATGCTTAAG CCAGGATAAA GAATTGTGGG
55651 ACACTGCTTT CTGCGTAGGC CCCCAGCGT GCTTGATTTT CTTTTGTAG
55701 TACATGTGTT TAATTATTCC AGCATTTGGG AAGAAAAAAG ATAATGTGGG
55751 AGAAAGGACC TGCAGTGGGA TCATAGAAAT TTTTGGCTTT GGATAGAAGC
55801 TATGTATGAT TCTGTCAATG GAGCTGGGAA TATAACTTAC CACTCTTTCA

55851 AATTTCTTCT CTCTAGATGA AGTATACCAT ATTTTAAAGG TACTCTTTCT
55901 CTTTGAGTTT GATGAACAAG GAAGGGAATT ACAGAAGGCC TTTGAAGATA
55951 CGCTGCAGTT GATGGAAAGG TCACTTCCAG AAATTTGGAC TCTTACTTAC
56001 CAGCAGAATT CAGCTACCCC GGTAAGTTTT CTCAGAGACG GTGTGCATT
56051 TTTTCATCAT TTTCATGGGT TATTGTATTC ACACAATCTC CAAGTCAAAA
56101 AGTTTTCTTG TTCTTAAAC ATAAGATGCC ATAGTTAAAT TATCTTAGCA
56151 TTTATGTGTA AGCTGTCAGT AAGATTTGAT ATTTGCCTGT AGAGTGAATA
56201 GTATACCTTG GCATAGGTTA AATGGACTGT CATTTTCCTT TCTGGATGAA
56251 GTAGCTGTCA TGGAGAAAAT GGGAAAGTCA CATGATTGCT CCTGGCCTTC
56301 AATGAGGTTG GAGTGGGGAG AGATGGGGGA AGATGGGGTC AGAGACGGCC
56351 TCTCACTTTC CTTTCAGAAC TCAGGGATGG GATCAGGCTT TAAAGGGACC
56401 CCAGGCAATT GCTTTTCCTT TTGTTTTATG AAAAATTGA CTTGTCACTT
56451 CTATGTTGTT ATGATGGACT TTGCGGGTTG TGTTTAAGGC TGAATCAGCT
56501 TTGTATCGCA GAATTCTAGT ATATTGTCAT CTGTTTATTA TTTATACCTC
56551 TGTTCACTCT CTTATACTTC AAGTCTATTG TTAAGAGTTT TTATTTGGAT
56601 TCAAAAAGGC TGGTGTATCA GTCAAGATCT AGAAAGGAAA ACAAAGCCT
56651 ATCTATTATT TTATCACAGA ATTTAATATA TGGATTTGTT AAATAAGTAT
56701 TAGAGGACTA AACAAGGCAA AAGGGAAATA CAGAGGAAGG ACATTGAGAT
56751 AGTAACTGTA GGAAGCAGCT TTACCCTCTA GCTGAGGGAA CAGGAGGAGT
56801 TGTTGGGAAT TATTAGAATT TAGAAGCCTG GAAGTGGGGC CCTGTAGAGC
56851 TGGCTCTTGA ACCTCTGAGA GGAGGGTGCC AGCCAGCTAA TCCTGGCATT
56901 TCTGAGGGAG CTGGTTCCAA GCGTACAGAA GTAAATGGAA ACTGGAAGGA
56951 ACAGCTGCTG CTGGGGGAAA AGCCAGCCGG TCGGGCCAGG TGTGGTGGTG
57001 GCTCACGCCT GTAATCCCAG CACTTTGGGA GGCCAAGGCA GGCGGATCAC
57051 CTGAAGTCAG GAGTTCGTGA CTAATGTGGC CAACATGGAG AAGCCCCGTC
57101 TCTACTAAAA ATACAAAATT ACCCGGGCAT GGTGGCGCAT GCCTGTAATC
57151 CCAGCTACTC AGGAGGCTGA GGCAAGAGAA TCGCTTGAAC CTGGGAGACA
57201 GAGGTTGTGA TGAGCCAAGA TCGTGCCATT GTACTCCAAC CTGGGCAGCA

57251 AGAGCGAATC TCCGTTTAAA AAAAAAAAAA AAAAAGCCAG CCAATCACGG
57301 AAGAAATCTA GAAATCTTTT GTTCATCCTC CAGCTTTGTA CTCCCCCTCT
57351 GGTGTTCACT GTAGGCAGGA CATGATGGGA AGCCAGCAGC AAGGAAGAAT
57401 ATCTTTCAGG TGCCCAGCCC CAGCACCACA AGCAGTGGAT AGAAGGGTGG
57451 GTTGGAGCTG AGAGATTACA AATCAGCTCA GTGTTTAGAA ACACATACGC
57501 TTATCATGTC TTGATTCCT CATTAGAAA TGGGCATAAG ACTTCTCTGT
57551 GTGCTTCAAT AGAATGCTTT GAAGGTTAAA TAAGAGGGTG TGTGTAAAAG
57601 CACTTTACAA ACCGTTGAAA TAAAGCAAC TAGGAATCAG GGCCCCAGAA
57651 CTTCTTGAAT TTATTATAAT AGGTATTTCT TAGAAGAAAT GTGATCATCA
57701 TCTTCAAAC TGTAGTACTT TTGAAGATAA TTGTTTTGT TTTTGAGAC
57751 AGGGTCTCAC TCTGTTGCTC AGGCTGGAGT GCAGTGATCA CCGCTCACTG
57801 CAGCATCCAC CGCCCCGGGC TCAGGTGATC CTCCCACCTC AGCCTCTTGA
57851 GTAGCTGGGA CTACAGGCGC ATGCCACAAC ACCTGGTTAA TTTTCAAAT
57901 TTCTGTAGAG ACAGGGTGTC ACCAAGTTGT CCCCCTGGT CTTGAACAAC
57951 TCCTGGGCTC AAGTGGTCTG CCCACCTCAC CTCTCCAAAG TGCTGGGACT
58001 ATAGGCATCA GCCACCATGC CCGGCTTGAA GATAATAATT TATAATACCA
58051 CTCCCATGAG TGATCTTCTC TTCTGATCAC ATATTCACAT TAAGGTCTAT
58101 TTTATTTTAT TTTTCTTG CTCTGTCACC CAGGCTAGAG TGCASTGACA
58151 GTATGATCAA TCATGGCTTG GTGCAGCCTC GAATGCCTGG GCTAAAGCAG
58201 TCCTCCCACC GCAGTCTCCT GAGTAATTGG GACCACAGGT GCACACCACC
58251 ATGCCCAGCT AATTTTAAAA TTTTTCCTA GACATGGGGA GAGGGAGTCT
58301 TGCTGTGTTG CCCAAGCTGG TCTTGAAGTC CTGGCCTCAA GTGATCCTCC
58351 TGCCTTGGCC TCCCAAAGTG CTGAGATTAC AGGTGTAAGC CACCATGCCT
58401 CCCACATTAA GTTCTAAGAC ATCAATTTTA TGATTGTGGT TTGATTGGT
58451 GAAGTATGGT TGTGGTATGT GCAGGATACC GTGAGTGAAT TCTCATGGCA
58501 TTGCTCTTGA GAGTGTGCCA CCAAGGGTCT GCACTAACCA GGGGTGTGCC
58551 CAGAGGCTCG CTGCAGGCTT GAAATTCCTG CGGAGTCTTG TGTTTTACCT
58601 GGAGCACATG TGCACAGTTT CCATTCTGCT CCATAGTATG CACATGTTTG

58651 TATTTATTTT AACCTAAAAA TGTTTGTTC CCATAACTCT TTGCGTATAA
58701 TTGATACTCT ACGTATTTGT AGCCTCTTTT ACTCTTTTCC CTTTCCTCAG
58751 GGAGTGGTTT GCTCATTTAG AAAAGGCCAA GATATATCAC TGTAGAGTTT
58801 CGTTTCTTTT CTTTTCTCC ACCCCCCATC TTTACCTTGT TCTGGGAGAA
58851 AGGAGAATTA GAAGTCTGAG TTGCAGCTGG AGAACTGGC AAATTAAAAA
58901 CACATTGGGA AAGAGAATTA CTGTGTTTCA CACCATACCA GTAGAAATGA
58951 CAGGCTGTTT TCTGCTGGTA GGGATTTGGC CTTTGGTATT GGCAGTCTTG
59001 AGAAGTATTA GATAATCTTT GCTGATACAG TCTATTTTCT CCTCAGGTTT
59051 TAGGTCCCAA TTCTACTGCA AATAGTATCA TGGCATCTTA TCAGCAACAG
59101 AAGACTTCGG TTCCTGTTCT TGGTTAGTAT TTTTCTCAT TTAATAATTAC
59151 AATACTAAGC AGAAGGACTA TCTTTCTGTA AGTATTGAGA AGATCAGCAG
59201 TATAAGGAGA GATTGGATAC AATTTTTCAC TACAAAAAAT TGACTACAAT
59251 TCTTCCTCAA TTCTAAGACC GCATCTTTAG TATGATCAGT TTCATGCTTC
59301 TAGCGGTGGG GGACCTGGTG CAGGAAAATC CAGCATGACC ATTGTATGTG
59351 TAATTTTAA AAATATTTAT GTGGCATATG CTTGTTTATA AAGGCACACC
59401 ACAGTTCCAG TTCAGTCTA AACTGTCTAC ATTTACATAT ACATCAAAAG
59451 ATTCTTCTGA AGCATCATTA CTGGCTATTG GCAGTTATGC TTTGCATCTT
59501 GGGGGCATT TCATAAACCT TGCTTATGAG TGGGACCTTT TTATTATGTT
59551 TAGGATTGAC AATATAATTT GAAGGCAAAT CCAAAGAATA TTAGCATTTT
59601 ATACATATTT CCTGTTTAGT TATGCATGAA GTGTTTTATT TGTTGAGGGG
59651 AGATGATTCT CAATTAGATT ACTTATTTCC CTAAAAATTA AAAACCTAA
59701 GCGCTTTCTT TTGAAAGTTG GTTAGAAACA TTTGATGAGT CAGCTTGGGA
59751 CTTTCAGTAT TTGCCCTTAC TTATAGTTGG ATCAATGAAG CATCTTAGCT
59801 TTGAAAAGTG AATGATAGTT TCTAAAATAA TTGGCAGTTT TAAC TGCTAT
59851 TATTTGCATT TCTAGCATGT GACAAGCAAC TTTCTGAAAT TTTTTCAC
59901 CGAAGTGCTA CACTGTAATA GCATTTTGAT GACATTTGAA GTAGCCTGTG
59951 GGGATTCAAA TTAAGTTTGA CTTTAACAGC TTATGTTGCT ACCAGGAAGA
60001 ACAGCTACCT TCCATCCCAG CTAACTCAT ACATCCAGAC TGTAACTACT

60051 GTATTCCTAG CTCCTCTTCT GTCTAGAGAA TGGCAAGGT CTTTTGGTAT
60101 GCAGTTTCGA CATATCCACT TATTCCTTTT TTTTCTTAA GTTTTTT CAT
60151 TTAGAAAAAA AACAGATGG GGTCTTAATA TGTTGCCAG GCTGGTCTCA
60201 GCCTCCTGGT CTCAAGTGAT CCTCCTGCCT CGGCCTCCCA AAGTGCTGGG
60251 ATTACAGGCG TCTGCCCCTG TGCCAGCCC ACTTATTCC CAGATGCTAG
60301 GAACTTACAT TAGACCTGAG GCCATTTGGT CATTGTTTAT TTTGTGCTGT
60351 AGTCCAATCC AGTTGTGATT TCTGCCTCCT GTGTTCTCG TTGCTGGCCT
60401 GATGCTGACC TTCAGGTTAG GTCAGTCCCA TCATTCCCCA GGGTATTCTA
60451 GATGGCTTTC CCACTTCAA GAGCACTTTC TTGTTTTCCA GCTGAGCCTT
60501 AAAGACACTC TGTAATATTT GAGAGCCCCT CATTATCTGA GTGTTTATTA
60551 TCATTACCCT TGTGGTTTCA AGGATGTATA GGAAAAGGTA AGTTCCTATA
60601 ATTCAAAAAT TGCCACTGAT GAACTAATCA CAAAATTAGT GCCACTCAA
60651 TATTACTCAG CTGCCCCTCC CCAGCTAACA ATAGTTAAGT ATATTGGCAC
60701 ATCCCCACAA GTGAAATCAA TGACTTGATG GGTCATTTCT GATTGTTCC
60751 TGCTTTGATG CAATACAATA TCATGCAGAT CAATTGCAAG TCTTGCAAAA
60801 ATTTAGTATT ACATAAAATA GATTAAAATG ATATTGGAAA AGTACTTGAA
60851 TCACAGCTGG GTTGGACTTG TTGCAATTGA TGACAAAATA AGTGCTTCAA
60901 ATGATTTTGA CTATCAAAGG ATTGAGAGAG GTCCTTAGAA AAATTGAAAA
60951 GCCCTCAAGT TATTTTATA AAAATGGCCT TTTTGTGTG CTGTGAAATC
61001 CACATATGGA AATGTGAAAT ATGTCATGTC CTGCTGTCAT ATAA TTTGTC
61051 AGAATAATTA CTTTCTTGCC CAAAAGTCTG TACTTTGTGT TTATTTCAAG
61101 TTAAGTCTAG AATCAAATAT AGTTGTAGTT ATGCCTAATT TTAAAAATG
61151 AGATAGAGCA CATTATTTT GTAAGTAGTT TTTTTTTTTT TTTTCAGAC
61201 AGAGTCTTGC TCTGTGGCCC AGGCGGGAGT GCAGTGGCGC AATCTCGGCT
61251 CACTGCAAGC TCCGCCTCCC GGGTTCACGC CATTCTCCTG CCTCACCCTC
61301 CTGAGTAGCT GGGACTACAG GCGCCCGCCA TCACGCCCGG CTAATTTTTT
61351 TGTATTTTGA GTAGAGACGG GGTTCACCG TGTTAGCCAG GATGGTCTCG
61401 ATCTCCTGAC CTCGTGATCC ACCCGCCTCG GCCTCCCAA GTGCTGGGAT

61451 TACAAGCGTG AGCCACCGCG CCCGGCCTGT AAATAGTTTT TTAAAGATAA
61501 AGTCTTATTC CAACTTTAAT TGGAAATTTAT GAAATACCTT GTTGATAGTG
61551 AATTTATTTA AGTAGCCTTT TTTCAGTATT GATATTCTTA TATCTTTATG
61601 GCACCATTTA GTGGAGAGAA ATGTAAACAA ACATAAAGAT GTAGTATTAA
61651 ATCATAACTG CATAAAATTA ACTGTAGTAT GTACTGCACT ACTGTAATAA
61701 TTTTGTAGCT ACCTCCTGTT GCTATTGTGG TGAGTGAGCT CAAGTGTTAC
61751 CAATATCTGC TTAAAATGCC ATGTGCCGCT AACCATCTCC ACATGAGCAG
61801 CACATGAGAG TCTCCATTAA TTGCATATGG CAGCGAAAAG TGATCTCTTG
61851 CATTGTCGTG TATTTTTTAT CACGTTTAAT GTAATATCGT AAACCTTAAA
61901 TAACACCATG AGACCTATAG GAAGTACCAC AAGTGTTGCT CCCAGGAAGC
61951 AGAGAAAAGT CATAACATTA CAAGAAAAAG TTGACTTGCT CGATATGTAC
62001 TATAGATTGA GGTCTGCAGC TGTAGTTGCC CACCACTTCA AGATAAATGA
62051 ACCCAGTGCA AGGACTATTA TAAAAGAAAA GGAAATTTAT GAAGCTGTCA
62101 CTGCAGTTAT GCCAGCAGGC ATGAAAACCT TGTACTTTTT GCAAATACC
62151 TTTTTATGTT GTATTGAAGA TGCAGCTTTT ATGTGGGTGC AGGATTGCTA
62201 TGAGAAAGGC ATACCTATAC AACTATTATG ATTTGAGAAA AAGCACAGTC
62251 ATTGTATGAG AACTTAAAGC AAAAAGATGA AGGATCAAAG CTGGAGAATT
62301 TAATGCCAGC AAAGGATGGT TTGATAATTT TAGAAAGAGG TTTGGCTTTG
62351 TAAATGTCTG GATAATAGGA AAAGCAGCTC CTGCCATCCA GGAGGCAGCA
62401 GCAAAGGCAG TCAGGTTTAT GATCAGGACT GCCCTTATCT GTAAAGCTGC
62451 TAACCCCCGA GCCTGGAAGG GAAAAGATTA ACACCAGCTG CCAGGCTTTT
62501 GGTGTACCA TACAACAAGA AGGCTTGGAC AAGGAGAACA CTTTTTCTGG
62551 ATTGGTTCCA TTGTCGATTT GTCCCTGAAG TTAAGTAGTA TCTTGCCAGT
62601 AAGGGGACTG CCTTTTAAAG TTCTTTTGAT ACTGGAGAAT GCCCGAGGCC
62651 ACCCCAAACT CCATGAGTTC AACACCGAAG ACATTGAAGT GATCTACTTG
62701 CCCCCAAACA CACATCTCTA ATTCAGCCTC TAGATCAGGG TGT CATAAGG
62751 ACCTTTAAGG CTCGTTACAA ACAGTACTCT ATAGAAAGGA TTGTCAAATG
62801 TATGGAAGG AACCTTGACA GAACATGAAA GTCTGAAAGA ATTACACCAT

62851 CAATGATGCC ATCATTGTTA TAGAAAAAGC TGTGAAAGCC ATCAA~~G~~CCCA
62901 GGACAATAAA TTCCTGCTAG AGAAAAGTGT GTCCAGATGT GCAT~~G~~ACTTC
62951 ACAGGCTTTA CGACAGCCAA TCAAGGAAAT CATGAAAAAG ATTG~~T~~GGATC
63001 TGGCACAAAA AAAAAAAAAA AAAAAAAAAA TGGTGCATGA AGGATTTCAA
63051 GATAGGAATC TTGGAGAAAT TCAAGAGGTG ATAGACATCA CACC~~G~~GAGGA
63101 ATTAACAGAA GATGACTTGA TGGAGATGAG TACTTCCAAA CCAG~~C~~GCCAG
63151 ACAATGAGGA AGATTACATA AAAGAAGCAG.TGCCAGAAAA TAA~~T~~TGACA
63201 TTTGTTCCAA AGGTTCCAAT TATTCAAGAC TGCCTTTGGC TTCTTTTACA
63251 ACATGGATGA TTCTATGTTA TGGGCACTGA AACTAAAAGA AACT~~G~~TGGAA
63301 GGATTGGTAC CTTAGAGAAA TGAAAAAGCA AAAACATCAG AA~~T~~TTATGGT
63351 GTATTTCTGT AAAGTTAGTG AACTGAGTG TGCCACCTC TCT~~G~~CCCTC
63401 TCTTTAACCT CCCCTACCTG TTTCATCTCT ACCACCCCTG AGACAGCAAG
63451 ACCAACCCT CCACCTCCTC CTCTACTTCA GCCTACTCAA CGTGAGATG
63501 ACAAAGATGA AGACCTTTAT GATGATCCAC TTCCATTAA TGAATAGTAA
63551 ATATTGTTTT CTTTATGATT TTCTTAATAT TTTCTTTTCT CTAGCTTACT
63601 TTATTGTAGG AATGTAGTAT ATAATACATA TAACATACAA AACATTTGTT
63651 AACTGACTTT TTATGCTGCC AATACACTGC CGAACAACAG TAAGCTATTG
63701 GACTTTGAGT TTTGGAGATT CAGAAGTTAA ACATGGGGCC AGGTGTGGTG
63751 GCTCACACCT GTAATCCCAG CACTTTGGGA GGCTGAGGTG GGTGGAACGA
63801 GACCAGGAGT TTTGAGAGTA GCCTGGGCAG CATGGTGAAA CCTTGTCTCT
63851 ACAGAAATTA GCCAGGTATG GTGGTGTACA CTTGTAGTCC CAGCTACTTG
63901 GGAGGCTGAG GCAGGAGAAT CGCTTGAACC CAGGGGGTCGAGGCTGCAGT
63951 GAGTCATGAT CGTGCCACTG CACTCCAACC TGGGCAACAA AATGAGACCC
64001 TGTCTCAAAA AAAGAAAAA AAAAGGTATA TGCAGATTTT TGACTGTGCA
64051 GGGGGGTCCG CACCCATAAC CCTACATTCA AGGATCAACT GTAATTTTTC
64101 ATGCCTGCAT GGCTCATATG TACAGATTTA CTGCTGGAAG TTTATCATAA
64151 ATAATGCTGA AAAAGAAAAT CCTTATATAT ACATATTTTC TCCTATCTCT
64201 GCTTGCAGTA TATGATTCCT GGTTAGAAAA GAACTTAAC AAATCTAAGT

64251 GAAAGAGTGC CTGGGAGTTT TAGGTTACAA TGACAGAATC TTTTCTAAC
64301 CCTCTCTCTC CATTCACTTT TTTTAAAGCA GGGGCATCTT TATTGATCAA
4351 CATGTTTGTC GAAGTTCAT CATAAAGTAG TTCCTGTCCA TTAACCTCAC
401 TTAAGTGAATA TGTGCTATCA CATTGCTGTA TTCCTTAAAA ATTGAGCTAG
51 ACTTTACATA TAGTGAAATG CAGAGATTTT AGGTGTACAA TTTGATGAGT
01 TTTAATAAAT GTATACAGCC ATGTGACTGC TGCCACCACC CCTCCACCA
551 GTTTGAAATA CAGAACATTC TTCCACTTTG AATCACTGGG TGAGCATGCC
01 TGAGGTTGAA ATGCAGTCCC TCCTCTCAGG GCGGGGCCTC CAGGTTGTGT
51 TTGCTCTGAC CTGGAGGTTG CAGGGGTAGC AGACACATGA ACTCTGGCTC
TGATGGTCTT ATTGCTGCAA ACTCCACCTG CCTAGTTTGT TTAGTTTAGA
CTGCCT CAGCGCCCTC CAACAAGAGT ATGTCTGTCA CAATTTCCCT
TCCTTTCTTG CTTTATAGATG CTGAGCTTTT TATACCACCA AAGATCAACA
51 GAAGAACCCA GTGGAAGCTG AGCCTGCTAG ACTGAGTGAC TGCAGTTAGG
4901 AGGGATCCGA CAGAGAAGAC CATTCCACT CATTCTGTT GTCTACCAC
34951 CCCTTGCTCT TTGAGGGCTG GCTATTGAGA ACTGGAAAGA GTAAATGAT
65001 AACTTACCTT AGCATTGCCA AGAACTTCAG CAGACAACAA GCAATTCTAT
65051 TTATTTTATG TTGTGTATAC ATCTTGATCA TTAGCAAGAC ATTAAGCTTT
65101 AACCATTATG GCACCATTTT GTGAGAATGA TTGTTCTTTC ACTTGGGCTG
65151 TTTGAGAGCA TAATTATGGT AATCATGAGA TTAATGTTTC ATGATTTCTA
65201 CCTCCAAAGT GTGAAGACAA GTAAACAAT GTTCTAAAT TGCTTATTT
65251 TGTTGGCGGA GAAGATTACA ATGGCTATTA GTGCTACATT TGGTCAAATG
65301 TAATCACTTA AATAGCTTCT TGTCACCTTA AACTAAAGCA GAATAAAAAG
65351 TATCCTTTGA AATTATAAGC CCTCCTTTGC TGACAGCTAT TATTTTGTA
65401 CATCTTACCA GGTATGTGC TTTAGTTAT AACTGGGCTG AGCCTCCTAT
65451 AATTACAATG TCTATAGGGA CTGTTTTACT GCCTGTGTAT TTCTTGCTAG
65501 AGAGTTAGCA ATGTTAGAGC TAGAACAGAT TAGAATTTCT AACAGTATC
65551 ATGCACAGTT GGTGTGAGTG ATCAGTGTGC ATTGTATGGC ATGCATGGT
65601 GTGAATTATT CTCTGTTCTC CAAATACTGT TTCTTTAACT CAGATATTTT

65651 TGTTAGTGTC TAGGCCACTT CATTTATTT TCGTCATGGT ACTTTACTGA
65701 CTTCTCTTTA TTCAATTCTC CACGCCCTCA CCAAAAAAAAA CTGTCTCAAA
65751 ATGAGAATAT TTTATTTTCA TGGTGAGTCT AGAAAACGCC CACTTCATTC
65801 TGATTAAAAA TTCTTCCATG TTTTAAATAT CAGAACCAGA CCTTCTTAC
65851 TGTGTATCTT AGCCCATTTG TGTCTCTATA ACAACAACCA GCTTTC AAAG
65901 GAACTAATAG AGTGAAAAC TACTCATTAC CACGAGGATG GCACAAGCGA
65951 TTCACGTAGG ATCTGCCCCT GTGACCAAAA CACCTCCCAT TGGGCCCCAC
66001 TTCCAACACT GGTGATCACA TTTCAACATG AGGTTTAGGG AAACA AATGC
66051 CTAAACTACA GCACTGTACA TAACTAACA GGAAATGCTG CTTTTGATCC
66101 TCAAAGAAGT GATATAGCCA AAATTGTAAT TTAAGAAGCC TTTCC CAGTA
66151 TAGCAAGATG TTA ACTATAG AATCAATCTA GGAGTATTCA CTGTAAAATT
66201 CAACTTTTCT GTATGTTTGA ACATTTTCAC AATCTCATAG GAGTTT TTA
66251 AAAGAAGAGA AAGAAGATAT ACTTTGCTTT GGAGAAATCT ACTTTT TGAC
66301 TTACATGGGT TTGCTGTAAT TAAGTGCCCA ATATTGAAAG GCTGCAAGTA
66351 CTTTGTAATC ACTCTTTGGC ATGGGTAAAT AAGCATGGTA ACTTA TATTG
66401 AAATATAGTG CTCTTGCTTT GGATAACTGT AAAGGGACCC ATGCTGATAG
66451 ACTGGAAATA GAAGTAAATG TGTTTATTG

FIGURE 7

```

1  ccagtgcctgg ggctgcctag ttgacgcacc cattgagtcg ctggcttctt tgcagcgctt
61  cagcggttttc ccctggaggg cgccctccatc cttggaggcc tagtgccgtc ggagagagag
121  cgggagccgc ggacagagac gcgtgcgcaa ttcggagccg actctgggtg cggactgtgg
181  gagctgactc tgggtagccg gctgcgcgtg gctggggagg cgaggccgga cgcacctctg
241  tttgggggtc ctcaagagatt aatgattcat caagggatag ttgtactgtt ctctgtggaa
301  tcaacttcac atgcgaaatc tgaaattatt tcggaccctg gagttcaggg atattcaagg
361  tccagggaat cctcagtgtc tctctctccg aactgaacag gggacgggtc tcatgtgttc
421  agaacatggc ctgatagaag tagaccctgt ctcaagagaa gtgaaaaatg aagtttcttt
481  ggtggcagaa ggctttctcc cagaggatgg aagtggccgc attgttggtg ttcaggactt
541  gctggatcag gagtctgtgt gtgtggccac agcctctgga gacgtcatac tctgcagtct
601  cagcacacaa cagctggagt gtgttgggag ttagccagt ggtatctctg ttatgagttg
661  gagtcctgac caagagctgg tgcttcttgc cacagggtcaa cagaccctga ttatgatgac
721  aaaagatttt gagccaatcc tggagcagca gatccatcag gatgattttg gtgaaagcaa
781  gtttatcact gttggatggg gtaggaaagg gacacagttc catggatcag aaggcagaca
841  agcagctttt cagatgcaaa tgcagtgtgc tgctttgccc tgggatgacc atagaccaca
901  agttacctgg cgggggggatg gacagttttt tgctgtgagt gttgtttgcc cagaaacagg
961  ggctcggaag gtcagagtgt ggaaccgaga gtttgctttg cagtcaacca gtgagcctgt
1021  ggcaggactg ggaccagccc tggcttgga accctcaggc agtttgattg catctacaca
1081  agataaacc aaccagcagg atattgtgtt ttttgagaaa aatggactcc ttcattggaca
1141  ctttacactt cccttcctta aagatgaggt taaggtaaat gacttgctct ggaatgcaga
1201  ttctctgtg cttgcagtct ggctggaaga ctttcagaga gaagaaagct ccattccgaa
1261  aacctgtgt cagctctgga ctgttggaat ctactactgg tatctcaagc aaagtttatc
1321  cttcagcacc tgtgggaaga gcaagattgt gtctctgatg tgggaccctg tgaccccata
1381  ccggctgcat gttctctgtc agggctggca ttacctcgcc tatgattggc actggacgac
1441  tgaccggagc gtgggagata attcaagtga cttgtccaat gtggctgtca ttgatggaaa
1501  cagggtgttg gtgacagtct tccggcagac tgtggttccg cctcccatgt gcacctacca
1561  actgctgttc ccacaccctg tgaatcaagt cacattctta gcacaccctc aaaagagtaa
1621  tgaccttgct gttctagatg ccagtaacca gatttctgtt tataaatgtg gtgattgtcc
1681  aagtgtgtg cctacagtga aactgggagc tgtgggtgga agtgattta aagtttgctt
1741  tagaactcct catttggaag agagatacaa aatccagttt gagaataatg aagatcaaga
1801  tgtaaacccg ctgaaactag gccttctcac ttggattgaa gaagacgtct tctgtgtgtg
1861  aagccacagt gagttcagcc cccggtctgt cattcaccat ttgactgcag cttcttctga
1921  gatggatgaa gagcatggac agctcaatgt cagttcatct gcagcgggtg atggggtcat
1981  aatcagtcta tgttgcaatt ccaagaccaa gtcagttaga ttacagctgg ctgatggcca
2041  gatatttaag tacctttggg agtcaccttc tctggctatt aaaccatgga agaactctgg
2101  tggatttctt gttcggtttc cttatccatg caccagacc gaattggcca tgattggaga
2161  agaggaatgt gtccttggtc tgactgacag gtgtcgcttt ttcattcaatg acattgaggt
2221  tgcgtaaaat atcacgtcat ttgcagtata tgatgagttt ttattgttga caaccattc
2281  ccatacctgc cagtgttttt gcctgaggga tgcttcattt aaaacattac aggcgggctt
2341  gagcagcaat catgtgtccc atggggaggt tctgcgaaa gtggagaggg gttcacggat
2401  tgtcactgtt gtgccccagg acacaaagct tgtattacag atgccaaggg gaaacttaga
2461  agttgttcat catcgagccc tggttttagc tcagattcgg aagtggttgg acaaacttat
2521  gtttaagag gcatttgaat gcatgagaaa gctgagaatc aatctcaatc tgatttatga
2581  tcataaccct aagggtgttc ttggaaatgt ggaacacctc attaaacaga tagattctgt
2641  gaatcatatt aacttgtttt ttacagaatt gaaagaagaa gatgtcacga agaccatgta
2701  ccctgcacca gttaccagca gtgtctacct gtccagggat cctgacggga ataaaataga
2761  ccttgctctg gatgctatga gagcagtcac ggagagcata aatcctcata aatactgcct
2821  atccatactt acatctcatg taaagaagac aacccagaa ctggaaattg tactgcaaaa
2881  agtacacgag cttcaaggaa atgtccctc tgatcctgat gctgtgagt ctgaagggc
2941  cttgaaatat ttgtgtcatc tggtagatgt taatgaatta tatgatcatt tatgttcac
3001  ctatgacttt gatttggtcc tcatgtgtgc tgagaagtca cagaaggatc ccaaagaata
3061  tcttccattt cttaatacac ttaagaaaat ggaaactaat tatcagcggg ttactataga
3121  caaatacttg aaacgatatg aaaaagccat tggccacctc agcaaatgtg gacctgagta

```

Figure 7

Continued

```
3181 cttcccagaa tgcttaaact tgataaaaga taaaaacttg tataacgaag ctctgaagtt
3241 atattcacca agctcacaaac agtaccagga tatcagcatt gcttatgggg agcacctgat
3301 gcaggagcac atgtatgagc cagcggggct catgtttgcc cgttgcggtg cccacgagaa
3361 agctctctca gcccttctca catgtggcaa ctggaagcaa gccctctgtg tggcagccca
3421 gcttaacttt accaaagacc agctgggtggg cctcggcaga actctggcag gaaagctggt
3481 tgagcagagg aagcacattg atgcggccat ggttttggaa gagagtgtcc aggattatga
3541 agaagctgtg ctcttgctgt tagaaggagc tgcctgggaa gaagctttga ggctggtata
3601 caaatataac agactggata ttatagaaac caacgtaaag ccttccattt tagaagccca
3661 gaaaaattat atggcatttc tggactctca gacagccaca ttcagtcgcc acaagaaacg
3721 tttattggta gttcgagagc tcaaggagca agcccagcag gcaggtctgg atgatgaggt
3781 accccacggg caagagtcag acctcttctc tgaaactagc agtgctgtga gtggcagtga
3841 gatgagtggc aaatactccc atagtaactc caggatatca gcgagatcat ccaagaatcg
3901 ccgaaaagcg gagcgggaaga agcacagcct caaagaaggc agtccgctgg aggacctggc
3961 cctcctggag gcactgagtg aagtgggtgca gaacactgaa aacctgaaag atgaagtata
4021 ccatatttta aaggtactct ttctctttga gtttgatgaa caaggaaggg aattacagaa
4081 ggcctttgaa gatacgctgc agttgatgga aaggtcactt ccagaaaattt ggactcttac
4141 ttaccagcag aattcagcta ccccggttct aggtcccaat tctactgcaa atagtatcat
4201 ggcattctat cagcaacaga agacttcggg tctgttctt gatgctgagc tttttatacc
4261 accaaagatc aacagaagaa cccagtgga gctgagcctg ctagactgag tgactgcagt
4321 taggagggat ccgacagaga agaccatttc cactcattcc tgttgtccta ccacccttg
4381 ctctttgagg gctggctatt gagaactgga aagagtaaaa tgataactta ccttagcatt
4441 gccagaactc tcagcagaca acaagcaatt ctatttattt tatgttgtgt atacatcttg
4501 atcattagca agacattaag ctttaaccat tatggcacca ttttgtgaga atgattgttc
4561 tttcacttgg gctgtttgag agcataatta tggtaatcat gagattaatg tttcatgatt
4621 tctacctcca aagtgtgaag acaagtaaaa caatgtttct aaattgtctt attttgttgg
4681 cggagaagat tacaatggct attagtgtca catttggtca aatgtaatca cttaaatagc
4741 ttcttgtcac cttaaactaa agcagaataa aaagtatcct ttgaaattat aagccctcct
4801 ttgctgacag ctattatttt gtaacatctt accaggctat gtgctttcag ttataactgg
4861 gctgagcctc ctataattac aatgtctata gggactgttt tactgcctgt gtattttctg
4921 ctagagagtt agcaatgtta gagctagaac agattagaat ttctaaacag tatcatgcac
4981 agttgggtgt agtgatcagt gtgcattgta tggcatgcat gggtgtgaat tattctctgt
5041 tctccaaata ctgtttcttt aactcagata tttttgttag tgtctaggcc acttcattta
5101 tttttcgtca tggtaactta ctgacttctc ttatttcaat tctccacgcc ctcacaaaaa
5161 aaaactgtct caaaatgaga atatttttat tcttcatggg gagtctagaa aacgccccac
5221 ttcattctga ttaaaaaatt cttccatgtt tttaaatata agaaccagac ctttcttact
5281 gtgtatctta gcccatthgt gtctctataa caacaaccag ctttcaaagg aactaataga
5341 gtgaaaactc actcattacc acgaggatgg cacaagcgat tcacgtagga tctgcccctg
5401 tgaccaaacc acctcccatt gggcccact tccaacactg gtgatcacat ttcaacatga
5461 ggtttaggga aacaaatgcc taaactacag cactgtacat aaactaacag gaaatgctgc
5521 ttttgatcct caaagaagtg atatagccaa aattgtaatt taagaagcct ttgtcagtat
5581 agcaagatgt taactataga atcaatctag gagtattcac tgtaaaattc aacttttctg
5641 tatgtttgaa cattttcaca atctcatagg agttttttaa aagaagagaa agaagatata
5701 ctttgctttg gagaaatcta ctttttgact tacatgggtt tgctgtaatt aagtgcccaa
5761 tattgaaagg ctgcaagtac tttgtaatca ctctttggca tgggtaaata agcatggtaa
5821 cttatattga aatatagtgc tcttgctttg gataactgta aagggaccca tgctgataga
5881 ctggaaatag aagtaaattg gtttattgaa aaaaaaaaaa aaaa
```

FIGURE 8

```
1 mrnlklfrtl efrdiqgpgn pqcfslrteq gtvligsehg lievdpsvre vknevsllvae
61 gflpedgsgr ivgvqdllldq esvcvatasg dvlcslstq qlecvgsvas gisvmswspd
121 qelvllatgq qlimmtkdf epileqqihq ddfgeskfit vgwgrketqf hgsegrqaaf
181 qmqmhesalp wddhrpqvtw rgdqqffavs vvcpetgark vrvwnrefal qstsepvagl
241 gpalawkpsg sliastqdkp nqqdivffek ngllhghftl pflkdevkvn dllwnadssv
301 lavrledlqr ekssipktcv qlwtvgnyhw ylkqslsfst cgkskivslm wdpvtpyrlh
361 vlcqgwhyla ydwhwttdrs vgdnssdlsn vavidgnrvl vtvfrqtvvp ppmctyqllf
421 phpvnqvtfl ahpqksndla vldasnqisv ykcgdcpsad ptvklgavgg sgfkvcrltp
481 hlekrykiqf ennedqdvnp lklglwtwie edvflavshs efsprsvihh ltaassemde
541 ehgqlnvsss aavdgviisl ccnsktksvv lqladgqifk ylwespslai kpwknsaggfp
601 vrfpypctqt elamigeeec vlgltdrcrf findievasn itsfavydef llltthshtc
661 qcfcldrdsf ktlqagllsn hvshgevlrk vergsrivtv vpqdtklvlq mprgnlevvh
721 hralvlaqir kwldklmfke afecmrklri nlnpiydhnp kvflgnvetf ikqidsvnhi
781 nlfftelkee dvtktmypap vtssvylsrd pdgnkidlvc damravmesi nphkyclsil
841 tshvkkttpe leivlqkvhe lqgnapsdpd avsaealky llhlvdvnel ydhslytydf
901 dlvlmvaeks qkdpkeylpf lntlkkmetn yqrftidkyl kryekaighl skcgpeyfpe
961 clnlikdknl ynealklysp ssqqyqdisi aygehlmqeh myepaglmfa rcgahekals
1021 afltcgnwkq alcvaaqlnf tkdqlvglgr tlagklveqr khidaamvle esaqdyeeav
1081 llllegaawe ealrlvykyn rldiietnvk psileaqkny mafldsqtat fsrhkkrllv
1141 vrelkeqaqq aglddevphg qesdlfsets svvsgsemkg kyshnsris arssknrrka
1201 erkkhslkeg spldlalle alsevvqnte nlkdevyhil kvlflfefde qgrelqkafe
1261 dtlqlmersl peiwtltyqq nsatpvlqpn stansimasy qqktsvpvl daelfippki
1321 nrrtqwkls1 ld
```

M_musculus	1	-----MRNLKLRITLFRDIQAPCKS-----QCECLRLSE..QGTVLIG
H_sapiens	1	-----MRNLKLRITLFRDIQCPCKS-----QCECLRLSE..QGTVLIG
D_melanogaster	1	-----MRNLKLYC.....QHLLEQPELGGSDIV
S_cerevisiae	1	MVENDKSGSKRQELRSNMRNLITLNKGRSEPTATAEGBEDDSEFTLIDVFTLDSIT
A_thaliana	1	-----MRNLKLFSEEP..QHLHSTETVQFAAEDDQSRLLFFSSAN
C_elegans	1	-----MRNLKLFSEEP..MKNLKLGSKTEENPEIAGADDP..HB
M_musculus	37	SERGLTEVDP..VRREVKTENSLVAEGFLPEDGSCIVGHQDILLDOESVCVATASGVIV
H_sapiens	37	SEHGLTEVDP..VSREVKNESLVAEGFLPEDGSGIVGVQDILLDOESVCVATASGVIV
D_melanogaster	36	FVYADNKTYYA..VQESGDVRLKTHAN..LEP.....IVGVVEFLQDNNKCVASSKGVIR
S_cerevisiae	61	CVLGSTDLTGAEVQVQFKKQGRNVLASENIQTFDDLTFSFVHFADINOVFVFEQSEHT
A_thaliana	43	FVYALQLSSFONESAGAKSAMPVEVCSIDIEPCD..FHTYDMLAKTESKLGATSHGLARV
C_elegans	27	PILOTIAVSFKNELLLENENISSIKWAEQRRELEKSTESERTQGNQVVLADGRAL
M_musculus	95	C.....NLSTOOLECVGSVAGSIVMSWSPDQELL..LATAQOTLIMMTKDFEVIAEQ
H_sapiens	95	C.....SLSTOOLECVGSVAGSIVMSWSPDQELL..LATGQOTLIMMTKDFEPIEQ
D_melanogaster	87	V.....EPQTGATSEGTFCQVGIEMASSENQENNAFVIRTHNNNTSTFEVIAEQP
S_cerevisiae	121	ATYDPVSLNPNETLEIMGLHONCLIAAOSYDEETLAVTKDRNLIAEIKLFEPIEYK
A_thaliana	102HNVEDVTEVEAGNCEGCKKCHSPNFTGDLGCIINGLGDENNYDMALNTEKA
C_elegans	87	VEDGEVMD.....CEIAELTDTTYSAAENNADEKTLALADN..QTLTYADSSLVPTERP
M_musculus	148	T..HODDFGEGKFVTVGWGSKTQFHGSEGRPMAPPV.....QDENALPDDR
H_sapiens	148	T..HODDFGESKFFTVGWGSKTQFHGSEGRQAAMQ.....QDENALPDDR
D_melanogaster	140	T..DAELDPQOQEVNVVGWKKETQFHGSEGRQAAMQ.....QDENALPDDR
S_cerevisiae	181	L..EVDDLKISKVTVGWGKKETQFCKGARAMERFASLSASGLVGNODRPPKMYND
A_thaliana	155	L.....GEVPEGGIV.....REF.....
C_elegans	140	LIFSENERRKSAVNVVGWGSSESTQFSGSAGLKPGEKKEK.....
M_musculus	195	R.....PH...IWRGDDGYFAVSUV.....CROTEARKIRVKNRE..FALQSTS
H_sapiens	195	R.....PQ...IWRGDDGYFAVSUV.....CPETGARKIRVKNRE..FALQSTS
D_melanogaster	187	L.....NOLYSISWRGDCGEYFVSUV.....AAQLGRTFFVYDSE..GILQTA
S_cerevisiae	240	TGQVIAEDSHEIRISWRGDCGEYFVSUV.....VVEVPEDDDETAKIRAFVRE..GOLDSES
A_thaliana	168NDHEANCGGISISWRGDCGYFAT..MGEVYSGCM.....BAKIRAFVRE..GOLDSES
C_elegans	181KQTEOHSKTSVWRGDCGEYFVSUV.....YSSNDIRNTVFRANGEILNHN
M_musculus	235	ESVPEGLPALAWKPSGLIASTQDK.....PHOODVVFEEKNGLLHGHTLPFLKDEVK.
H_sapiens	235	EPVAGLGPALAWKPSGLIASTQDK.....PHOODVVFEEKNGLLHGHTLPFLKDEVK.
D_melanogaster	229	EKSANLKDPMVWRPQGNWIAVPOF.....PHKSTIALFEKNGLRHLVLEPDIQEP.
S_cerevisiae	299	EPVTCHEHOLHWKPSGLIASTQDK.....PHKSTIALFEKNGLRHLVLEPDIQEP.
A_thaliana	219	BTKEFTQGLIEMWPSGLIAVYRK..SDOSSPSIAFFENGLRHSRREGEPTATES
C_elegans	230	IRNIYLSHCTAHKPNANLCSATQENGSD.....RIVIRERNGETRNSVYKWPARESD
M_musculus	289	...VNDLLWNDOSSVLAWLEDLQEDSSITLKNYVOLWTVGNVHWYLKQSLPSTCSKQ
H_sapiens	289	...VNDLLWNDOSSVLAWLEDLQEDSSITLKNYVOLWTVGNVHWYLKQSLPSTCSKQ
D_melanogaster	283	...VVQLRNSDSDSLAT..RTCAKEEQR.....VYLYTEGNYHWYLKQSLPSTCSKQ
S_cerevisiae	357	...VESMCNNSNSEALAY.....VLAHRTQLWTSKNYHWYLKQSLPSTCSKQ
A_thaliana	277	...CENKKNNSADSLCA..GMVSCKYDQ.....TRNFFSNHNYWYLKQSLPSTCSKQ
C_elegans	286	RRITKKEENSTGTALRN.....QTSLGKPHOHEFWHTSNVEFTKCKYKFESE....
M_musculus	346	IVSLRWDP..VTPCRLHLVLCGWRKLCDDHWTDRSSGNSANOLINVAVIDGNRVLVTV
H_sapiens	346	IVSLRWDP..VTPMRLHLVLCGWRKLCDDHWTDRSSGNSANOLINVAVIDGNRVLVTV
D_melanogaster	331	HALLEWDTRCGKEHTLHLVLESKHLVYRWAFVORNN.....SIVGVILGKRELEID
S_cerevisiae	398	ISYKWEPE..KDETUMFSADAFINIV..DFAYKMAOGPTLEPPYNGTSLVDGRTNRP
A_thaliana	325	IVSLRWDP..TKPLOLICHTL8GQVSVRHFHVA.....AVREDSTAFVIONSEVVP
C_elegans	334	...SYWKWSTVEQNTZVILESGOFFSVH...ITPTASPSVIESONVVVATD..ELRNTS
M_musculus	404	FRQTVVPPPMCTYRLILPHPVNOVIFS...AH..LCNDLAVLDASNOISVYKCC..DLEN
H_sapiens	404	FRQTVVPPPMCTYQLLFPHPVNOVIFL...AHPOKSNOLAVLDASNOISVYKCG..DCE
D_melanogaster	384	EDATVPPPMCKE...LQKPE.....MLHPDA..KESGLHLE..HLTE
S_cerevisiae	455	LALINVPMPMYRDFETEGNVLDVACSFSENEIYAAINKDVLFFAAVPSIREMKG..KPS
A_thaliana	376	LSLLEPPPMYLESLSSAVRDEIAYYRNS.....KFCCLAVFLDGNHAFV...EPPA
C_elegans	387	LCRRNVPPPMCTYQLLSDI..VAKESSTHEVHVITSDMKSTSCMLFFKKKIRANYSDP
M_musculus	457	MSSEVKLGAVGGMGFKVPDITPHLEKRYSIQFCNNESEEBOTALQLSFLTWVEQIFLA
H_sapiens	459	ADPTVKLGAVGGSGFKVCLRTPHLEKRYKIQERNNEEDQVN..PLKUGLLTKRDEDFLA
D_melanogaster	420	ESBYHLLATHSSAG.....STRLLLSYK...DNDKPGG.....C.....EYR
S_cerevisiae	514	IVCE.....EPKSEFSEPSLRQMAINDSIVGVLLDQDNLISRLHDIQDI..
A_thaliana	427	PNTWEDDEGKDFSEIISDCKDALGSFVRLNWLNVHSLLCVSAYGSSHNK..CLSSGGYDT
C_elegans	445	GRKKYILEIKVPSRHTYFACFAGSQDTCYKFNQSRASIDEV.....PHQZVTEGICG

FIG. 1. Comparison of the amino acid sequence of Ikap across several species. Alignment of the amino acid sequence of Ikap (M_musculus) with that of *Homo sapiens* (H_sapiens), *Drosophila melanogaster* (D_melanogaster), *Saccharomyces cerevisiae* (S_cerevisiae), *Arabidopsis thaliana* (A_thaliana), and *Caenorhabditis elegans* (C_elegans). Black boxes indicate identical AA, while conserved AA residues are shown in gray. Asterisk (*) at AA position 696 for mouse and human proteins indicates the location of the heterozygous R696P mutation found in only 4 FD patients. Sequence alignments were made using Pileup and Boxshade commands from GCG Wisconsin Package V.9.0 (Madison, WI).

Figure 9

M_musculus	517	ISYSSSSQSHIHHLTVHSEVDEEGQLVSSSVTVDGVVIGLCCS.SKTRSEVQLAD
H_sapiens	517	VSRSETPSPASVIHHLTRASSEDEPHGQLVSSSVTVDGVVIGLCCN.SKTRSEVQLAD
D_melanogaster	456	V.HSSPRINGENAMVAPYATPEFYV.TVNNGHITYE...KADKLLVVERVY
S_cerevisiae	562	TOPLLHIVEVDLAVFLRSFIDYHLYV...TROGTVCOLD...
A_thaliana	486	EHCSYHOEVEVYCHDEVDVTCSGFKASTCFQNLQSPVTLAWNPSKRDSAVVTEFG
C_elegans	500	FVYDEPSESYSIWNVSHHKKHETS...REGANPEKIFEGENICWIGVNPSPNKHREBASNO
M_musculus	576	GOVLKILWESPSLAHPPWKNSEGIPIVRFVHPCTOMEVATIGGEECVLGLTDRCRFTILVT
H_sapiens	576	GOVFKYLWESPSLAHPPWKNSEGIPIVRFVHPCTOTEMAMICEECVLGLTDRCRFTIHDE
D_melanogaster	507	VOR...HEPDDQIDNVIVKG...CIWD...GYTGAETLRYCHLLEIGY
S_cerevisiae	604	GOLVET.KEPOLNRDFVVKR...VNTSAEDDDNWKESSSLVAFGCTNNGLEBANOT
A_thaliana	546	CKVLCYASRSEIMETRSDDSVCFPSTCHVVRVAQVDAAGVHRPLCCGLDPMGRLSINGK
C_elegans	556	CKFEDENTKEELFKIKFESSEVHFQVCHGILNHHVIOQ...DNSMLSEISE
M_musculus	636	EVASNITSFA.....VCDFELLTTHSH...TCQCFSLSCASLKNLQAALSSSHEA
H_sapiens	636	EVASNITSFA.....VYDFELLTTHSH...TCQCFCLRDASFRTLOAGLSSNHVS
D_melanogaster	548	REGEDYTSFC.....VVIHLLVYTO...LNAMHEVILD...DRQVA
S_cerevisiae	659	LEASATISLE.....STDSFLFTTAQH...NLOFVHLNSDEKPLPLVEEG...V
A_thaliana	606	NECNCSSESYSELANEVVTHLEFLTKQDFLFIOTKDVNLGCVLGHFFVFDGRARD
C_elegans	606	RVSQRAISILTRG.....SDILLDFDNLRFTDAE...B
M_musculus	684	SGEM...ARKVVWGSRIIVTVV...PQDKKILOMPRGNLEVVHHRALVLAQIRKWLDKLMFKE
H_sapiens	684	HGEM...ARKVERGHRIVTVV...PQDKKILOMPRGNLEVVHHRALVLAQIRKWLDKLMFKE
D_melanogaster	584	S...RNTERGSRIVTAV...ARKAEVVLQTPRGNLEAICPRVLVLELIGDILRG...OK
S_cerevisiae	704	EDGR...VRABERGSIIVSVT...PSKESVLOATRGNLETIYPRIVLAEVRKNEMAKREKE
A_thaliana	666	EENNSYVNIWERSGSGVIGDAAVILQTMGRNLECIYPRVLVLSITNAQAQREKE
C_elegans	638	GKTIEDVRNVEACGEV...ACHSOSANVILQARGNLETIOPRRVYVATRDOLDLKEBIA
M_musculus	741	AFECMRKLRLINLNLIDH.NHPKVFLNVEVTFVQIDSVNHNILFFTELKEEDVTKTYPP
H_sapiens	741	AFECMRKLRLINLNLIDH.NHPKVFLNVEVTFVQIDSVNHNILFFTELKEEDVTKTYPP
D_melanogaster	637	AEEMSRKKORINLNLIDH.HNVKRFVSVGAFQDINEPFWCLFELSEONEDFTKCYSS
S_cerevisiae	761	AFIVCRTHRINLNLIDH.YAPEFLENVEVFINOIGRVGYENLIECLSEONEDFTKCYKE
A_thaliana	726	AFNLVRAHRIQFNLVLDLYGWAFLQSAVAFVEOVNHNHYTEVCAKKNEDVTFNRYK
C_elegans	797	SEKMKKKHRMMS.....FAMKYKGGDDTDDH...B
M_musculus	800PITK.SVOMST...HPDGKKKDLVCDAMRAAM...EAINPRKCLS
H_sapiens	800PVTS.SVYKSE...DPDGKKKDLVCDAMRAAM...EAINPRKCLS
D_melanogaster	696	NY.....DAEK.QTYPSD...YRVDKVEYVCRLEEQM...NRF.VSHEEP
S_cerevisiae	820	TLVSGISKSPGMPAPITEMOYVKKKPPDKMSKVYKEDAVLNVLNPEYKELQLO
A_thaliana	786	FSKSKKGDEVF.....HYKSCSNKVSSVLQAKERKAEHEHIESPESREHC
C_elegans	725	IWLKTSNDSQMEQQLIACEVTV...PDAGSSLCMTVARYRD...LSQAEKTKQEP
M_musculus	839	ILTSHVKKTTPELE...IVLQKVQELQGNLPSDP...ESVSVEEALKYLLLLVDVNELE
H_sapiens	839	ILTSHVKKTTPELE...IVLQKVHQLQGNLPSDP...QVSAEEALKYLLHLVDVNELE
D_melanogaster	736	ITATYVVKLGC...LE...ALKQVHEKEQ...QE...DASLADLQHLVLDVNELE
S_cerevisiae	880	ITATYASQNPONLS...AALKLESELE...NSERKDSCTYLCLQDVNVV
A_thaliana	831	ILTALASDPPAREESLIRKSVREHLLNSDDIRKKSCPSAEEALKHLLWLROSEAE
C_elegans	777	ITATLEKSKPSKYNRC...LKEVQE...HVEKIADKDVTERNSLEHSEFFVAKKEP
M_musculus	892	NHSLGTYDFNLVLMVAEKSQKDPKEYLPFLNLTKK.METNYORFTIDKYLKRYEALGHL
H_sapiens	892	DHSLGTYDFNLVLMVAEKSQKDPKEYLPFLNLTKK.METNYORFTIDKYLKRYEALGHL
D_melanogaster	782	NVALGTYDFGLVLVVAEKSQKDPKEYLPFLNLTKK.TPIDYRFRIDDELKRYTALSHL
S_cerevisiae	926	KSALSLYDVSLALVVAEKSQKDPKEYLPFLNLTKK.NEPLRRELIDDYLGNYEKALEHL
A_thaliana	891	EALGLYDLNLAAKVALNSQKDPKEYLPFLNLTKK.SPESLMSEIDIKLORRESALRN
C_elegans	829	NCALSTYDLKLAQVAAESYOPKEYLEVNLNLNVMCTLERQYRINNVREAMIDAMSSD
M_musculus	951SKCGPE..YEPECLNLIKDK.NLYKEALKLYRPOSFOYQANSMAYGEHLMOEHL
H_sapiens	951SKCGPE..YEPECLNLIKDK.NLYNEALKLYSPSSQYQDISIAYGEHLMOEHL
D_melanogaster	841ACGGEY..HMEEALEYIRKE.GLYTDELAFYREHIEFOKNIYVAYAHILRATAK
S_cerevisiae	985SEIDKGNVSEVYVYHESH.GLYKHELALYRYDSEKOHVIYNIYAKHSSNQ
A_thaliana	950VSAG..VGVEEDCNLIRKNPCLFLELLIT.DPEKKLVVLEAWAGHLEDEER
C_elegans	889	FLOSSKERGSEETWNNIDEIIO.REKLYQALALVVEGDRRYKOCCELYAAERKRVH
M_musculus	1002	YEPAGLVARCGAOKALEAFLKCSQOALCVAAQLQMSKDLVAGLARTLAGKLVQQRK
H_sapiens	1002	YEPAGLVARCGAOKALEAFLKCSQOALCVAAQLNFTKDOUGLERTLAGKLVQQRK
D_melanogaster	892	LDNAGLMYERGGOLQALLSAKHTLQORVLEAKKLSEPLDOV...AQSLVGPLOEQCK
S_cerevisiae	1038	YDAAVAYEMLSKLEAMGATQAKREKAMSAAVQ.KEP.EVESEAEELISSITFE
A_thaliana	1001	REDAAITYLCCCKLEKASKALRECGQSGVLRVGCALFKLGKDEKDAYELCEEANLCK
C_elegans	948	WRPAALFYELSGNSERTLKCEWMSRVDGLAASARREAVDAGKRIHAIKMTTIREAQ

Figure 9

Continued

```

M_musculus      1062 HSEAAATVLECYAODYEEAVLLLLLEGFAWEEALRLVYKYDRVOIIEISAKPSILEAOKNYM
H_sapiens       1062 HETAAAVLEESAQDYEEAVLLLLLEGFAWEEALRLVYKYDRVOIIEITNVKPSILEAOKNYM
D_melanogaster  949 HMEAYEERKEHCODRKROFDLLEGLYSRAEYEAGLED...DDISEKRAPELAYGVHLE
S_cerevisiae    1096 YVDAADHOLEYLDNVKEAVALYCKYRYHIASLVAIKAKDEEVEEVVDGGEFGIHA
A_thaliana      1061 PAAAKALALEYCSDISGETSLLENREWEELRVALLHTADDRISVVKSSALECASCCH
C_elegans       1008 PKEAKAKKLKACSSSTMIVHFLCEFFELDASREVEVGK....EEAKKRAISRNDDE

M_musculus      1122 DFLDSATATFRRHKNRLQVVRALKRQAPQVHDEVAHGFESDLFSETSSIS.SSEMS
H_sapiens       1122 AFLDSATATFRRHKKRLLVRELKEQAQCGADEVPHGCESDLFSETSSIS.SSEMS
D_melanogaster  1007 SSLQNLQLFEDYKORLLDERRNKAKEGTEHDTIVNLKEVDLLSDTTSRHS..S.SYS
S_cerevisiae    1156 ELADCKGQINSQRLRLREERAKKEENPYAFYGBETEQADEVSHAPSETSEQESFFERY
A_thaliana      1120 SEFKESIERYVGYLTRYLAVRRELLLAALKSEERFVVLDODDTASASSENISGMSAVE
C_elegans       1063 MDERRRKEEENYKKRLAVVRENKLRVQFAAGEV.....DDLDRDISVSSISSR..

M_musculus      1180 .GKYSHSNR..ISARSSKNRR..KAERKKHSLKEGSPLEGLALLEAL....SEVVQ.SVE
H_sapiens       1180 .GKYSHSNR..ISARSSKNRR..KAERKKHSLKEGSPLEGLALLEAL....SEVVQ.SVE
D_melanogaster  1063 .GTSRRTCK...FRSSKNRR..KERKLFSLKFGNDEEDALDALHNEVTKHAQ..QOE
S_cerevisiae    1216 .GKTGGKTKTGASRTAKNRR..EKERKHARGKKGTYEE...EYLVQSVGTE...RLN
A_thaliana      1180 LGTRGSAISVSSENATSRARDLRRKSGKERRAGSAGEEALVDEL....KGR.MDE
C_elegans       1115 .....SGSSKSMASIVRRRK.QIERKKSSLKEGCEYEDSALLNVLSNRYRWHEHIGSE

M_musculus      1231 RLKDEVRAILKVLFLFEFDEQAKELORAFESTLQLMERAVPEIWTTPAGQOSS..ATPVLG
H_sapiens       1231 RLKDEVYHILKVLFLFEFDEQARELOMAFESTLQLMERAVPEIWTLYQONS..ATPVLG
D_melanogaster  1116 FVROTCKARLQANAAADPLAALLOREFKTLQAVTAHDEINTPELRGNGLADHTG
S_cerevisiae    1268 QTKPDVAVRYLEGICRRNMREQAHEEONNEVAVLDLKKANVKEIYSIEKDRERVNEN..G
A_thaliana      1234 GGNRELKSLICLVTLGEMESAQKLQOTASE.FQPSVVAVEL.AHDTVSSSESVDSEVYC
C_elegans       1168 FCFPWNFNLL-----

M_musculus      1289 PSTANSIMASYQOQKTCVPALDAGVLPFKKIPPSHOWKLSLLP
H_sapiens       1289 PNSTANSIMASYQOQKTSVPILDAEFPFKKIPPSHOWKLSLLP
D_melanogaster  1176 PN..VRYTALQREORYELISPLKR..EKPQLI..MMDQHEEILQ
S_cerevisiae    1326 EVYIPEIPVPEIHDFPKSHYDF-----
A_thaliana      1292 FERYAQKTRSTARDSDPSWQK..VFISF-----
C_elegans       1178 -----

```

Figure 9

Continued

TABLE 2. COMPARISON OF THE NOVEL MOUSE *Ikbkap* GENE WITH MULTIPLE SPECIES HOMOLOGS

Species	Gene name	No. of amino acids	Molecular weight (kDa)	% aa identity with M.m.	GenBank Accession No.
<i>Mus musculus</i> (M.m.)	<i>Ikbkap</i>	1332	149.11	—	AF367244
<i>Homo sapiens</i>	<i>IKBKAP</i>	1332	149.11	80	AF153419
<i>Drosophila melanogaster</i>	<i>CG10535</i>	1213	138.21	32	AAF54670
<i>Saccharomyces cerevisiae</i>	<i>Elp1/Iki3p</i>	1349	152.99	29	AAB67278
<i>Arabidopsis thaliana</i>	Unknown	1308	146.63	27	BAB08695
<i>Caenorhabditis elegans</i>	Unknown	1177	134.80	24	AAF60430

Figure 10

TABLE I. MOUSE *Ikbk*p EXON AND INTRON BOUNDARIES

Exon	Acceptor site	Donor site	Size (bp)	cDNA position
1		AGgtgagcattcgcgcg	129	1..129 ^a
2	ttttttccctcagAA	AAgtaggtcactgatgc	163	130..292 ^b
3	tatgctttgtgaagGT	AGtaggtgtaaggcct	153	293..445
4	ttttctctgatgcagCT	AGgtaagctttgcactg*	82	446..527
5	acatgaactcctaagCT	AGgtaagcgtttcttgg	81	528..608
6	cttgaaaaactgtagGC	TGgtaagcgaggatgat	86	609..694
7	gggtctctcttccagCC	TGgtctctcttccagc*	97	695..791
8	ctacctctttgcagAG	AAgtgagtgcataaaa*	91	792..882
9	aggttctgtttcagAC	AGgtaggggtcagaggt	124	883..1006
10	ttttgtccctaccagGT	TGgtatgacagcttgtg	94	1007..1100
11	tccctccacacacagTC	AAgtgagtgtctgcgaa	231	1101..1331
12	ctttcattgtgtagAC	TGgtgagtggaagcagg	165	1332..1496
13	ttttgttttctagGT	TCgtgagtctcctaata	100	1497..1596
14	ctaataattgaacagGA	AGgtatcatgggttcatc	189	1597..1785
15	ttttttgtcttagTT	GGgtgaggtacagaggt	107	1786..1892
16	ttaatcttacaacagAG	AGgtgaatagacacggc	104	1893..1996
17	ttcatttcttgcagGA	AGgtatgtaggcttgg	54	1997..2050
18	tcctgcctgttgcagGT	AAgtgagctctctcata	106	2051..2156
19	cactgggtatttttagTG	AGgtgagctgactcttc*	116	2157..2272
20	gggttttatttgagAT	AAgtgagtatttattct*	74	2273..2346
21	ttcctgtcctcacagAC	AGgtacactttgcgtct	79	2347..2425
22	tactttcttgatagGT	AGgtgagtatttgata*	80	2426..2505
23	tactgtgggtcttagGG	AAgtgggtgctgtgtgt	138	2506..2643
24	cacttactacctcagGT	AGgtgagacctgcgcg*	86	2644..2729
25	cttaaaactccaacagGA	AGgtatgtggagttag*	149	2730..2878
26	aactttttcttaggGA	TGgtgagggttttttt	124	2879..3002
27	ttttttttttcagGA	AGgtatgtgggtgggtta*	98	3003..3100
28	cgctcttgtcacagGC	AGgtgagcagggccatt	202	3101..3302
29	ttgtgtctttcagGA	AGgtgagctctccccg	62	3303..3364
30	ctcttcccttgcagGA	TGgtgagggaagctctga	63	3365..3427
31	ttcttccctcttagGT	AGgtgaggattacatt*	61	3428..3488
32	attatgcatcctcagCC	GGgtgagtgcctccaaa*	114	3489..3602
33	gttcatcttcttagAT	GCgtacgtacgagacct*	112	3603..3714
34	tgtatattctgacagGA	AGgtatggcttcagtgc	128	3715..3842
35	ccatttcttcttagAT	CGgtgagcttccacaga	155	3843..3997
36	ctgtttctgcttagGT	CGgtgtactgctcgttc	76	3998..4073
37	cattctgcttccagAT		709	4074..4799 ^c

Figure 11




Figure 12

